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ABSTRACT 
Stephen Joseph Godin: Species differences in the metabolism of pyrethroid pesticides: 
potential implications for human health risk assessment 
(Under the direction of Michael J. DeVito Ph.D.) 
 
 Pyrethroids are a class of synthetic pesticides derived from the pyrethrins, the natural 
insecticidal ingredients of the pyrethrum extract of Chrysanthemum cinerariaefolium.  In an 
effort to aid species extrapolation of exposure-dose relationships for pyrethroids, this 
dissertation aimed to develop appropriate data sets and models to address pharmacokinetic 
uncertainties for this class of chemicals.  Based on experimental data in rats and mice it was 
previously thought that the rate of metabolism of a pyrethroid directly influenced its toxic 
potency.  Preliminary results indicated that the pyrethroid deltamethrin was metabolized 
nearly twice as rapidly in human liver microsomes (HLM) as it was in rat liver microsomes 
(RLM).  This is in contrast to esfenvalerate, which was metabolized nearly 3 times slower in 
HLM compared to RLM.  Our hypothesis was that hepatic metabolism of pyrethroids drives 
blood and brain concentrations thus influencing their toxic potency.  Research was conducted 
to understanding species differences in the hepatic metabolism of deltamethrin and 
esfenvalerate, and to develop a PBPK model of deltamethrin exposure to examine the 
influence of hepatic metabolism on exposure-dose relationships between rats and humans. 
 Results indicate that initial phase I biotransformation (detoxification) of deltamethrin 
and esfenvalerate occurs via cytochrome P450 oxidation in RLM.  This occurs by the same 
set of P450s for both compounds.  In contrast while esfenvalerate is metabolized primarily by 
P450 oxidation in HLM, deltamethrin is metabolized primarily via esterase hydrolysis in 
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HLM. Hepatic clearance rates were calculated from microsomal metabolism studies and 
utilized to parameterize PBPK models of exposure to deltamethrin.   
 A PBPK model of deltamethrin was developed in rats and evaluated based on 
literature data.  The current PBPK model of deltamethrin displays diffusion limited kinetics 
in all tissue compartments.  This has the effect of limiting the influence of species differences 
in the hepatic clearance of the pyrethroids.  Based on these results it is concluded that 
diffusion of pyrethroids into and out of the liver and brain are more responsible for the 
pharmacokinetic influence on toxic potency compared to hepatic metabolism in contrast to 
what has been previously thought. 
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GENERAL INTRODUCTION AND LITERATURE REVIEW
2 
GENERAL INTRODUCTION 
 
Pyrethroids are one of the major classes of commercial pesticides along with the 
organochlorines, organophosphates, carbamates and others.  Due to use restriction, and 
removal of other pesticides from the market, the use of pyrethroids has been increasing.  
According to a Freedonia Market Research, Inc. report in 2004, the use of pyrethroids has 
risen from 2.8% of the market share of pesticides in 1993 to an expected 30% in the year 
2008.  A better understanding of the human health risks associated with exposure to 
pyrethroids is therefore increasingly important. 
Regulatory agencies are responsible for assessing the potential human risk associated 
with exposure to environmental contaminants such as pesticides.  These efforts necessitate 
dose-response assessment (i.e., how the frequency of adverse effects changes with decreasing 
dose) and typically involve extrapolations from high to low doses and from a nonhuman 
species to humans.  Typically, this is done with little to no direct human data.  Thus, the 
process of toxicological risk assessment of environmental contaminants is fraught with 
uncertainties.  Regulatory agencies have historically applied default approaches (the use of 
uncertainty and safety factors) in estimating the potential human risk associated with 
environmental exposures; this is the case for many pesticide chemicals, including 
pyrethroids.  To improve the scientific basis for risk assessment, the development of 
sophisticated models, such as physiologically based pharmacokinetic models (PBPK), have 
been utilized.  The goal of these approaches has been to better link what is known about 
exposure and toxicity, thus reducing the uncertainties in the risk assessment process. 
Pyrethroids and other pesticides have been regulated on a single chemical basis 
utilizing laboratory animal data and default uncertainty factors.  Based on the Food Quality 
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Protection Act of 1996 (FQPA), which amended the Federal Insecticide Fungicide and 
Rodenticide Act and the Federal Food, Drug and Cosmetic Act regarding regulation of 
pesticides on food products, the pyrethroids are currently undergoing assessment for a 
possible cumulative risk assessment by the USEPA Office of Pesticide Programs.  Thus, 
research efforts in the field of pyrethroids have recently been focused on current data gaps to 
aid a possible risk assessment.  A major uncertainty in estimating human risk associated with 
exposure to pyrethroids is the extrapolation of laboratory animal toxicology data to human 
beings.      
Species extrapolation of toxicology data is complicated by species differences in both 
the pharmacokinetics (PK) and pharmacodynamics (PD) of a toxicant.  In the absence of 
direct human data, an ideal way to conduct an extrapolation is through a parallelogram 
approach (Fig. 1.1).  Incorporation of a PBPK/PD model enables comparison of exposure-
dose relationship at a target tissue to a toxic response (Andersen, 2003).  The steps of the 
parallelogram approach include:  (1) developing a hypothesis based model that includes 
descriptions of the proposed PK and PD determinants in a surrogate mammalian species (2) 
Determine the influence of the PK and PD determinants in the surrogate species, these are 
understood through the PBPK/PD model in the surrogate species.  (3)  in vitro determinants 
are compared with one another in the human and surrogate mammalian system.  (4) Human 
in vitro data is then incorporated in the PBPK/PD model with the pertinent human 
anatomical/physiological data.  Empirical adjustments for in vitro to in vivo scaling derived 
from the mammalian surrogate are applied if necessary, establishing the human PBPK/PD 
model.  To conduct a risk assessment, population distributions of exposure, either measured 
or modeled can then be interpreted by the human PBPK/PD model rendering population 
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distributions of a relevant dose-metric for the toxicological outcome.  The potential risk from 
these exposures is extrapolated from the dose metric based on dose response relationships 
understood in the rodent system.    
 
Figure 1.1.  Parallelogram approach for extrapolation of pharmacokinetics      
 
 
 
The research presented in this dissertation attempts to address uncertainties in the 
species extrapolation of exposure-dose relationships for pyrethroid pesticides.  This will be 
done utilizing the parallelogram approach to develop rat and human PBPK models of 
exposure to a pyrethroid and address uncertainties in extrapolating pyrethroid 
pharmacokinetics.  Four primary objectives have been identified from the parallelogram 
approach; (1) formulation of a hypothesis driven model for pyrethroid tissue dosimetry in a 
mammalian surrogate (the rat); (2) explore the PK determinants of pyrethroid disposition in 
the rat and human beings; (3) develop a PBPK model of exposure to a pyrethroid in the rat, 
and; (4) extrapolate the rat PBPK model to a human PBPK model of exposure to a 
pyrethroid. 
The following is a general literature review of the current state of knowledge in the 
field of pyrethroid pesticides.  Based on current knowledge, formulation of an initial 
hypothesis driven model will be described, data gaps will be enumerated, and the needs for 
Rodent (in vivo) 
Rodent (in vitro) 
Human (in vivo) 
Human (in vitro) 
5 
development of rat and human PBPK models will be discussed.  Within this framework the 
specific aims of this dissertation will be detailed. 
 
 
THE PYRETHROIDS 
 
Pyrethroids are synthetic pesticides which have been developed through an iterative 
process of changes to the chemical structures of the natural pyrethrins (Fig 1.2). Pyrethrins 
are the insecticidal components of the pyrethrum extract which is derived from the flowers of 
Chrysanthemum cinerariaefolium and Chrysanthemum cineum.  While the pyrethrins make 
excellent natural pesticides and have low mammalian toxicity, they are labile in light, air, and 
moisture making them a less than ideal product for commercial use (Ueda et al. 1974).  The 
pyrethroids were therefore developed to yield more environmentally stable and commercially 
viable pesticides. 
 
Figure 1.2.  Structure of the natural pyrethrins. 
 
O
O
O
R
 
 
Pyrethrin I, R = CH3,  Pyrethrin II, R = CO2CH3 
 
 
Pyrethroids are composed of two basic structural moieties, an acid and an alcohol 
(Elliot et al. 1965; Elliot 1969) (Fig 1.3).  For first generation pyrethroids, the acid portion is 
based on chrysanthemic acid, a cyclopropane ring bonded to a carboxylic acid moiety and a 
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variety of halogenated and non-halogenated substituents. Later developed pyrethroids, such 
as fenvalerate, do not have a cyclopropane ring.  The alcohol portion is either a primary or a 
secondary alcohol, which is bound to a variety of heterocyclic structures.  In addition, several 
of the pyrethroids have a cyano substituent bound to the α-methylene of the alcohol, which 
results in enhanced toxicity of the compound.  Pyrethroids lacking the α-cyano substituent 
are termed Type I compounds and the pyrethroids with the α-cyano substituent are termed 
Type II compounds.  Figure 1.3 shows the structures of a Type I pyrethroid, permethrin, and 
a Type II pyrethroid, cypermethrin. 
An important aspect of the chemical and toxicological properties of pyrethroids is 
their overall stereochemical configuration.  The cis- and trans- designation indicates how a 
substituent on carbon-3 of the cyclopropane ring is oriented in relation to the carboxylic acid 
group bound to carbon-1 (Figure 1.4).  Pyrethroids with the trans configuration and a 
primary alcohol (e.g., trans-permethrin) are hydrolyzed more readily by esterases than those 
with the cis configuration (e.g., cis-permethrin, deltamethrin).  This may explain in part the 
reason pyrethroids with the trans configuration demonstrate less mammalian toxicity than 
those with the cis configuration (Table 1.1). 
In a review of pyrethroid development and metabolism from early to newer, more 
potent pyrethroids, Soderlund (1992) describes how changes to the chemical structure of the 
pyrethrins and the pyrethroids not only affected their environmental stability, but also their 
metabolic stability.  The removal of unsaturated side chains from the pyrethrins (Fig 1.2) 
decreased chemical oxidation in the environment as well as enzymatic oxidation of the 
pyrethroids in animals.  Addition of the alpha-cyano group resulted in decreased hydrolysis 
of pyrethroids in the environment and by insect and mammalian esterases.  These changes 
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resulted in more potent and commercially viable pesticides produced.  The consequence of 
which is also more stable environmental contaminants which are more potent to mammalian 
species. 
 
 
Figure 1.3.  The structures of permethrin and cypermethrin. 
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Figure 1.4.  Structure of deltamethrin ((S)-alpha-cyano-3-phenoxybenzyl (1R)-cis-3-(2,2-
dibromovinyl)-2,2-dimethylcyclopropane carboxylate). 
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Table 1.1.  Acute oral toxicity of permethrin isomers in micea
. 
 
Compound Male Female 
Racemic Permethrin 490b 490 
cis permethrin 107 85 
trans permethrin 3100 3200 
    aData from Miyamoto (1976) 
    bLD50, mg/kg 
 
 
MAMMALIAN TOXICITY OF PYRETHROIDS 
 
The pyrethroids are a class of excitatory neurotoxic chemicals whose insecticidal and 
mammalian effects are thought to be primarily the result of modulation of nerve axon voltage 
gated sodium channels by the parent chemical.  Numerous studies exist and multiple reviews 
have been written on the subject (Narahashi 1982 and 1985; Vijverberg and Van Den 
Bercken 1982 and 1990).  Recently, Smith et al. (1997) demonstrated that point mutations in 
a house fly sodium channel result in loss of susceptibility to pyrethroids.  The interaction of 
the parent chemical with the sodium channel alters the normal gating kinetics of the sodium 
channel causing varied firing patterns in the nervous system leading to neurobehavioral 
alterations. The neurotoxic behaviors elicited by Type I pyrethroids in laboratory animals are 
aggression, hyperexcitability, fine tremor, prostration with coarse whole body tremor, 
increased body temperature, coma and death.  These neurobehavioral responses are termed 
the T-syndrome because of the fine tremors induced by the Type I pyrethroids (Gammon et 
al. 1981) (Lawrence and Casida 1982).  For Type II pyrethroids, the neurotoxic behaviors 
include pawing and burrowing, salivation, hyperexcitability, abnormal hind limb movements, 
coarse whole body tremor, sinuous writing or choreoathotosis, coma and death.  These 
neurobehavioral responses are termed the CS-syndrome for the choreoathotosis and 
salivation observed in laboratory animals (Gammon et al. 1981) (Lawrence and Casida 
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1982).    Some pyrethroids such as fenpropathrin and cyphenothrin may elicit mixed 
behaviors of the T- and CS-syndromes.  The T-and CS-syndromes are considered to be acute 
responses to exposure to pyrethroids and are dose-dependent.   
While there is a substantial body of evidence suggesting a prominent role of the 
sodium channels in the toxicity of Type I and II pyrethroids, uncertainties remain 
surrounding their mechanism(s) of toxicity particularly since there is also evidence that 
alterations of chloride, calcium and other channels by pyrethroids may also play a role in the 
toxicity of these chemicals.  Moreover, the pyrethroid sodium channel binding site has not 
been identified.  Type I and II pyrethroids are believed to slow the activation (opening) and 
the inactivation (closing) of the sodium channels.  These delays in opening and closing of the 
sodium channel prolong the sodium current.  The length of this current is dependent on 
whether the chemical is a Type I or Type II pyrethroid.  The Type I pyrethroids open the 
channel just long enough to cause a repetitive firing of the neuron.  The Type II pyrethroids 
hold the channel open long enough so that the neuron becomes depolarized and no longer 
fires (Soderlund et al., 2002; Ray and Fry, 2006). 
The induction of neurotoxic effects of pyrethroids in laboratory animals is largely 
dependent on the distribution of the pyrethroid into the CNS.  White et al. (1976) examined 
brain concentrations of cismethrin and bioresmethrin after an oral dose and reported 
threshold concentrations in the brain necessary to induce signs of pyrethroid toxicity.  
Rickard and Brodie (1985) utilized IP injection of deltamethrin, and extensive tissue 
concentration time profiles in the brain and found a correlation between the onset of the 
different symptoms of pyrethroid intoxication and brain concentrations.  Threshold 
concentrations of deltamethrin required for each symptom were identified and symptoms 
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persisted as long as the threshold brain concentration was maintained (Rickard and Brodie 
1985).  With direct injection of deltamethrin and cismethrin into the central nervous system 
the characteristic symptoms of pyrethroid intoxication are evident (Gray and Rickard 
(1982a).  Based on these data it is thought that the actions of the pyrethroid parent chemical 
within the central nervous system are the principal mode of action for pyrethroid toxicity. 
Human toxicity data is very limited for the pyrethroids.  Gotoh et al. (1998) reported 
on a case of permethrin ingestion.  In this study a 59 year-old man ingested approximately 
600mL of a 20% permethrin emulsion in an apparent suicide attempt.  It was reported that 
there were no reported signs of clinical neurotoxicity.  It is unclear however how much of the 
ingested permethrin was absorbed into the systemic circulation as a portion of the ingested 
permethrin was recovered from the stomach of the individual.  He et al. (1989) compiled a 
review of 573 cases of pyrethroid poisoning (229 cases of occupational poisoning and 344 
cases of accidental poisoning) reported in the Chinese medical literature from 1983-1989.  
These cases included 325 deltamethrin, 196 fenvalerate, 45 cypermethrin, and 7 other 
pyrethroids poisonings.  In the most severe cases, ingestion of pyrethroids induced symptoms 
consistent with central nervous system excitation as disturbances in consciousness, 
convulsions, and seizures were apparent.  In less severe cases following occupational 
exposures patients presented with abnormal facial sensations (burning, itching, or tingling 
sensations), muscular fasciculations, myopia, and other symptoms.  These symptoms indicate 
probable excitation of the peripheral nervous system (PNS) suggesting that the PNS is 
affected by pyrethroids.  The clinical effects of acute pyrethroid poisoning in humans 
describe a similar set of symptoms (He et al. 1989) to those seen in laboratory animals.  
Similar clinical effects suggest a similar mode of action across species.   
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  The similarities in laboratory animal studies and known human exposures indicate 
that there is likely a common mode of action across species for the pyrethroids.  The potency 
of individual pyrethroids, however, is determined by a combination of their 
pharmacodynamic and pharmacokinetic properties.  There are therefore numerous 
uncertainties in extrapolating the toxic potency of pyrethroids from laboratory animals to 
humans.   
There is currently little known about the pharmacodynamic cascade of events 
following the interaction of the pyrethroid with the nerve axon sodium channel.   How these 
events eventually lead to the symptoms of pyrethroid intoxication is unclear in laboratory 
animals and humans.   A better understanding of the pharmacokinetic determinants of 
pyrethroid potency, however, is available from studying pyrethroids in laboratory animals. 
 
 
PYRETHROID METABOLISM AND POTENTIAL IMPACT ON TOXIC POTENCY 
 
The rate of systemic clearance (metabolism) of a xenobiotic, from which toxic effects 
are the result of the parent compound, may influence its toxic potency.  More rapid 
metabolism can lead to lower target tissue concentrations.  Slower metabolism can lead to 
increased target tissue concentrations due to greater systemic availability of the parent 
compound. 
The potency of some pyrethroid isomers in mammals appears to be inversely related 
to the rate of metabolic elimination of the parent chemical (Abernathy and Casida 1973; 
White et al. 1976; Soderlund and Casida 1977).  Abernathy and Casida (1973) were the first 
to report that the rate of metabolism of pyrethroids might be directly correlated to differences 
in their potency.  Bioresmethrin, the trans-isomer of resmethrin, has an LD50 50 times higher 
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than its cis-isomer, cismethrin, and is metabolized in vitro approximately 10-times more 
rapidly in mice (Abernathy and Casida (1973).  Additionally the onset of neurobehavioral 
symptoms following exposure to cismethrin require brain concentrations only 5-8 times less 
than bioresmethrin to cause similar neurotoxic effects (White et al. 1976).  White et al. 
(1976) concluded based on these results, and the results of Abernathy and Casida (1973), that 
both pharmacodynamic and pharmacokinetic properties must play a role in the differential 
potency of these two pyrethroids, which differ only in their stereochemistry. 
The detoxification of a xenobiotic, whose parent form is the primary toxicant, can 
occur via a number of different pathways including phase I biotransformation pathways 
and/or phase II conjugation pathways.  The initial biotransformation of pyrethroids follows 
one of two phase I pathways, cytochrome P450 (P450) oxidation, or esterase hydrolysis and 
takes place primarily in the liver of mammals (Soderlund and Casida 1977).  These processes 
result in the production of numerous metabolites (Cole et al 1982; Crawford et al 1981a and 
b; Ruzo et al. 1978; Gaughan et al. 1976; Shono et al. 1979).  The terminal phase of 
pyrethroid metabolism is the formation of glucuronide and glycine conjugates (Cole et al. 
1982; Ruzo et al. 1978).  These pathways appear similar between laboratory animals and 
humans.  Common metabolites are found in the urine of both laboratory animals and humans 
(Cole et al. 1982; Heudorf and Angerer 2001). 
The rate and pathway of phase I biotrasfomation of pyrethroids is in part dependent 
on their chemical structure (Shono et al. 1979; Soderlund and Casida 1977; Ueda et al. 1975).  
The stereochemistry around the cyclopropane functional group of the acid moiety of 
pyrethroids directly impacts the pathways by which the initial biotransformation of a 
pyrethroid occurs.  Trans-isomers are more rapidly metabolized by hydrolytic (esterase) 
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pathways while cis-isomers are preferentially metabolized by slower oxidative (P450) 
pathways (Abernathy and Casida 1973; Shono et al. 1979; Soderlund and Casida 1977).  The 
previous discussed examples of the two resmethrin isomers and two permethrin isomers are 
good examples of this (Shono et al. 1979; Soderlund and Casida 1977).  This general trend of 
pyrethroid metabolism and toxicity is further confirmed by the studies of Soderlund and 
Casida (1977) in which the metabolism of numerous pyrethroids and pyrethroid analogs were 
examined.  For nearly every pyrethroid studied the cis-isomers were metabolized at slower 
rates by oxidative metabolism compared to the trans-isomers which were preferentially 
metabolized more rapidly by hydrolysis. The work on bioresmethrin and cismethrin, 
however, are the only studies that have attempted to correlate rates of metabolism with brain 
concentrations (Abernathy and Casida 1973; White et al. 1976).  Comparison of other 
pyrethroid potencies in relation to metabolic rates has utilized acute oral LD50 (administered 
dose) values as the dose metric for comparison (see Table 1.1 as an example).  Further 
examination of the relationship between metabolism and potency is therefore needed. 
A potentially important aspect in species extrapolation during risk assessment is 
understanding how individuals in a population may differ.  To understand how individuals in 
a population may differ in their ability to metabolize pyrethroids it would be helpful to 
understand individual enzymes that metabolize them. The expression and activity of 
individual P450s and esterase in the human population are available for some P450s and 
carboxylesterases (Hosokowa et al. 1995; Rodrigues 1999).  If an individual enzyme is 
responsible for the metabolism of a pyrethroid there is greater potential for significant 
variability in clearance rates within the population.  In contrast, if there are numerous 
enzymes capable of metabolizing a pyrethroid there is likely to be less variability in 
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clearance rates in the general population.  While the pathways that metabolize pyrethroids are 
fairly well understood in laboratory animals, and appear similar in humans, much less is 
known about the individual enzymes responsible for the biotransformation of the pyrethroids.   
Until recently there have been no reports on individual esterases or P450s, which 
metabolize the pyrethroids.  A recent study by Anand et al. (2006) briefly reported on the 
metabolism of deltamethrin by rat P450’s.  In this study CYPs 1A1, 1A2 and 2C11 were 
identified as P450s capable of metabolizing deltamethrin.   CYPs 2A1, 2A2, 2B1, 2C6, 
2C12, 2C13, 2D1, 2D2, 2E1, 3A1, and 3A2 were incapable of metabolizing deltamethrin.  
These experiments were done at a single saturating concentration.  CYP 1A1 and 1A2 
metabolized deltamethrin at a rate of approximately 9 and 13ng/pmole P450/min.  CYP 2C11 
metabolize deltamethrin at a rate of approximately 2ng/pmole P450/min. The activity of 
these enzymes however does not appear to account for the oxidative metabolism of 
deltamethrin observed in rat liver microsomes reported by Anand et al. (2006).  Rat CYPs 
1A1 and 1A2 are not highly expressed in the rat (Guengerich et al. 1982) or human liver 
(Rodrigues 1999) under basal conditions.  These P450s are therefore unlikely to be 
responsible for the metabolism of deltamethrin in the rat liver microsomes.  The observed 
rate of metabolism by CYP 2C11 accounted for elimination of approximately 2% of the mass 
of deltamethrin in the described assay conditions by Anand et al. (2006).  It is therefore 
unlikely that CYP2C11 alone is responsible for the metabolism of deltamethrin in rat liver 
microsomes.  Based on these results it is likely that we still do not know which P450s are 
responsible for the metabolism of the pyrethroids in rats.  There are currently no literature 
reports on the metabolism of pyrethroids by human P450s.    
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The hydrolytic metabolism of pyrethroids has been studied more extensively in recent 
years compared to the P450’s.  Esterases were previously identified as the enzymes which 
are responsible for the hydrolytic metabolism of pyrethroids (Abernathy and Casida 1973; 
Casida et al. 1975).  More recentlycarboxylesterases have been identified as the family of 
esterase which hydrolyze the pyrethroids in animals and humans (Shan and Hammock 2001; 
Stock et al. 2004).  These studies purified, cloned, and expressed two pyrethroid hydrolyzing 
carboxylesterases from mouse liver.  Huang et al. (2005) explored the hydrolysis of 
pyrethroid-like substrates by human, murine, porcine, and rabbit carboxylesterases.  These 
studies also further confirmed that the trans-isomer pyrethroid-like substrates were more 
rapidly metabolized as compared to their cis-isomer counterparts by purified esterases.   
Ross et al. (2006) also explored the hydrolysis of a number of pyrethroids by a rabbit 
carboxylesterase and two rat carboxylesterases, which all share greater than 80% homology 
in their amino acid sequence.  Each of these enzyme metabolized trans-permethrin more 
effectively than cis-permethrin.  In addition two cyano containing pyrethroids, deltamethrin 
and cis-cypermethrin, were metabolized by the rabbit esterase significantly slower than cis-
permethrin, which does not contain a cyano moiety (Ross et al. 2006).  This appears to verify 
that the cyano group further inhibits the hydrolysis of pyrethroids as was previously believed.   
Esterase hydrolysis of pyrethroids may also be important in the blood.  The blood of 
rats contains carboxylesterases (McCracken et al. 1993).  Anand et al. 2006 described the 
ability of the serum of rats to metabolize the pyrethroid deltamethrin.  Human blood however 
does not contain carboxylesterases (Li et al. 2005).  There is potentially a significant species 
differences in the metabolism of pyrethroids in the blood that could impact systemic 
concentrations of pyrethroids.  
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Limited work has focused on the human metabolism of pyrethroids.  Nishi et al. 
(2006) identified two human liver carboxylesterases, hCE-1 and hCE-2, which hydrolyze 
pyrethroids.  Ross et al (2006) also examined the metabolism of select pyrethroids by these 
human carboxylesteraes and found them capable of metabolizing pyrethroids. 
Choi et al.’s (2002) examined the metabolism of permethrin by human liver 
microsomes.  The extensive hydrolytic metabolism of trans-permethrin in rat and mouse liver 
microsomes (Shono et al. 1979; Soderlund and Casida 1977) is also evident in human liver 
microsomes (Choi et al. 2002).  This corresponds well with the observed metabolism of 
trans-permethrin by the human liver carboxylesterase (Nishi et al. 2006; Ross et al. 2006).  
The cis-isomer of permethrin, which is metabolized predominantly by P450’s in laboratory 
animals (Shono et al. 1979; Soderlund and Casida 1977), was not detectably metabolized in 
human liver microsomes in the presence or absence of an NADPH regenerating system (Choi 
et al. 2002).  This raises questions regarding species differences in oxidative metabolism of 
pyrethroids.  Is this due to species differences in the expression or catalytic ability of P450’s 
that metbaolize cis-isomer pyrethroids, the more potent isomer in laboratory animal studies?  
This would be of significant concern to human health as decreased metabolism of pyrethroids 
in humans could lead to increased exposure at the target tissue and therefore increased 
potency.  This lack of, or very slow, hepatic metabolism of cis-permethrin corresponds with 
blood concentration data obtained by Gotoh et al. (1998) from the permethrin emulsion 
intoxication case previously described.  The ingested emulsion mixture was approximately 
56% trans- and 44% cis-permethrin.  Examination of serum concentrations after ingestion 
revealed trans- and cis-permethrin were at 96 and 118ng/ml respectively upon admission of 
the patient.  These levels rose to 253 and 615ng/ml of trans- and cis-permethrin, respectively, 
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3 hours after admission. Trans-permethrin was then rapidly eliminated from the blood and 
was at undetectable levels after 25 hours, cis-permethrin however was still detectable after 10 
days.   
Because human pyrethoid toxicity appears to be mediated by the same mechanism of 
action as in laboratory animals, it is appropriate to hypothesize that there may be a 
relationship between metabolism and potency in humans as well.  In addition, the example of 
cis-permethrin demonstrates that there may be species differences in the metabolism of 
pyrethroids.  Such differences could impact target tissue dosimetry, and the potency of 
pyrethroids in humans as compared to laboratory animals.  This demonstrates that there is a 
need to further understand how human metabolism of pyrethroids compares to laboratory 
animals in pathway, rate of metabolism, and enzymes which metabolize the pyrethroids.  
Further understanding of these differences would help to reduce the uncertainties 
surrounding extrapolation of relative potencies of individual pyrethroids between laboratory 
animals and humans. 
 
ABSORPTION, DISTRIBUTION, ELIMINATION AND TOXICOKINETIC 
MODELING OF PYRETHROIDS 
 
Literature descriptions of the absorption, distribution, and metabolism/elimination of 
the pyrethroids vary widely in methods, chemicals utilized and data gathered.  The available 
data while incomplete for a single chemical may be taken as a whole to better understand the 
important determinants of pyrethroid tissue dosimetry.       
 
 
18 
Absorption 
Oral absorption is an area of great uncertainty with the pyrethroids and likely the least 
understood.  A number of different studies have identified large portions of oral doses 
unchanged in the feces (Cole et al. 1982; Ruzo et al 1978; Bosch 1990; Crawford et al. 
1981a,b).  This is possibly the result of limited solubility of the chemical in the 
gastrointestinal tract.  The pyrethroids are highly lipohillic chemicals with Log Kow values in 
the rage of 4-6.  Crofton et al. (1995) found that vehicle plays a role in the potency of 
pyrethroids, and this is likely due to the different absorption characteristics of each vehicle, 
altering the rate and amount of chemical entering the animal.  More recently Kim et al., 
(2007) conducted a set of bioavailability experiments with different vehicles in rats.  IV and 
oral dosing studies were conducted with two vehicles.  Deltamethrin was dissolved in 
glycerol formal or suspended in Alkamuls (formerly known as Emulphor®).  The soluble 
preparation of deltamethrin had higher peak blood concentrations and greater bioavailability 
of an oral dose (15% compared to 1.7%) (Kim et al. 2007).  These data underscore the 
importance of accurately describing absorption of pyrethroids as it can directly impact the 
toxic potency of the pyrethroid by affecting systemic concentrations. 
Other routes of exposure have not been thoroughly examined.  Dermal exposure has 
been found to lead to minimal systemic absorption of the pyrethroids (unpublished, Hughes 
et al.).  No known studies of inhalation exposure have been conducted. 
 
Distribution 
Marei et al (1982) examined the persistence of a number of pyrethroids in the fat and 
brains of rats.  Their findings indicate rapid disposition of the pyrethroids into both the brain 
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and fat with peak levels of pyrethroid within the first few hours after dosing.  The 
concentration of pyrethroid in fat was significantly higher than in the brain and persisted 
longer.  In addition pretreatment with metabolic enzyme inhibitors increased the disposition 
of trans-permethrin into the fat and brain; however this did not occur with cis-permethrin. 
A series of studies was conducted on toxicokinetics of deltamethrin and cismethrin in 
rats (Gray et al. 1980; Gray and Rickard 1981; Gray and Rickard 1982b).  Studies by Gray 
and Rickard (1981;1982) followed the disposition of deltamethrin after intravenous injection 
of a toxic dose.  Deltamethrin was rapidly distributed into all body tissues with the highest 
concentrations in fat (Gray and Rickard 1981).  An important finding of these studies was 
lower than expected brain concentrations of deltamethrin based on previous findings with 
cismethrin (Gray et al. 1980). Comparing equitoxic doses of cismethrin and deltamethrin all 
tissues examined except the brain had tissue concentration ratios equal to the dose ratio (Gray 
et al 1980; Gray and Rickard 1981).  This raises questions surrounding the impact of 
metabolism on distribution of pyrethroids to the brain.  If metabolic differences between 
deltamethrin and cismethrin were resulting in the differences in brain concentrations it would 
be expected that other tissue would be affected in a similar manner.   It was postulated that 
the difference in brain distribution were due to decreased blood-brain-barrier (BBB) 
permeability based on greater polarity of the deltamethrin molecule as compared to 
cismethrin (Gray and Rickard 1981).  The distribution of pyrethroids into the brain is not 
well understood and even though the pyrethroids are structurally similar compounds the 
differences in their metabolism clearly demonstrate that their interaction with biological 
molecules can be significantly different.  Distribution of pyrethroids into the brain may be 
affected by biological processes other than simple descriptions of diffusion from the blood. 
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Elimination 
Crawford et al. (1981a,b) and Gaughan et al. (1976) studied the in vivo fate of 
radiolabeled cypermethrin and permethrin respectively.  Cypermethrin and permethrin differ 
only in the presence of the alpha-cyano group on the cypermethrin molecule, and both are 
mixtures of cis- and trans-isomers.  Both chemicals had similar metabolic fates in vivo in 
which the trans-isomer was eliminated from the animals more rapidly than the cis-isomer.  In 
addition greater quantities of hydroxylated metabolites were identified from the cis-isomers 
and greater quantities of hydrolysis products were identified from the trans-isomers in direct 
correlation with in vitro studies of their metabolism.   
Cole et al. (1982) examined the in vivo fate of the pyrethroids tralomethrin, 
traolcythrin, deltamethrin, and cis-cypermethrin in rats orally dosed.  Greater than 70% of the 
dose of these pyrethroids was eliminated in the urine and feces in the first 24 hours.  
Radiolabeled pyrethroid was detectably eliminated in both urine and feces up to 7 days post 
dose (Cole et al. 1982).  Ruzo et al. (1978) conducted a similar study with deltamethrin.  Rats 
were dosed with three similar doses (0.64, 0.9, and 1.60 mg/Kg) each of which was 
radiolabled in a different position of the pyrethroid molecule.  In this study greater than 80% 
of the doses were eliminated from the rat within the first 24 hours with detectable levels of 
radiolabel also evident for up to 8 days in the urine and feces.  Radiolabel detected in the 
urine was that of metabolites only, no parent chemical was identified in the urine.  Parent 
deltamethrin and small amounts of hydroxylated deltamethrin metabolites were found in the 
feces.  Crawford et al. (1981a) found approximately 1% of the total radioactivity of an oral 
dose of cypermethrin in the bile of rats.  Crawford et al. (1981b) also identified small 
amounts of hydroxylated cypermethrin in the feces of rats.  Biliary elimination of 
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hydroxylated metabolites prior to their hydrolytic cleavage likely accounts for the 
identification of hydroxylated metabolites of cypermethrin and deltamethrin in feces. 
Bosch et al. (1990) also studied the urinary and fecal excretion of deltamethrin in rats.  
Two doses, 0.55 mg/kg and 5.5 mg/kg, were utilized.  Between 17 and 35% of the dose was 
found unchanged with only trace levels of hydroxylated metabolites identified in the feces 
indicating incomplete absorption of deltamethrin.  Dose dependency of absorption of 
deltamethrin is potentially apparent in this study as fecal excretion of the 0.55 mg/kg dose 
averaged 26% of the dose in male and female rats while excretion of the 5.5 mg/kg dose 
averaged 36% of the dose (Bosch 1990).  Urinalysis indicated only hydrolyzed metabolites of 
deltamethrin were excreted in the urine. 
 
Toxicokinetic Modeling 
Anadon et al. (1991,1996) published limited toxicokinetic studies of permethrin and 
deltamethrin in rats.  Deltamethrin and permethrin were rapidly absorbed with peak tissue 
concentrations occurring within hours similar to previous reports (Cole et al. 1982; Crawford 
et al. 1981).  Anadon et al.’s (1991,1996) toxicokinetic modeling of deltamethrin and 
permethrin were fitted to two compartment models where maximal plasma concentrations 
were reached after 2-4hrs with elimination half lives of 38hr and 12hr respectively.  Volume 
of distribution was reported by Anadon et al. (1991, 1996) for permethrin at 1.7 L while the 
value for deltamethrin was calculated as 5.33 L.  Bioavailability of the parent chemical was 
significantly different for these two chemicals as well.  Bioavailability of permethrin was 
reported to be 60% while it was only 15% for deltamethrin.  These differences may be 
indicative of a number of differences in the pharmacokinetics of these two pyrethroids even 
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though they are structurally similar chemicals.  Differences in absorption, distribution, and 
metabolism of these two chemicals may be responsible for the observed differences. 
A PBPK model of deltamethrin has recently been developed in the rat by 
Mirfazaelian et al. (2006).  This model revealed continued uncertainties in the modeling of 
deltamethrin which if addressed may increase confidence in species extrapolation.  The 
model of Mirfazaelian et al. (2006) required a saturable efflux process to describe fecal 
excretion in which a greater percentage of an oral dose was absorbed at higher doses.  This is 
contrary to published data regarding fecal excretion of pyrethroids.  The work of Bosch 
1990; Cole et al., 1982; Ruzo et al., 1978  show that varying amounts of deltamethrin 
(between 15-35%) are excreted unchanged in the feces of male rats with no clear dose 
dependency in the results. 
The PBPK model of Mirfazaelian et al. (2006) however also make clear some of the 
major uncertainties involved with modeling of pyrethroids.  As with previous studies 
distribution of deltamethrin into the brain was low with brain-blood ratios of less than one.  
This again raises questions about the influence of the BBB permeability, the possibility of 
export transporters along the BBB, and the impact of metabolic rate on brain concentrations.  
The model also does not describe the tissue time course of the liver.  Understanding the 
distribution of the chemical in the liver may be important in determining the appropriate 
structure of the model.  The importance of metabolic differences between chemicals would 
be greater in a model of a flow limited liver compartment as compared to a diffusion limited 
liver compartment.  This could play a significant role in understanding how species 
differences in the metabolism of a pyrethroid may affect exposure-dose relationships 
between rats and humans. 
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Based on the available data it appears evident that the pyrethroids are rapidly, 
however incompletely, absorbed.  They rapidly distribute throughout the body with the 
greatest disposition in the fat.  There appear to be multiple factors that can play a role in 
determining exposure dose relationships in the brain in rats including, extent of absorption, 
rate of metabolic elimination and the ability of the chemical to penetrate the blood brain 
barrier. 
Very little is known about the human kinetics for pyrethroids.  The study of blood 
concentrations from an accidental exposure to a permethrin mixture by Gotoh et al. (1998) is 
the only published literature on the subject.  This study reveled that trans-permethrin was 
rapidly eliminated from the blood while cis-permethrin was eliminated very slowly.  How 
this might relate to the toxicokinetics of other cis-isomer pyrethroids in humans, typically the 
more toxic isomers, is unknown.  It is clearly important to understand as much as possible 
about toxicokinetic similarities/differences between species to most accurately extrapolate 
dose response data in a risk assessment. 
 
THE USE OF UNCERTATINTY/SAFETY FACTORS AND PBPK MODELING FOR 
SPECIES EXTRAPOLATION IN RISK ASSESSMENT 
 
Risk assessment consists of four parts; hazard identification, dose-response 
assessment, exposure assessment, and risk characterization.  With little to no human data 
typically available for environmental chemicals, animal data and default uncertainty/safety 
factors are routinely utilized in human health risk assessment to extrapolate dose response.  
The use of uncertainty or safety factors has been utilized in human health risk assessment for 
over 30 years (Renwick and Lazarus 1998).  They have been utilized to convert no-observed-
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adverse-effect levels (NOAEL) for noncancer end points into human intake levels that are 
believed to be “without appreciable health risk” (Renwick and Lazarus 1998; WHO, 1987).  
NOAELs are generally determined through appropriate animal studies and human reference 
doses are established by applying various uncertainty factors.  The 1987 World Health 
Organization’s (WHO) Environmental Health Criteria (EHC vol 70) recommends a safety 
factor of 100 for extrapolation of an animal NOAEL.  The 100 factor for uncertainty in 
species extrapolation can be broken down into a factor of 10 for interspecies differences and 
10 for inter-individual differences in the human population (WHO, 1987).  Uncertainty 
factors are also added due to reliance on acute instead of chronic studies, database 
inadequacy, and for conversion of lowest-observed-adverse-effect level (LOAEL) to a 
NOAEL (Andersen 1995: Renwick and Lazarus 1998).  Uncertainty factors however are 
used irrespective of the species used in the animal studies (Schneider et al. 2004).  Further 
safety factors can also be added based on risk to susceptible populations such as children or 
the elderly. 
More recently an appreciation for the use of pharmacokinetic and pharmacodynamic 
data which may augment or refine the understanding of species differences have been shown 
to be able to displace some of the uncertainty in risk assessment (Andersen 1995; Renwick 
and Lazarus 1998).  The 10 fold factors each for inter-species extrapolation and inter-
individual variability can be broken down into individual components for toxicodynamics 
and toxicokinetics to account for available data (Barnes and Dourson 1988; Renwick 1993).  
Thus, if data were available to better inform about species differences in a risk assessment a 
portion of the uncertainty factor may be removed.  In WHOs 1994 EHC vol. 170 this 
paradigm was accepted and it was stated that “In situations where appropriate toxicokinetic 
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and/or toxicodynamic data exist for a particular compound, then the relevant uncertainty 
factor should be replaced by the data derived factor”. 
The need for better methods of extrapolating equivalent doses by predicting target 
tissue dose across species, including humans, has lead to the development and use of PBPK 
models in risk assessment.  PBPK models utilize physiological and biochemical parameters 
from both the test species and humans to describe the differences in the disposition of a 
chemical at the target site.  While changes in physiological parameters across species are 
independent of chemical a number of parameters are chemical dependent.  It is necessary to 
determine differences in biochemical parameters such as absorption, metabolism, and 
excretion in both the test species and humans in order to more accurately extrapolate tissue 
dosimetry.  PBPK models have been utilized to improve species extrapolation of equivalent 
dose in dose-response assessments for previous human health risk assessment.  An example 
of which is the use of a PBPK model to assess the risk of exposure to methylene chloride 
(Andersen et al. 1987).  The use of the PBPK model showed that the default methods of 
applying uncertainty factors overestimated the risk to humans from methylene chloride by 
100-200-fold (Andersend et al. 1987).  PBPK models have also been utilized in risk 
assessments for vinyl chloride, and 2-butoxyethanol (Clewell et al. 2002).  Combined with 
animal studies these models were able to provide more accurate assessments of the risks to 
humans from exposure to these chemicals as compared to the use of default uncertainty 
factors.   
PBPK modeling is also a tool that unlike uncertainty factors can be used to predict 
internal dose based on different exposure scenarios across species including humans 
(Andersen 2005).  If an understanding of the appropriate biochemical and physiological 
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parameters is available in the test species and humans a PBPK model can be utilized.  This 
allows an assessment of how species differences in pharmacokinetic parameters may effect 
the calculation of an equivalent dose based on a target tissue concentration.  PBPK modeling 
also allows for a possible examination of how population variability in PK parameters could 
lead to susceptible populations.  For example if there is considerable variability in the human 
population with respect to the expression or activity of a metabolizing enzyme (due to 
genetic variability, age, life style, other environmental exposures) which is responsible for 
the metabolism of a xenobiotic a portion of the population may be more or less susceptible to 
an exposure.  
Important to understanding population susceptibility and the risks that are posed to 
the human population from an environmental contaminant is an understanding of human 
exposure.  Understanding who is exposed to an environmental contaminant (general 
population, occupational groups, children, elderly) and by which route is important for not 
only identifying who is at the greatest risk from exposure, but what the appropriate method 
for modeling that exposure will be.  
 
HUMAN EXPOSURE AND CURRENT REGUULATION OF PYRETHROIDS 
 
Pyrethroids are used in the protection of a wide range of commercial crops, 
ornamentals, and trees.  In addition, they are used in domestic insect control and are 
ectoparasiticides in both human and veterinary medicine (Roberts and Hutson 1999).  Due to 
their numerous uses and increasing use world wide the potential for ubiquitous human 
exposure to pyrethroids exists.  Evidence of this is seen in exposure studies of both 
occupational cohorts (Zhang et al. 1991) (Smith et al. 2002) and the general population.  
Heudorf and Angerer (2001), and Schettgen et al. (2002) found chemical residues of multiple 
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pyrethroid pesticides in human urine samples in urban populations of individuals with no 
known use exposure.  Schettgen et al. (2002) propose that the majority of this exposure is due 
to oral intake of pyrethroid residues in the daily diet.  The USDA’s pesticide data program 
(PDP) demonstrates the presence of pyrethroids in a variety of foods at part per billion and 
part per million concentrations.  In addition the CDC’s Third National Report on Human 
Exposure to Environmental Chemicals details human exposure to pyrethroids utilizing data 
from the National Health and Nutritional Examination Survey (NHANES), which also 
reports urinary levels of pyrethroid metabolites.  These studies indicate that humans are 
exposed to a variety of pyrethroid pesticides by both occupational, direct use, and dietary 
means.  The major route of exposure to pyrethroids is expected to be orally through dietary 
and hand to mouth exposure and should be the focus of risk assessment efforts.   
Previously the pyrethroids have been regulated on a single chemical basis utilizing 
default uncertainty factors to arrive at human equivalent doses or references doses.  
Deltamethrin for example has a rat no observable adverse effect level (NOAEL) of 1 mg/kg.  
This has been extrapolated to a safe human exposure level by the United States 
Environemental Protection Agency (USEPA) by dividing by 100 (a 10 fold factor for species 
difference and a 10 fold factor for human population variability).  This yields a human 
reference dose (RfD) calculation of 0.01mg/kg/day for deltamethrin (Federal Register 2004). 
The 1996 food quality protection act (FQPA) mandated that the USEPA conduct 
cumulative risk assessments of environmental chemicals that act by a common mechanism of 
toxicity.  The EPA defines common mechanism of toxicity as “…substances that cause a 
common toxic effect to human health by the same, or essentially the same, sequences of 
major biochemical events.  Hence, the underlying basis of the toxicity is the same, or 
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essentially the same, for each chemical.”  (EPA 2002).  The neurotoxic actions of all 
pyrethroids are primarily the result of the interaction of the parent chemical with nerve axon 
sodium channels in mammals.  There is limited evidence that other biochemical pathways 
may be involved in the neurobehavioral toxicity of pyrethroids, including interactions with 
calcium, chloride and GABA channels in the central nervous system (see review by 
Soderlund et al 2002).  However because the preponderance of evidence points to the sodium 
channel as the primary biochemical pathway by which the pyrethroids induce their toxicity 
they are currently under evaluation to assess if they can be considered  in a common 
mechanism group of chemicals. 
Research is thus needed to aid a potential risk assessment.  Work which includes 
understanding of mixture neurtoxicology, whether these chemicals act dose additively or not, 
as well as mixture pharmacokinetics will be useful.  Understanding mixture 
pharmacokinetics however necessitates an understanding of individual pyrethroid 
pharmacokinetics. 
CURRENT RESEARCH NEEDS 
 
While there is a large volume of literature on the toxicity and metabolic fate of 
pyrethroids in animals, it is unknown how this translates to human risk.  It would be 
beneficial to risk assessors to have a better understanding of pyrethroid pharmacokinetics 
between species to better extrapolate relative potencies. In the absence of human data the 
optimal way to conduct a species extrapolation is the use of PBPK models that can 
quantitatively describe differences in the pharmacokinetics and tissue dosimetry of 
pyrethroids across species. 
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As described above (Fig 1.1), the parallelogram approach to species extrapolation is 
the most desirable method for developing a PBPK model in the absences of human data.  A 
PBPK model can be utilized in a risk assessment in the absences of actual human derived 
data to calculate equivalent dose.  The steps to developing a PBPK model through the 
parallelogram approach include.  (1) Developing a hypothesis based model that includes 
descriptions of the proposed PK determinants of disposition (tissue dosimetry).  (2) 
Determining the influence of PK determinants (rodent in vitro) on a surrogate mammalian 
system in the proposed PBPK model.  This can be done by examining the tissues, pathways, 
rates, and enzymes responsible for the metabolism of the pyrethroids. (3) Comparing 
important PK parameters in the human and a surrogate mammalian system.  Conduct parallel 
experiments in available rat and human tissue fractions.  (4) incorporate in vitro human 
parameters into a PBPK model with pertinent human anatomical/physiological data. 
A PBPK model of pyrethroid exposure needs to be able to describe the absorption, 
distribution, metabolism/elimination of the toxicant (the parent chemical for pyrethroids).  
Based on the current knowledge of pyrethroids the following hypothesis driven model can be 
identified.  Human exposure estimates suggest the oral exposure pathway appears to 
dominate as the primary route of exposure, thus the gastrointestinal tract, the rate of 
absorption, and the percent parent chemical absorbed (or fecal elimination) will be important 
model parameters.  Liver and adipose tissue should be included in the model as organs 
involved in the metabolism and distribution of the pyrethroids, respectively.  Metabolism 
must be understood in both the mammalian surrogate (the rat) and humans to properly 
extrapolate a PBPK model.  The effects of pyrethroids on the CNS appear to mediate the 
neurotoxicity. There is however suggestive evidence that the PNS may also be involved in 
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the neurotoxicity.  Based on the current understanding of the mode of action, the model 
should include a CNS tissue compartment (brain compartment), as a likely target tissue.  
Since the PNS is a rather diffuse system and the exact site of action of pyrethroids on this 
system is uncertain, blood concentrations may be an adequate surrogate for this tissue.  
Understanding both blood and brain concentrations will enable identification of an 
appropriate dose metric if the PBPK model is combined with a model of pyrethroid 
pharmacodynamics in a risk assessment.  The inclusion of additional compartments such as 
rapidly and slowly perfused tissue may be necessary to further describe the disposition of the 
pyrethroids throughout the body.  The description of model compartments as either flow or 
diffusion limited, particularly the brain and liver compartments, is important to 
understanding the influence of metabolism on brain concentrations and therefore toxic 
potency. 
In addition to extrapolation of dose response, understanding human population 
variability is also an important variable in a population based risk assessment.  There is 
currently little to no data regarding which individual enzymes metabolize the pyrethroids.  A 
comparison of the enzymes that metabolize the pyrethroids between species may aid the 
understanding of how factors that influence the expression and activity of metabolizing 
enzymes may impact the toxic potency of the pyrethroids across a population.  This may aid 
in elucidating potential variability in the human population and possibly identify susceptible 
populations.  In addition knowledge of the enzymes that metabolize the pyrethroids will aid 
in the understanding of potential pharmacokinetic interactions at the level of metabolism in a 
cumulative risk assessment as well as in concomitant exposure with other environmental 
contaminants. 
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HYPOTHESIS, SPECIFIC AIMS, AND CONTENT OF DISSERTATION 
 
While a general review of pyrethroids has been presented here, this dissertation 
focuses on the pharmacokinetics of two pyrethroids, deltamethrin and esfenvalerate. These 
two pyrethroids were chosen for the following reasons; (1) They are both single isomer 
pyrethroids, (2) and are two of the most potent pyrethroids based on oral LD50 in rats and 
mice. (3) They have consistently been identified in human exposure assessments, and (4) 
initial experiments showed that they displayed species differences in their metabolism 
between rats and humans that would allow valuable comparisons to be made. 
The working hypothesis of this dissertation is that the clearance of pyrethroids from 
the liver will drive blood concentrations of pyrethroids and therefore impact brain 
concentrations and potency of pyrethroids.  The specific aims of this research are to; (1) 
Explore the hepatic metabolism of deltamethrin and esfenvalerate to understand differences 
in rates and pathways of clearance in rats and humans, (2) examine rat and human 
extrahepatic tissues for their ability to metabolize these pyrethroids, (3) determine the 
enzymes responsible for the metabolism of deltamethrin and esfenvalerate in rats and 
humans, (4) develop a PBPK models of exposure to deltamethrin in the rat, and (5) 
extrapolate the rat PBPK model to a human PBPK model which can be used to derive human 
equivalent doses based on target tissue dosimetry. 
 Chapter II of this dissertation was based on the hypothesis that hepatic metabolism is 
similar between rats and humans.  Results however identified species differences in the 
hepatic metabolism of deltamethrin and esfenvalerate.  Also included in chapter II is a 
comparison of rat and human carboxylesterases.  The ability of rat and human hepatic 
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carboxylesterase to metabolize deltamethrin and esfenvalerate were examined in an effort to 
elucidate the mechanisms behind the observed species differences. 
 Chapter III focuses on understanding the role of oxidative metabolism in the species 
differences in the hepatic metabolism of deltamethrin and esfenvalerate.  The hypothesis was 
that different rat and human P450s metabolize these two pyrethroids based on the species 
difference observed in chapter II.  Also included in chapter III is an examination of the 
metabolism of deltamethrin and esfenvalerate by rat and human serum and serum esterases to 
explore potential species differences. 
 Chapter IV explores the working hypothesis that the rate of hepatic metabolism will 
drive blood concentrations and therefore brain concentrations influencing the toxic potency 
of deltamethrin between rats and humans.  A PBPK model was developed for rats and 
extrapolated to humans to examine this hypothesis. 
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ABSTRACT 
 
Pyrethroids are neurotoxic pesticides whose pharmacokinetic behavior plays a role in 
their potency.  This study examined the elimination of esfenvalerate and deltamethrin from 
rat and human liver microsomes.  A parent depletion approach in the presence and absence of 
NADPH was utilized to assess species differences in biotransformation pathways, rates of 
elimination, and intrinsic hepatic clearance.  Esfenvalerate was eliminated primarily via 
NADPH-dependent oxidative metabolism in both rat and human liver microsomes.  The 
intrinsic hepatic clearance (CLINT) of esfenvalerate was estimated to be three- fold greater in 
rodents than in humans on a per kg body weight basis.  Deltamethrin was also eliminated 
primarily via NADPH-dependent oxidative metabolism in rat liver microsomes; however, in 
human liver microsomes, deltamethrin was eliminated almost entirely via NADPH-
independent hydrolytic metabolism.  The  CLINT for deltamethrin was estimated to be two-
fold more rapid in humans than in rats on a per kg body weight basis.  Metabolism by 
purified rat and human carboxylesterases (CEs) were utilized to further examine the species 
in hydrolysis of deltamethrin and esfenvalerate.  Results of CE metabolism revealed that 
human carboxylesterase 1 (hCE-1) was markedly more active towards deltamethrin than the 
class 1 rat CEs Hydrolase A and B and the class 2 human CE (hCE-2); however, Hydrolase 
A metabolized esfenvalerate 2-fold faster than hCE-1, while Hydrolase B and hCE-1 
hydrolyzed esfenvalerate at equal rates.  These studies demonstrate a significant species 
difference in the in vitro pathways of biotransformation of deltamethrin in rat and human 
liver microsomes, which is due in part to differences in the intrinsic activities of rat and 
human carboxylestersases. 
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INTRODUCTION 
  
Pyrethroids are synthetic analogues of the natural pyrethrins, the insecticidal 
components of extracts from the pyrethrum flower (Chrysanthemum cinerariaefolium).  The 
pyrethroids modulate nerve axon sodium channels, resulting in neurotoxic effects (Narahashi 
1982; Smith et al., 1997).  The adverse effects produced by pyrethroids are due to the parent 
compounds in that no evidence currently exists that pyrethroid metabolites alter sodium 
channels and are neurotoxic.  For the limited number of pyrethroids evaluated, the brain 
concentrations of pesticide appear to correlate with acute neurotoxicity (Rickard and Brodie, 
1985; White et al., 1976).  Pharmacokinetic parameters, particularly clearance of the parent 
chemical from the blood, will influence the effective concentration in the brain and therefore 
can have a significant influence on their toxic potency.  
The metabolic pathway and rate of phase I biotransformation of pyrethroids is 
dependent upon their chemical structure and stereochemistry (Shono et al., 1979; Soderlund 
and Casida, 1977; Ueda et al., 1975).  In laboratory animals, different metabolic pathways 
preferentially transform cis- and trans- isomers of pyrethroids; trans-isomers are typically 
transformed by the more rapid hydrolytic pathways, while cis-isomers are preferentially 
transformed by slower oxidative pathways (Shono et al., 1979; Soderlund and Casida, 1977).  
This difference correlates with the greater toxicity of several cis-isomers of individual 
pyrethroids (Soderlund et al., 2002).  For example, cismethrin is about 50 times more acutely 
toxic in mice than its trans-isomer, bioresmethrin, when based on administered dose.  This is 
due in part to the approximate 10-fold greater rate of metabolism of bioresmethrin than 
cismethrin (Abernathy and Casida, 1973).   
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Species differences in the contributions of hydrolytic and oxidative pathways to the 
metabolism of pyrethroids exist between mice and rats (Shono et al., 1979; Soderlund and 
Casida, 1977).  For example, trans-permethrin is metabolized predominately by hydrolytic 
metabolism in rats.  In contrast, both oxidative and hydrolytic pathways contribute to trans-
permethrin metabolism in mice (Shono et al., 1979; Soderlund and Casida, 1977).  For cis-
permethrin, oxidative metabolism is 3- and 8-fold greater than hydrolysis in rats and mice, 
respectively (Shono et al., 1979).  While there are numerous studies that have examined 
laboratory animal metabolism of pyrethroids, there are relatively few examples of human 
metabolism of pyrethroids (Choi et al., 2002; Nishi et al., 2006; Ross et al., 2006).  In these 
studies, the extensive hydrolysis of trans-permethrin in rat and mouse liver microsomes 
(Shono et al., 1979; Soderlund and Casida, 1977) and by mouse carboxylesterases (Stok et 
al., 2004) was also evident in human liver microsomes (Choi et al., 2002; Ross et al., 2006).  
For cis-permethrin however, Choi et al. (2002) reported that there was no detectable 
oxidative or hydrolytic metabolism in human liver fractions (Choi et al, 2002).  Ross et al. 
(2006) observed limited hydrolysis of cis-permethrin in human liver microsomes as 
compared to rat liver microsomes.  Ross et al., (2006) and Nishi et al. (2006) also reported 
limited hydrolysis of cis-permethrin by purified human carboxylesterases.  These results with 
cis-permethrin show that species differences in pyrethroid metabolism may exist between 
laboratory animals and humans.  Differences in pathways or rates of metabolism of 
pyrethroids between species could lead to altered systemic bioavailability, exposure dose 
relationships, and toxic potency for a pyrethroid.   
The present study examines the potential for species differences in the phase I 
biotransformation of two pyrethroids, deltamethrin and esfenvalerate (Fig 2.1).  Rat and 
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human liver microsomes were used to compare the contribution of oxidative and hydrolytic 
pathways of metabolism between species.  These two pathways are the primary known 
mechanisms of pyrethroid detoxification; no evidence exists that conjugative or reductive 
mechanisms of parent pyrethroid are involved.  In laboratory animals there are numerous 
metabolites (Roberts and Hutson 1999) of deltamethrin and esfenvalerate likely produced by 
a number of enzymes including multiple cytochrome P450’s (Anand et al. 2006) (Dayal et al. 
2003) and esterases (Ross et al. 2006; Nishi et al. 2006).  Therefore, liver microsomes 
represent a simple method of comparing the phase I detoxification step in pyrethroid 
metabolism between species.  Since phase I biotransformation of a pyrethroid is the 
detoxification step, it allows the use of the parent depletion approach to examine hepatic 
elimination and estimate intrinsic clearance (Obach 1999).  For the purposes of this 
manuscript, the term elimination is synonymous with metabolism or biotransformation.  
Based on results obtained with liver microsomes, purified enzyme preparations of rat and 
human carboxylesterases were also utilized in this research to better understand observed 
differences in rat and human metabolism of these two pyrethroids. 
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MATERIALS AND METHODS 
 
Chemicals  
Deltamethrin (98.9% purity) ((S)-alpha-cyano-3-phenoxybenzyl (1R)-cis-3-(2,2-
dibromovinyl)-2,2-dimethylcyclopropane carboxylate) was a gift from Bayer Crop Sciences 
(Research Triangle Park, NC USA).  Esfenvalerate (98.6% purity) (cyano-3-phenoxybenzyl 
(αS)-2-(4-chlorophenyl)-3-methylbutyrate) was a gift from Dupont (Johnston, IA USA).  
These chemicals were used in the microsomal elimination studies.  Bifenthrin and 
tetraethylpyrophosphate (TEPP) were obtained from ChemService Inc (West Chester, PA).  
Deltamethrin (> 98%) and esfenvalerate (>98%) used for the in vitro carboxylesterase 
kinetics studies were obtained from ChemService Inc (West Chester, PA).  LC/MS analysis 
of pyrethroids from the different sources did not reveal any differences in their chemical 
composition.  Chromasolv® acetonitrile and methanol for LC/MS applications were from 
Riedel-de Haën (Seelze, Germany).  Ammonium formate, sucrose, EDTA, KCl, NaHepes, 
glycerol, dithiothreitol (DTT), Trizma-base, β-nicotinamide adenine dinucleotide phosphate 
reduced form (NADPH), and 3-phenoxybenzaldehyde were purchased from Sigma-Aldrich 
(St. Louis, MO USA).  Unless otherwise specified chemicals were of the highest grade 
commercially available.  
 
Animals 
All animal procedures were approved by the USEPA National Health and 
Environmental Effects Research Laboratory Institutional Animal Care and Use Committee.  
Male Long Evans rats (70 days old) were obtained from Charles River Laboratory (Raleigh, 
NC USA).    Animals were allowed to acclimate for a minimum of four days in an 
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Association for Assessment and Accreditation of Laboratory Animal Care approved animal 
facility prior to their use.  Two animals were housed per plastic cage (45 cm x 24 cm x 20 
cm) with heat-treated pine shavings bedding.  Animals were maintained at 21-±2°C, 50 ± 
10% humidity and a photoperiod of 12L:12D (0600-1800 hr).  Feed (Purina Rodent Chow 
5001, Barnes Supply Co., Durham, NC USA) and tap water were provided ad libitum.  
 
Rat liver microsomal preparation 
Animals were anesthetized with CO2 and sacrificed via cardiac puncture.  Livers were 
removed for microsomal preparation according to the method described by DeVito et al 
(1997).  Three separate pools of rat liver microsomes were prepared.  Each pool was 
prepared from the livers of two rats.  From each pool of microsomes 1.0 mL aliquots were 
flash frozen in liquid nitrogen and stored at -80°C until use.  Microsomal protein (MSP) 
content was quantified using the Bio-Rad Bradford protein assay (Bio-Rad, Hercules, CA 
USA) standardized with bovine serum albumin. 
  
Human microsomes 
 Pooled human liver microsomes were purchased from CellzDirect (Phoenix, AZ 
USA) (Lot# HMMC-PL020), Cedra (Austin, TX USA) (Lot#821-1), and Xenotech (Lenexa, 
KS USA) (Lot#0310241).  These microsomes were stored at -80°C until use. 
 
Determination of Km apparent (Kmapp) in rat and human liver microsomes  
To ensure that the elimination assays (see below) were performed at concentrations 
<<Kmapp, estimates of the Kmapp for deltamethrin and esfenvalerate elimination in rat and 
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human liver microsomes were determined using a single microsomal sample from each 
species.  The reaction volume was 1.5 mL and consisted of 0.1 M Tris (pH 7.4), 1.0 mg 
MSP/mL and 1.0 mg NADPH /mL.  Following preincubation for 10 min at 37 °C, the 
reaction was initiated by the addition of 60 µL of working stock solutions of deltamethrin or 
esfenvalerate dissolved in 50% acetonitrile solution to obtain final assay concentrations of 1, 
2, 5, 7, 10, 20, and 50 µM pyrethroid. Pilot studies demonstrated that this percentage of 
acetonitrile did not to interfere with oxidative or hydrolytic metabolism in these assays (data 
not shown).  Assays were carried out in duplicate in a shaking water bath and 250 µL 
aliquots of the reaction mixture were removed from the reaction vial at 0, 2.5, 5.0, 7.5 and 
10.0 min.  These time points were previously found to be in a linear range of elimination of 
deltamethrin and esfenvalerate (data not shown).  Aliquots were immediately placed in 1.25-
ml cold 50% ACN containing 0.1 mg/ml bifenthrin (internal surrogate of recovery) to stop 
the reaction.  Samples were vortexed for 5 min and centrifuged at approximately 1,500 x g 
for 10 min.  The supernatant was removed and placed in autosampler vials for LC/MS/MS 
analyses (see below).  Non enzymatic controls were performed in the Tris buffer in the 
absence of microsomal protein to ensure all elimination of chemical was enzymatic.  
Concentration of substrate was monitored over the time course and converted to moles of 
substrate remaining.  Substrate remaining was converted to product formed and plotted vs. 
time to produce a reaction velocity.  Kmapp values in rat and human liver microsomes were 
estimated for deltamethrin with Lineweaver-Burk linear regression analysis from GraphPad 
Prism (v 4.0, GraphPad Software, San Diego California, USA).  The 50 uM reactions appear 
to be approaching maximal elimination rates.  However, because a clear maximum was not 
defined, a Lineweaver-Burk analysis was utilized for deltamethrin analysis.  The Kmapp in rat 
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and human microsomes for esfenvalerate were estimated with Graph Pad Prism software 
using Michaelis-Menten nonlinear regression analysis. 
 
Rat and human microsomal elimination assays 
Microsomal elimination assays with deltamethrin and esfenvalerate were carried out 
using the parent depletion approach described above.  Briefly, 1uM pyrethroid was found 
from kinetic studies to be below the Kmapp for both deltamethrin and esfenvalerate 
elimination from both rat and human liver microsomes.  1uM pyrethroid was incubated from 
0-10min in 1.5mL 0.1M Tris containing 1.0mg MSP/mL, and 1.0 mg NADPH/mL.  NADPH 
independent assays were carried out from 0-30min to insure sufficient elimination to 
calculate elimination rates.  Assays were carried out in duplicate in a shaking water bath at 
37°C and 250µl aliquots were removed at each time point for LC/MS/MS analysis.  Assays 
were repeated in the presence of 200uM TEPP to inhibit esterase activity (Soderlund and 
Casida, 1977).  A volume of 10µl of 30mM TEPP in methanol was added to the assay prior 
to incubating for 10min at 37°C before the addition of pyrethroid.   
 
Identification, recovery, and quantification of deltamethrin and esfenvalerate.   
An Agilent (Palo Alto, CA USA) 1100 series LC/MSD VL ion trap mass 
spectrometer and HP Chemstation software were used for identification and quantification of 
pyrethroid parent chemicals.  Isocratic elution of chemicals was accomplished with an 
Agilent Zorbax Eclipse XDB – C18 column (4.6 x 100 mm, 3.5 µm pore size) and XDB C-
18 guard column with a mobile phase of 90% methanol and 10% 5 mM ammonium formate 
at a flow rate of 0.5 ml/min.  Deltamethrin identification and quantitation was accomplished 
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by fragmentation of the ammonium adducted ion [M+NH4]+  (m/z 523) to produce the parent 
ion [M+H]+ (m/z 506).  Esfenvalerate identification and quantitation was accomplished via 
the ammonium adducted ion [M+NH4]+ (m/z 437).  Bifenthrin was identified and quantified 
using the ammonium adducted ion [M+NH4]+ (m/z 440).  Recovery of deltamethrin and 
esfenvalerate from microsomal assays was assessed at all concentrations utilized in standard 
curves (0.1, 0.5, 1, 2, 5, 7, 10, 20, and 50µM) and compared to an equivalent concentration in 
the absence of microsomal protein.  Recovery was found to be greater than 95% at all 
concentrations.  Precision of points on standard curves were calculated to be within 5% of 
standards in buffer.  Quantification was accomplished using the peak area ratios of the 
analyte and internal surrogate.  Standard curves were developed from standards in the 
reaction buffer containing microsomal protein.  Standard curves were linear over the range of 
concentrations used in the experiments with r2 values of at least 0.99.  Accuracy limits of 
20% were utilized for inclusion in standard curves by the Agilent Chemstation software.   
 
Calculation of elimination rates, elimination rate constants, and intrinsic hepatic 
clearance rates 
 Elimination rate, elimination rate constants and estimates of intrinsic hepatic 
clearance of deltamethrin and esfenvalerate were determined from the elimination of parent 
chemical from the microsomal assay at a single concentration (1 µM) over a time course of 
0-10min.  The concentration of the parent chemical was measured at each time point and 
converted to moles of substrate remaining.  Calculation of elimination rates was 
accomplished by linear regression of substrate remaining vs. time plots.  First order 
elimination rate constants (k) were determined from the plot of the ln of the % remaining vs. 
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time where the slope of the linear regression line = k (min-1).  The 1µM concentration was 
found to be below the Kmapp for each chemical in both rat and human liver microsomes (Table 
2.1).  At substrate concentrations significantly below Km the clearance of a chemical is 
constant (Iwatsubo et al., 1997), and can be calculated using the first order elimination rate 
constant, k (Obach, 1999).  Intrinsic clearance (CLINT), on a per kg body weight basis was 
estimated based on the equation described below (Obach et al., 1997; Obach, 1999). 
 
CLint = k(min-1) * ml incubation/mg microsomes * mg microsomes/g liver * g liver/kg body 
weight. 
 
It was assumed that humans and rats have 40 and 25.7gm of liver per Kg body weight, 
respectively (Davies and Morris, 1993).  Microsomal content of the livers were assumed to 
be 52.5 and 45 mg microsomal protein per gm of liver for humans (Iwatsubo et al., 1997) and 
rats (Houston, 1994), respectively.  
 
Human and rat carboxylesterases 
The recombinant carboxylesterases, human CE-1 (hCE-1) and CE-2 (hCE-2), were 
expressed in a Spodoptera frugiperda-derived cell line using baculovirus and purified to 
homogeneity as previously described (Morton and Potter, 2000).  Rat CEs termed Hydrolases 
A and B (Morgan et al., 1994), were purified to homogeneity from male Sprague-Dawley rat 
liver by the procedure of Sanghani et al. (2002) with slight modification.  This entailed 
removal of an 80-kDa impurity present in Hydrolase A by anion exchange chromatography.  
The purified rat CEs were digested with trypsin and analyzed by MALDI-TOF/TOF mass 
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spectrometery.  The proteins were shown to be identical to rat Hydrolase A (also termed ES-
10) and Hydrolase B (termed RL1) (Morgan et al., 1994). 
 
Hydrolysis reactions catalyzed by CEs 
Hydrolysis of deltamethrin and esfenvalerate by rat and human CEs were performed 
at a single saturating concentration of pyrethroid (50µM) in order to compare the hydrolysis 
rates of each enzyme (specific activity).  Kinetic experiments with deltamethrin were also 
performed to obtain kcat, Km and kcat/Km parameters for each CE; these parameters were not 
obtained for esfenvalerate in this study.  Hydrolysis of pyrethroids by rat and human CEs was 
performed in reaction volumes of 100 µL as described previously (Ross et al., 2006).  In the 
kinetic experiments, varying amounts of deltamethrin (5–100 µM, final concentration) were 
pre-incubated for 5 min in 50 mM Tris-HCl buffer (pH 7.4) at 37 °C.  The hydrolytic 
reactions were initiated by addition of the CE enzyme (2.5 µg per 100µL reaction) and the 
reaction was allowed to proceed for 30 min at 37 °C.  The reactions were quenched by the 
addition of an equal volume of ice-cold acetonitrile.  The samples were centrifuged for 5 min 
at 13,200 x g (4 °C) and an aliquot was analyzed by HPLC to quantify the hydrolysis 
products.  Non-enzymatic reactions were also performed (i.e., no CE enzyme was added to 
the buffer/pyrethroid mixture) and found to have negligible rates (data not shown).  Specific 
activity reactions of each CE with deltamethrin and esfenvalerate were performed in the 
same manner as above except that a single pyrethroid concentration of 50 µM was used.  
Substrate concentration-velocity reactions and specific activity reaction were performed by 
repetitive assays (N=3 independent experiments).  The pyretrhoids were added to reaction 
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mixtures from stock solution prepared with acetonitrile and the organic solvent content in the 
reactions were kept <1% v/v. 
 
Quantitation of CE-catalyzed hydrolytic products by HPLC analysis   
Authentic standards are available for the hydrolysis products of deltamethrin and 
esfenvalerate.  Furthermore, in contrast to the extensive number of hydroxylated pyrethroid 
metabolites produced by cytochrome P450 metabolism, there are only two hydrolysis 
products, the acid and alcohol metabolites.  Thus, we have detected and quantified the 
products of the hydrolysis reactions by HPLC analysis.  HPLC-UV analysis of pyrethroid 
hydrolytic products was performed on a Surveyor LC system (Thermo Electron, San Jose, 
CA) using a reversed-phase HPLC column (2.1 mm x 100 mm, C18, Thermo Electron).  The 
mobile phases used were solvent A (1:1 v/v, water: acetonitrile containing 0.1% v/v acetic 
acid) and solvent B (100% acetonitrile containing 0.1% v/v acetic acid).  The analytes were 
eluted with the following linear gradient program: 0 min (100% A, 0% B), 6 min (100% A, 
0% B), 20 min (50% A, 50% B), 25 min (50% A, 50% B), and 30 min (100% A, 0% B), at a 
flow rate of 0.2 ml/min. Products were detected at 230 nm.  Calibration standards of the 
hydrolysis products were routinely run along with the samples.  For esfenvalerate and 
deltamethrin, hydrolysis rates were based on the production of 3-phenoxybenzaldehyde, 
which is spontaneously formed from the cyanohydrin (Wheelock et al., 2003). 
 
Kinetic analysis and statistics 
Non-linear regression of substrate concentration versus reaction velocity curves were 
analyzed using SigmaPlot v. 8.02 software (Systat Software, Inc., Point Richmond, CA) by 
 53 
fitting experimental data to the Michaelis-Menten equation.  The kinetic parameters reported 
for the human and rat CE’s are the mean (± SD) of three independent kinetic assays.  The 
specific activity data are reported as the mean (± SD) of three replicates. 
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RESULTS 
 
Elimination of deltamethrin and esfenvalerate from rat liver microsomes 
 Both oxidative and hydrolytic pathways mediate the biotransformation of pyrethroids 
by hepatic microsomes.  Initial studies indicate that the Kmapp for deltamethrin and 
esfenvalerate in rat and human liver microsomal incubations ranged between 21 and 75 µM 
(Table 2.1).  Thus, substrate concentrations of 1µM were used in the elimination assays in 
order to estimate first order rate constants (Obach et al., 1999).  Elimination of deltamethrin 
and esfenvalerate from rat liver microsomes occurred predominantly via NADPH-dependent 
metabolic pathways (Fig. 2.2).  The rate of NADPH-independent elimination of deltamethrin 
was only 20% of the total elimination rate in the presence of NADPH (Table 2.2).  The 
addition of the esterase inhibitor TEPP completely inhibited the NADPH-independent 
elimination of deltamethrin (Table 2.2).  TEPP also inhibited elimination of deltamethrin in 
the presence of NADPH by 20%, which is consistent with the role of esterases in 
deltamethrin elimination.  The rate of NADPH-independent elimination of esfenvalerate was 
11% the total elimination (Table 2.2), however, esfenvalerate elimination in the presence of 
NADPH was decreased by nearly 50% following addition of TEPP.  These results are 
inconsistent with TEPP inhibiting only esterase metabolism.  TEPP is an organophosphate 
pesticide that is also metabolized by cytochrome P450’s (Kulkarmi and Hodgson 1984).  
Thus, competitive inhibition of cytochrome P450 metabolism of esfenvalerate by TEPP may 
be occurring in rat liver microsomes.  In addition, this did not occur with deltamethrin, 
indicating potential differences in the cytochrome P450’s metabolizing deltamethrin and 
esfenvalerate in rat liver microsomes.  Deltamethrin metabolism was completely inhibited by 
TEPP in the absence of NADPH (Table 2.2). 
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Elimination of deltamethrin and esfenvalerate from human liver microsomes 
 The elimination of deltamethrin from human liver microsomes occurs almost entirely 
by NADPH-independent metabolic pathways (Fig. 2.3).  The rate of elimination of 
deltamethrin from human liver microsomes was similar in the presence and absence of 
NADPH.  The addition of TEPP into the reaction mixture decreased the total elimination rate 
by nearly 90% (Table 2.2).  The elimination of esfenvalerate from human liver microsomes 
occurred predominantly via NADPH-dependent metabolic pathways (Fig. 2.3).  The 
NADPH-independent elimination rate of esfenvalerate was 12% of the elimination rate in the 
presence of NADPH (Table 2.2).  In contrast to rat microsomes, TEPP decreased elimination 
of esfenvalerate in the presence of NADPH by only 10%, consistent with the role of esterases 
in the elimination of esfenvalerate (Table 2.2).  This may indicate that there are differences in 
the enzymes metabolizing esfenvalerate or TEPP between species.  There was no detectable 
elimination of esfenvalerate following the addition of TEPP to the reaction mixture in the 
absence of NADPH. 
 
Rat and human intrinsic hepatic clearance estimates for deltamethrin and esfenvalerate 
 Intrinsic hepatic clearance (Clint) values of deltamethrin and esfenvalerate for rats and 
humans were scaled to a per kg body weight basis for purposes of comparison.  The scaled 
estimate for deltamethrin Clint in humans was approximately 2-fold more rapid than in rats 
(Table 2.1).  In contrast, the scaled Clint for esfenvalerate was approximately 3-fold more 
rapid in rats than in humans.  
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Hydrolysis of deltamethrin and esfenvalerate by purified human and rat 
carboxylesterases 
 The rates of hydrolysis of deltamethrin and esfenvalerate were examined by two 
purified human CEs (hCE-1 and hCE-2) and two purified rat CEs (Hydrolases A and B).  
The most effective CE for deltamethrin hydrolysis was hCE-1, which was 25-, 4-, and 16-
fold more active than hCE-2, Hydrolase A, and Hydrolase B, respectively (Table 2.3).  
Consistent with the differential rates of hydrolysis of deltamethrin and esfenvalerate by 
human liver microsomes described above, the rates of deltamethrin hydrolysis by hCE-1 and 
hCE-2 were markedly faster than those for esfenvalerate (4- and 5-fold, respectively; Table 
2.3).  Rat Hydrolase A was the most effective CE catalyst of esfenvalerate hydrolysis, with 2-
fold more activity than either rat Hydrolase B or hCE-1, and 73-fold more activity than hCE-
2 (Table 2.3).  
The kinetic parameters for deltamethrin hydrolysis were also estimated for each 
human and rat CE (Table 2.4).  Among the four esterases examined, hCE-1 had the highest 
Km and  kcat, and the highest catalytic efficiency (kcat/Km).  Figure 2.4 demonstrates results 
from a representative substrate-velocity experiment comparing hCE-1 and rat Hydrolase A.  
The rates of deltamethrin hydrolysis catalyzed by hCE-1 were more rapid at all 
concentrations utilized as compared to rat Hydrolase A.  It should also be noted that the 
kinetic parameters shown in Table 2.4 were estimated by non-linear regression methods 
using all concentrations of substrate (5–100 µM) (Fig. 2.4) and that similar kinetic 
parameters were also obtained when the kinetic data was analyzed instead using the 
Lineweaver-Burk plot (data not shown).  A reliable CE kinetic parameter for comparison 
with respect to deltamethrin hydrolysis is the turnover numbers (kcat).  The kcat values 
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obtained are in good agreement with the measured specific activity values that were 
determined at a substrate concentration of 50 µM (Table 2.3).  While this is a relatively high 
concentration of substrate, it is necessary in order to detect the hydrolysis product 3-
phenoxybenzaldehyde by HPLC analysis.  Figure 2.5 compares the kcat values of rat 
Hydrolase A and hCE-1 for deltamethrin and esfenvalerate hydrolysis with those of other 
pyrethroids (Ross et al. 2006).  This result clearly demonstrates the species difference in the 
activities of rat Hydrolase A and hCE-1 that is unique for deltamethrin when compared to the 
general similarity in hydrolytic rates observed with the other pyrethroids.  
 58 
DISCUSSION 
 
The biochemical pathways that contribute to the metabolism of pyrethroid pesticides 
in laboratory animals are understood relatively well (Soderlund and Casida 1977; Casida and 
Ruzo, 1980).  Fewer studies have examined the metabolism of pyrethroids by humans (Choi 
et al 2002;  Ross et al 2006; Nishi et al 2006).  Recent studies by Ross et al. (2006) suggest 
that there may be quantitative and qualitative differences in the metabolism of pyrethroids by 
rat and human esterases.  The present study compares the elimination of deltamethrin and 
esfenvalerate from rat and human liver microsomes.  Consistent with previous work 
(Soderlund and Casida 1977; Shono et al. 1979; Anand et al., 2006) the elimination of 
deltamethrin and esfenvalerate in rat liver microsomes occurred primarily through an 
NADPH-dependent oxidative pathway.  Esfenvalerate elimination from human liver 
microsomes also occurs primarily by the NADPH-dependent oxidative pathways.  In 
contrast, NADPH-independent hydrolytic pathways predominately eliminate deltamethrin in 
human liver microsomes.   
The observed species difference in the metabolism of deltamethrin led to the 
examination of the metabolism of deltamethrin and esfenvalerate by purified rat and human 
CE enzymes.  Human carboxylesterase 1 (hCE-1) had a specific activity that was 4- to 15-
fold greater than rat Hydrolases A and B when rates of deltamethrin hydrolysis were 
compared (Table 2.3).  The specific activity obtained for Hydrolase A in our current study is 
in agreement with the deltamethrin hydrolysis activity obtained using a rabbit 
carboxylesterase (Ross et al., 2006), which is 99% identical to Hydrolase A in terms of 
amino acid sequence homology.  The differential hydrolysis rates by human and rat CEs 
suggests that differences in esterase activity are likely responsible, at least in part, for the 
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differences in the metabolism of deltamethrin observed between rat and human liver 
microsomes.  Indeed, the kcat values for the human and rat CEs (which is a measure of the 
rate of enzymatic reaction at saturating concentrations of substrate) did correlate with the 
species difference in deltamethrin metabolism using the liver microsomes; however, 
differences in kcat/Km values were not remarkably different between hCE-1 and Hydrolase A 
(Table 2.4).  Caution needs to be exercised when correlating kinetic parameters of pure 
enzymes with the species difference in deltamethrin hydrolysis rates found using hepatic 
microsomes.  This is because of  kcat/Km and kcat values are a metric of an enzyme’s intrinsic 
catalytic efficiency and turnover in a pure preparation, not in a crude mixture of proteins 
found in tissue fractions where protein-protein interaction may modulate enzyme activity 
(Saghatelian et al., 2004).  Also, differences in hydrolysis rates in hepatic microsomes 
between species may reflect the spectrum of esterase isoforms that are present in each species 
and their relative expression levels in liver.  For example, if hCE-1 and Hydrolase A have 
similar catalytic efficiencies and thus metabolize deltamethrin equally well at low 
concentrations of substrate (which does not saturate the enzyme), then the observed 
differences in hydrolytic rates using hepatic microsomes may reflect differences in the 
relative expression levels of hCE-1 versus Hydrolase A.  Alternatively, it cannot be excluded 
that an unidentified esterase is present in human liver microsomes that is much more efficient 
(much larger kcat/Km) than the rat liver esterases, thus accounting for the observed differential 
hydrolysis rates.                      
In contrast to hCE-1, human carboxylesterase 2 (hCE-2)was shown to have 
significantly less activity towards deltamethrin.  hCE-1 is expressed abundantly in human 
liver, while hCE-2 is expressed at relatively lower levels in this tissue (Satoh et al, 2002).  
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Thus, based on our findings, it is likely that hCE-1 plays a greater role in the metabolism of 
deltamethrin in human liver than does hCE-2.  Recently Nishi et al. (2006) reported on the 
activity of hCE-1 and hCE-2 towards a number of pyrethroids including deltamethrin and 
esfenvalerate.  The specific activities in Nishi et al. (2006) are similar to those reported here 
except in one case.  In their studies, hCE-2 had greater activity towards deltamethrin than 
hCE-1.  While this is inconsistent with the data presented in this study, this may be explained 
by differences in the intrinsic activity of the preparations used.  The intrinsic activity of hCE-
2 in Nishi et al., (2006) was more than two fold greater than the hCE-2 used in our studies 
(reported in Ross et al., 2006) towards the standard substrate p-nitrophenyl acetate. 
Carboxylesterases (EC 3.1.1.1) are members of the esterase family of serine 
hydrolase enzymes (Satoh and Hosokawa, 1998).  The catalytic mechanism of CEs requires a 
triad of amino acid residues (Ser, His, and Glu or Asp) that are essential for activity.  The rat 
CE isozymes named Hydrolase A and Hydrolase B are the two most abundant 
carboxylesterases present in rat liver, accounting for 80% of the total hepatic 
carboxylesterase protein under basal conditions (Morgan et al., 1994; Sanghani et al., 2002).  
These rat enzymes share ~70% amino acid sequence identity with each other and have 
overlapping substrate specificities.  Hydrolases A and B have amino acid sequences that are 
approximately 70-80% identical with the major human hepatic carboxylesterase (hCE-1) 
(Redinbo and Potter, 2005).  Thus, these CE isozymes are classified as being within the class 
1 family of CE enzymes.  In contrast, hCE-2 is quite distinct from the rat CEs and hCE-1 in 
terms of sequence identity and substrate specificity (Satoh and Hosokawa, 1998).  hCE-2 
shares less than 50% sequence identity with hCE-1 and Hydrolases A and B and is classified 
as a class 2 carboxylesterase.   
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The amino acid sequences that flank the catalytic triad of Ser, His, and Glu residues 
in hCE-1 and Hydrolase A are nearly identical to each other, thus they are highly conserved.  
The differences in catalytic specificity observed for hCE-1 and Hydrolase A toward 
deltamethrin is potentially related to differences in the types of amino acids that line the 
substrate-binding gorge and/or active site of the enzymes.  Future studies that create site-
specific mutants of hCE-1 and/or Hydrolase A may yield insight into the underlying 
specificity differences observed between rat and human CEs.  Furthermore, computational 
approaches that involve molecular modeling of hCE-1 and Hydrolase A will be of potential 
value.      
The present study indicates that deltamethrin (a cis-isomer) is metabolized primarily 
by an NADPH-independent hydrolytic pathway in human liver microsomes.  This finding is 
not consistent with structure-metabolism relationships found in laboratory animals.  A 
number of studies demonstrate that in laboratory animals oxidative pathways generally 
metabolize cis-isomers of pyrethroids more rapidly compared to their trans-isomers, which 
are generally more rapidly metabolized by hydrolytic pathways (Soderlund and Casida, 1977; 
Shono et al., 1979).  Recently, Anand et al. (2006) described the ability of a number of rat 
hepatic CYP450s to metabolize deltamethrin.  Their results indicate that CYP1A1, CYP1A2, 
and CYP2C11 may be active in the metabolism of deltamethrin in rat liver microsomes, with 
CYP1A2 being the most active.  Based on these results we examined the metabolism of 
deltamethrin by human CYP1A2, but did not see significant evidence of metabolism 
(unpublished data, Godin et al.).  This suggests that there may be marked differences in 
CYP450 activities between rats and humans toward deltamethrin.  It is also possible that the 
difference in oxidative metabolism is related to differences in expression of these enzymes 
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between rat and human liver.  For example CYP2C11 is highly expressed in the rat liver 
(Guengerich et al., 1982), while one of its human homologues 2C18 has very low expression 
in the liver (Rodrigues 1999).  A comparison of the full complement of rat and human 
CYP450 isozymes would be needed to confirm these initial findings and to understand the 
lack of P450 mediated metabolism in human liver microsomes.  The lack of CYP450 
mediated metabolism of deltamethrin in human liver microsomes may be as important in the 
species difference as is the differences in the activities of rat and human carboxylesterases.    
In addition to differences in the pathways of biotransformation of the parent chemical 
there were also differences in the rates of elimination and calculated intrinsic hepatic 
clearance for deltamethrin and esfenvalerate.  Since the parent chemical is the primary 
toxicant for pyrethroids, elimination of the parent chemical can be considered the 
detoxification step in their metabolism.  The CLint of esfenvalerate, which was eliminated by 
similar pathways in both species, was estimated to be nearly three-fold greater in rats than in 
humans.  In contrast, the CLint of deltamethrin was estimated to be twice as rapid in humans 
that in rats.  In addition, deltamethrin was eliminated by different pathways in rat and human 
liver microsomes.   
These results indicate that laboratory rodents may not be a good model for 
understanding and extrapolating the results of metabolism studies of all pyrethroids in a 
human health risk assessment.  It is therefore necessary to more completely understand the 
human metabolism of individual pyrethroids to reduce uncertainties in a risk assessment. 
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Table 2.1.  Kmapp and scaled intrinsic hepatic clearance (CLINT) values for deltamethrin 
and esfenvalerate in rats and humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data is mean ± SD (N=3) 
 
 
 
 
Deltamethrin Kmapp (µM)     Clearance (mL/min/kg b.w) 
     
Rat Microsomes 39 89.0 ± 23.7 
      
Human Microsomes 75 162.1± 32.7 
      
      Esfenvalerate 
    
  
    
Rat Microsomes 22 108.2 ± 2.2 
      
Human Microsomes 21 37.3 ± 10.3 
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Table 2.2. Elimination rates for deltamethrin and esfenvalerate from rat and human 
liver microsomes.   
 
+ NADPH, total clearance (oxidative and hydrolytic) of parent chemical from microsomal 
assay.   
– NADPH, NADPH-independent hydrolytic clearance of parent chemical from microsomal 
incubation.  
+ TEPP, tetraethylpyrophosphate (200µM) used to inhibit hydrolytic metabolism.  
ND, no detectable elimination.  
Data is mean ± SD. (N=3) 
Elimination rate (pmoles/min/mg microsomal protein) 
Deltamethrin + NADPH - NADPH 
     
Rat Microsomes 30.4 ± 7.3 8.8 ± 0.23 
      
Rat Microsomes + TEPP 24.6 ± 3.7 ND 
      
Human Microsomes 52.8 ± 6.2 58.0 ± 3.0 
      
Human Microsomes + TEPP 5.8 ± 5.4 ND 
      
Esfenvalerate 
    
 
    
Rat Microsomes 45.3 ± 2.4 4.8 ± 1.4 
      
Rat Microsomes + TEPP 23.4 ± 9.0 ND 
      
Human Microsomes 20.9 ± 4.4 2.6 ± 1.6 
      
Human Microsomes + TEPP 18.9 ± 2.7 ND 
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Table 2.3. Specific activity of human and rat carboxylesterase hydrolysis of 
deltamethrin and esfenvalerate 
 
a
 50 µM deltamethrin or esfenvalerate in assay (n=3).  Incubation time of 30 min.  Rates were 
based on the formation of 3-phenoxybenzaldeyde. 
b
 Relative to the human CE-1 specific aactivity for deltamethrin hydrolysis. 
 Deltamethrin Esfenvalerate 
Enzyme specific activitya fold specific activitya fold 
 (nmol/min/mg) differenceb (nmol/min/mg) differenceb 
     
human CE-1a 12.2 ± 0.6 1.00 3.1 ± 0.2 0.25 
 
    
human CE-2a 0.5 ± 0.0 0.04 0.1 ± 0.0 0.01 
 
    
rat Hydrolase A 3.0 ± 0.2 0.25 6.6 ± 0.3 0.54 
 
    
rat Hydrolase B 0.8 ± 0.1 0.07 3.0 ± 0.3 0.25 
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Table 2.4. Hydrolysis of deltamethrin: Kinetic parameters of human and rat 
carboxylesterases. 
 
 Km Vmax kcat kcat/Km 
Enzyme (µM) (nmol/min/mg) (min-1) (min-1 mM-1) 
     
human CE-1a 22.6 ± 3.7 21.4 ± 7.2 1.3 ± 0.4 56.3 
 
    
human CE-2a 1.6 ± 1.6 0.6 ± 0.1 0.035 ± 0.003 21.1 
 
    
rat Hydrolase A 6.3 ± 0.4 4.5 ± 0.8 0.27 ± 0.04 42.7 
 
    
rat Hydrolase B 2.0 ± 4.9 1.1 ± 0.3 0.07 ± 0.02 35.2 
     
 
a Eight different concentration of deltamethrin were assayed (5-100µM) in each kinetic 
experiment—rates are based on the formation of 3-phenoxynezaldehyde.  Parameters are the 
means ± SD obtained from three independent kinetic experiments. 
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Figure 2.1.  Structures of the pyrethroid pesticides deltamethrin and esfenvalerate. 
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Figure 2.2. Elimination of deltamethrin and esfenvalerate from rat liver microsomes.  
Elimination examined at 1µM deltamethrin or esfenvalerate in the presence of ( solid line) 
or absence of (▲ dashed line) NADPH, with and without TEPP. Line represents linear 
regression of data points. Data represented as the mean ± SD (N=3). 
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Figure 2.3. Elimination of deltamethrin and esfenvalerate from human liver 
microsomes.  Elimination examined at 1µM deltamethrin or esfenvalerate in the presence of 
( solid line) or absence of (▲ dashed line) NADPH, with and without TEPP. Line 
represents linear regression of data points. Data represented as the mean ± SD (N=3). 
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Figure 2.4. Kinetics of deltamethrin hydrolysis by hCE-1 and Hydrolase A.  Velocity 
was measured by the amount of 3-phenoxybenzyladehyde (3PBCHO) released during the 
reaction.  Data (symbols) were fit to the Michaelis-Menten equation and the non-linear 
regression results are plotted (lines). Each point represents the mean ± SD (N=3). 
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Figure 2.5. Comparison of turnover numbers (kcat) for human CE (hCE-1) and rat CE 
(Hydrolase A).  Hydrolysis of five different pyrethroids are compared.  Data for cis-per, 
trans-per, and biores are from Ross et al. (2006).  Abbreviations: cis-per, cis-permethrin; 
esfen, esfenvalerate; delta, deltamethrin; biores, bioresmethrin; trans-per, trans-permethrin. 
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ABSTRACT 
 
The metabolism of deltamethrin and esfenvalerate by rat and human liver microsomes 
differ with respect to the biotransformation pathway (oxidation versus hydrolysis) 
responsible for their clearance.  This study aims to further explore the species differences in 
the metabolism of these chemicals.  Using a parent depletion approach, rat and human CYPs 
were screened for their ability to eliminate deltamethrin or esfenvalerate during in vitro 
incubations.  Rat CYP isoforms 1A1, 2C6, 2C11, 3A2 and human CYP isoforms 2C8, 
2C19,and 3A5 were capable of metabolizing either pyrethroid.  Human CYP2C9 
metabolized esfenvalerate but not deltamethrin.  Rat and human CYPs that metabolize 
esfenvalerate and deltamethrin do so with similar kinetics.  In addition to the liver, a potential 
site of metabolic elimination of pyrethroids is the blood via serum carboxylesterase (CEs) 
hydrolysis.  The serum of rats, but not humans, contains significant quantities of CEs.   
Deltamethrin and esfenvalerate were metabolized effectively by rat serum and a purified rat 
serum CE.  In contrast, neither pyrethroid was metabolized by human serum or purified 
human serum esterases (acetylcholinesterase and butyrylcholinesterase).  These studies 
suggest that the difference in rates of oxidative metabolism of pyrethroids by rat and human 
hepatic microsomes are dependent on the expression levels of individual CYP isoforms 
rather than their specific activity.    Furthermore, these studies show that the metabolic 
elimination of deltamethrin and esfenvalerate in blood may be important to their disposition 
in the rat but not in the human. 
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INTRODUCTION 
Pyrethroid pesticides are synthetic analogs of pyrethrins, the natural insecticidal 
products of Chrysanthemum cinerariaefolium.  Compared to the pyrethrins, the pyrethroids 
display enhanced insecticidal activity, greater environmental stability, greater resistance to 
metabolism and increased mammalian toxicity (Elliot, 1989; Soderlund, 1992).  There is no 
evidence that metabolites of the pyrethrins or pyrethroids induce neurobehavioral changes or 
other toxic effects.  Thus, the neurotoxicity of pyrethrins and pyrethroids is produced by the 
parent chemical (Narahashi, 1982; Smith et al., 1997).  Furthermore, the toxic potency of 
pyrethroids in mammals is inversely related to their rates of metabolic elimination 
(Abernathy and Casida, 1973; White et al. 1976).    
 Pyrethroids are biotransformed by two pathways, CYP-dependent oxidation and 
esterase-mediated hydrolysis (Soderlund and Casida, 1977).  The type II pyrethroids 
deltamethrin and esfenvalerate are metabolized primarily by CYP-dependent oxidation in 
mouse and rat liver microsomes (Soderlund and Casida, 1977; Godin et al., 2006).  The type 
II pyrethroids are distinguished from type I pyrethroids by the presence of a cyano group at 
the alpha carbon of the esterified alcohol.  In human liver microsomes, esfenvalerate is 
metabolized primarily by CYP enzymes, whereas deltamethrin is metabolized mainly by 
esterase-mediated hydrolysis (Godin et al., 2006).  Consistent with this finding, recombinant 
human carboxylesterases (CEs) display greater enzymatic activity towards deltamethrin than 
esfenvalerate.  The CEs appear to be the major human enzyme responsible for hepatic 
metabolism of deltamethrin (Godin et al., 2006; Nishi et al., 2006).     
The role of specific CYPs in the species difference observed in human and rodent 
microsomal metabolism of these two chemicals is not clear.  Oxidative metabolism of 
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deltamethrin in human liver microsomes is minimal, and while oxidative metabolism of 
esfenvalerate is relatively efficient compared to deltamethrin, it is still considerably slower 
than in rat liver microsomes.  Pyrethroids that are metabolized rapidly by esterases are 
typically less toxic than pyrethroids metabolized by slower oxidative pathways (Abernathy 
and Casida, 1973: Soderlund and Casida, 1977; Soderlund, 1992; Soderlund et al., 2002).  
Inter-individual variability in the expression or activity of xenobiotic-metabolizing enzymes, 
which can be caused by genetic polymorphisms, disease state, life stage and environmental 
exposures (i.e., induction or suppression of CYPs) can lead to altered susceptibility in 
populations, particularly when a specific enzyme is responsible for the vast majority of a 
chemical’s clearance.  It is therefore important to not only characterize the specific enzymes 
responsible for the metabolism of pyrethroids, but also to understand the relative flux through 
each pathway in order to determine which is responsible for metabolic elimination of the 
pyrethroids.   
 In addition to the liver, blood is a site of metabolism for pyrethroids in laboratory 
animals (Anand et al., 2006; Mirfazaelian et al., 2006).  Rat serum contains 
carboxylesterase(s) that are capable of metabolizing pyrethroids (Anand et al., 2006).  The 
activity of serum CEs in the rat may be important in the overall pharmacokinetic disposition 
of pyrethroids (Anand et al., 2006; Mirfazaelian et al., 2006), particularly since pyrethroids 
will encounter serum CEs immediately upon absorption from the gut.  In contrast to 
laboratory animals, human serum does not contain carboxylesterase activity (Li et al., 2005).  
Therefore, while blood may be an important tissue for the metabolic elimination of 
pyrethroids in rats it may not be in humans.  This is supported by the fact that there are 
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currently no literature reports on the metabolism of pyrethroids in human blood or by human 
serum esterases.   
 In the present study we examined the ability of specific rat and human CYPs to 
metabolize deltamethrin and esfenvalerate in vitro.  Deltamethrin and esfenvalerate were 
chosen for this study because they are two of the most potent and commonly used 
pyrethroids.  In addition, a clear difference exists in the rates of CYP-mediated metabolism 
of deltamethrin and esfenvalerate in human liver microsomes but not in rat liver microsomes 
(Godin et al., 2006).  A comparison of the species specific CYP isoforms that can 
biotransform these pyrethroids is therefore an ideal approach for examining possible 
determinants of their rates of clearance.  A potential species difference in the metabolism of 
deltamethrin and esfenvalerate in serum was also explored using rat and human sera and 
purified serum esterases. The results obtained yield a clearer understanding of the differences 
in the metabolism of deltamethrin and esfenvalerate between rats and humans.  Furthermore, 
improved characterization of the important pathways that metabolize pyrethroids in rats and 
humans was obtained.  The resulting information will be useful for human health risk 
assessments by decreasing the uncertainty in extrapolating laboratory animal 
pharmacokinetic data to humans. 
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MATERIALS AND METHODS 
 
Chemicals 
Deltamethrin (98.9% purity) ((αS)--cyano-3-phenoxybenzyl (1R, 3R)-cis-3-(2,2-
dibromovinyl)-2,2-dimethylcyclopropane carboxylate) was a gift from Bayer Crop Sciences 
(Research Triangle Park, NC, USA).  Esfenvalerate (98.6% purity) ((αS)-cyano-3-
phenoxybenzyl 2-(4-chlorophenyl)-3-methylbutyrate) was a gift from Dupont (Johnston, IA, 
USA).  Bifenthrin, used as an internal standard, was obtained from Chem Service Inc (West 
Chester, PA, USA).  These chemicals were used in all CYP assays and serum elimination 
studies.  Deltamethrin (>98%) and esfenvalerate (>98%) used in the carboxylesterase and 
serum metabolite formation assays were obtained from Chem Service Inc.  LC/MS analysis 
of pyrethroids from the various sources did not reveal any differences in their chemical 
composition.  Chromasolv® acetonitrile and methanol for LC/MS applications were from 
Riedel-de Haën (Seelze, Germany).  Ammonium formate, Trizma-base, β-nicotinamide 
adenine dinucleotide phosphate reduced form (NADPH), 3-phenoxybenzyl alcohol 
(3PBAlc), cis/trans-3-(2′,2′-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid (a 1:1 
mixture of cis and trans isomers) [also called cis/trans-dichlorochrysanthemic acid (Cl2CA)], 
and 3-phenoxybenzaldehyde (3PBCHO) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA).  Unless otherwise specified all chemicals were of the highest grade 
commercially available.   
 
Rat and Human CYPs 
 Rat CYP 1A1, 1A2, 2A1, 2B1, 2C6, 2C11, 2C12, 2C13, and 3A2 and human CYP 
1A2, 2A6, 2B6, 2E1, 2C8, 2C9*1, 2C9*2, 2C19, 2D6*1, 3A4, and 3A5 were purchased from 
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BD Biosciences (Woburn, USA).  The concentration of these enzymes ranged from 1000-
2000 pmoles CYP/ml. 
 
CYP-catalyzed Elimination of Pyrethroids: Screening Assays 
 Each rat and human CYP was screened for its ability to oxidize and eliminate 
deltamethrin and esfenvalerate from the assay mixture.  Assay conditions were 0.5 ml of 0.1 
M Tris-HCl (pH 7.4), 10 pmoles P450/ml and 1 mg/ml NADPH.  The assay mixture 
containing enzyme and NADPH were preincubated for 10 min at 37 °C.  To initiate the 
reaction, 5 µL of 100 µM stock solutions of deltamethrin or esfenvalerate dissolved in 50% 
acetonitrile were added for a final concentration of 1 µM pyrethroid (final concentration of 
acetonitrile in each reaction was 0.5% v/v). The 1µM concentration was previously used in 
microsomal clearance assays and determined to be below the Km for microsomal elimination 
of these pyrethroids (Godin et al., 2006). Each assay was conducted in duplicate.  Reactions 
were carried out at 37 °C over 20 min.  At selected time points, 100 µL aliquots were 
removed and the reaction was terminated by adding 1-ml ice cold 75% acetonitrile 
containing 1 µg/ml bifenthrin as an internal surrogate of recovery.  Samples were vortexed 
for 10 min and placed into auto-sampler vials for LC/MS analysis.  LC/MS identification and 
quantification of pyrethroids was accomplished as previously described (Godin et al., 2006).  
Recovery of internal standard was greater than 95%.  The duplicate samples were averaged 
and values are reported as the percentage of pyrethroid eliminated over the first 10 min of 
incubation, a time interval for which the elimination rate was found to be linear.  Control 
reactions were run in the absence of NADPH to verify that metabolism was enzymatic. 
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CYP Isozyme Kinetic Assays 
 The kinetic parameters Km and Vmax were determined for the CYPs identified as 
being metabolically active toward deltamethrin and/or esfenvalerate in the initial screening 
assay.  The assay mixture consisted of 0.5 ml of 0.1 M Tris-HCl (pH 7.4), 10 pmoles 
P450/ml and 1 mg/ml NADPH.  The assay buffer containing enzyme and NADPH was 
preincubated for 10 min at 37°C.  The reaction was initiated by addition of 5 µL of stock 
solutions of varying concentration of pyrethroid (0.05-2.5 mM) to yield final pyrethroid 
concentrations of 0.5-25 µM.  Assays were carried out for 10 min.  Reactions were 
terminated by the addition of 1 ml of ice cold 75% acetonitrile containing 1 µg/ml bifenthrin.  
Samples were vortexed for 10 min and LC/MS analysis was carried out as previously 
described.  Each assay was performed in triplicate.  Rates of elimination were converted to 
product formation velocities and plotted versus substrate concentrations.  Km and Vmax 
parameters were determined using GraphPad Prism (v 4.0, GraphPad Software, San Diego 
CA, USA).    by fitting the experimental data to the Michaelis-Menten equation by non-
linear regression. Vmax and Km were unobtainable for CYP3A5 as it displayed linear 
kinetics in the range of concentrations utilized.  Therefore, all data was also analyzed by 
linear regression of product formation velocities plotted against substrate concentration in the 
linear range to obtain catalytic efficiencies (Vmax/Km) from the slope of the regression line. 
 
Rat and Human Serum Elimination Assays 
 Whole blood was collected from 30 adult male Long-Evans rats (approximately 90 
day old) (Charles River, Raleigh, NC, USA).  The blood was allowed to clot 1 hr before 
being centrifuged for 20 min at 2,000 x g to enable serum collection.  Three pools of rat 
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serum were generated (n=3 samples), each from 10 different animals.  Pooled human serum 
(10 donors per pool) was purchased from Bioreclamation (Hicksville, NY, USA) (Lot 
#BRH88162, Lot #BRH88163) and Innovative Research (Southfield, MI, USA) (Lot #IR05-
044).  Rat and human sera were diluted to 50% with 0.1 M Tris-HCl (pH 7.4) buffer.  One ml 
of the 50% serum was preincubated at 37°C for 10 min prior to pyrethroid addition.  Ten µL 
of 100 µM stocks of deltamethrin or esfenvalerate were added for a final concentration of 1 
µM.  Serial aliquots (100 µL) were removed at 0, 20, 40 and 60 min and placed in 2 ml of 
ice-cold hexane containing bifenthrin as an internal surrogate of recovery.  Samples were 
vortexed and centrifuged for 10 min.  The supernatant was removed and the extraction was 
repeated twice more with 2 ml of hexane.  The combined extracts were evaporated to dryness 
under a stream of N2.  Samples were reconstituted in 1 ml of 75:25 (v/v) methanol:water and 
placed in autosampler vials for LC/MS analysis.  Assays were conducted in triplicate.  
LC/MS analysis was carried out as previously described (Godin et al., 2006).  The 
concentration of pyrethroid was determined over the time course of the assay and plotted 
versus time.  The slope of the linear regression represents the rate of elimination of 
pyrethroid.  Values were scaled to per ml of serum. 
 
Human and Rat Serum Hydrolysis Assays 
Blood was collected from five adult male Sprague-Dawley rats (70–110 day) 
(Sprague-Dawley rats were obtained from an in-house colony at Mississippi State 
University).  The blood was allowed to stand for one hr to clot and was subsequently 
centrifuged at 2,000 x g for 20 min to enable serum collection. The sera were then pooled 
together to form a single pool of rat serum.  Human serum obtained from a pool of adult male 
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donors was purchased from Sigma-Aldrich (St. Louis, MO, USA).   Pyrethroid hydrolysis 
reactions in human or rat sera were conducted as follows.  The pyrethroids were pre-
incubated in 200–225 µL of 50 mM Tris-HCl buffer (pH 7.4) for 5 min before adding 25 µL 
of pooled rat serum or 50 µL of pooled human serum to each sample.  For specific activity 
assays the final concentration of pyrethroid in each sample was 50 µM.  When variable 
pyrethroid concentrations were added to serum incubations, pyrethroid concentrations ranged 
from 5–100 µM.  The samples were incubated at 37 °C for 30 min before quenching with an 
equal volume of cold acetonitrile.  Following centrifugation, the hydrolysis products in the 
supernatant were analyzed by HPLC-UV on a Surveyor LC system (Thermo Electron, San 
Jose, CA) using a reversed-phase HPLC column (2.1 mm x 100 mm, C18, Thermo Electron) 
as previously described for trans-permethrin (Ross et al., 2006). 
 
Purified rat serum carboxylesterase  
Rat serum CE protein was purified to homogeneity as described by Crow et al. 
(2007).  Hydrolysis reactions catalyzed by purified rat serum CE were performed in 100-µL 
volumes at 37 °C.  Varying amounts of pyrethroid (5–100 µM) were pre-incubated for 5 min 
in 50 mM Tris-HCl buffer (pH 7.4) at 37°C.  The hydrolytic reactions were initiated by 
addition of the pure CE (2.5 µg protein per reaction).  After 30 min of incubation the 
reactions were quenched by the addition of an equal volume of ice-cold acetonitrile.  The 
samples were centrifuged and an aliquot of the supernatant was analyzed by HPLC to 
quantify the hydrolysis products.  Rates of hydrolysis reactions catalyzed by pure CEs have 
been demonstrated to be linear up to 60 min (Ross et al., 2006).  Non-enzymatic controls 
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were also included and found to have negligible rates.  Serum CE reactions at each substrate 
concentration were performed in duplicate.   
 
Human Serum Esterases 
Human butyrlcholinesterases (BChE) and acetylcholinesterases (AChE) were 
purchased from Sigma Aldrich (St. Louis, MO USA).  Incubation of pyrethroid with BChE 
or AChE was done in the same manner as the reactions catalyzed by rat serum CE. 
 
Immunoblotting of pooled human liver microsomes: hCE1 and hCE2 protein levels 
The recombinant human carboxylesterase (CE) proteins (hCE1 and hCE2) were 
expressed in baculovirus-infected Spodoptera frugiperda cells and purified (Morton and 
Potter, 2000).  Polyclonal antibodies against hCE-1 and hCE-2 were kindly provided by Dr. 
M. Hosokawa (Chiba University, Japan) and Dr. P. Potter (St. Jude Children’s Research 
Hospital, Memphis, TN, USA), respectively.  Pooled human liver microsomes from four 
different vendors, CellzDirect (Phoenix, AZ USA) (Lot# HMMC-PL020), Cedra (Austin, TX 
USA) (Lot#821-1), Xenotech (Lenexa, KS USA) (Lot#0310241) and BD Biosciences (San 
Jose, CA USA) (Lot # 26738), were subjected to SDS-PAGE using standard protocols (Ross 
and Borazjani, 2007).  After electrophoresis, the proteins were transferred to 
polyvinyldifluoride membranes and probed with either anti-hCE-1 (1:4000, v/v) or anti-hCE-
2 (1:5000, v/v) polyclonal antibody in Tris-buffered saline/5% milk.  Immuno-complexes 
were localized on the membrane with a horse radish peroxidase-conjugated goat anti-rabbit 
secondary antibody and the SuperSignal West Pico chemiluminescent substrate (Pierce, 
Rockford, IL, USA).  The chemiluminescent signal was captured using a digital camera 
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(Alpha Innotech gel documentation system).  Bands on the digital images were quantified 
using NIH Image J software (v.1.33u).  Known quantities of recombinant hCE1 and hCE2 
proteins were loaded on the same gels to establish calibration curves.       
 
Kinetic analysis and statistics for carboxylesterase studies 
Non-linear regression of substrate concentration versus reaction velocity plots were 
analyzed using SigmaPlot v. 8.02 software (San Jose, CA. USA) by fitting experimental data 
to the Michaelis-Menten equation.  Each substrate concentration in the kinetic experiments 
was evaluated in duplicate.  The specific activity data obtained using pooled rat serum (n=5 
animals/pool) are reported as the mean (± S.D.) of three replicates.   
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RESULTS 
 
Rat CYP screening assays 
 The ability of rat CYP isoforms to metabolize deltamethrin and esfenvalerate were 
studied by evaluating the elimination of 1 µM pyrethroid.  Rat CYPs 1A1, 2C6, 2C11, and 
3A2 metabolized both deltamethrin and esfenvalerate (Fig. 3.1).  However, rat CYPs 1A2, 
2A1, 2B1, 2C12, and 2C13 did not metabolize either compound (Fig. 3.1).  Rat CYP2C6 
eliminated the greatest percentage of deltamethrin followed by 1A1>2C11> 3A2 (Fig. 3.1).  
Rat CYP2C6 also eliminated the greatest percentage of esfenvalerate followed by 
2C11>3A2> 1A1 (Fig. 3.1).  CYP2C11 eliminated a similar percentage of both pyrethroids.  
CYPs 2C6 and 1A1 eliminated a significantly greater of deltamethrin than esfenvalerate, 
while CYP3A2 eliminated a greater percentage of esfenvalerate than deltamethrin (Fig. 3.1).  
These CYP isoforms were chosen for this study based on their relatively high expression in 
rat liver microsomes (e.g., 2C6, 2C11, 3A2; Guengerich et al., 1982) and because previous 
studies indicated they may be involved in pyrethroid metabolism (e.g., 1A1, 1A2, 2B1) 
(Anand et al., 2006; Dyal et al., 2001).  CYPs 2C12 and 2C13 were chosen due to their sex 
specific expression, thus allowing the potential influence of gender on the metabolism of 
deltamethrin and esfenvalerate to be determined.    
 
Human CYP screening assays 
 The ability of human CYP isoforms to metabolize deltamethrin and esfenvalerate 
were also studied by evaluating the elimination of 1 µM pyrethroid.  Deltamethrin was 
metabolized by human CYPs 2C8, 2C19, 3A4 and 3A5 (Fig. 3.2).  Esfenvalerate was 
metabolized by human CYPs 2C8, 2C9*1, 2C9*2, 2C19, 3A4 and 3A5 (Fig. 3.2). However, 
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human CYPs 1A2, 2A6, 2B6, 2E1, and 2D6*1 did not metabolize either deltamethrin or 
esfenvalerate (Fig. 3.2).  CYP2C19 eliminated the greatest percentage of deltamethrin 
followed by 2C8 > 3A5 > 3A4 (Fig. 3.2).  CYP2C19 also eliminated the greatest percentage 
of esfenvalerate followed by 2C8 > 2C9*1 > 3A5 = 2C9*2 > 3A4.  CYPs 2C8, 2C19, 3A4, 
and 3A5 eliminated a similar percentage of esfenvalerate and deltamethrin (Fig. 3.2), while 
CYPs 2C9*1 and 2C9*2 metabolized esfenvalerate but not deltamethrin (Fig. 3.2).  These 
CYP isozymes were chosen for study based on their relatively high expression in human liver 
microsomes and their known contributions to xenobiotic metabolism (Rodrgiues 1999). 
 
Kinetic analysis of deltamethrin metabolism by rat and human CYPs 
The kinetic parameters of deltamethrin metabolism by rat CYPs 2C6, 2C11, 3A2, and 
human CYP 2C8 and 2C19 were examined because they appear to contribute significantly to 
pyrethroid metabolic clearance.   Rat CYP2C6 and 2C11 had the highest Km and Vmax values 
among rat CYPs examined for deltamethrin metabolism (Table 3.1).  Rat CYP3A2 
eliminated deltamethrin at a significantly slower rate than CYPs 2C6 and 2C11; however, it 
also exhibited a lower Km value (Table 3.1).  
 Human CYP2C8 and 2C19  have similar Km and Vmax values for deltamethrin (Table 
3.1).  Km and Vmax values were unobtainable for CYP 3A5 using non-linear regression as the 
data appeared to display linear kinetics across the range of pyrethroid concentrations utilized 
in these experiments.  Catalytic efficiencies (Vmax/Km) for each enzyme were therefore 
obtained from the slopes of the linear region of the substrate-velocity plots and used to 
compare to the catalytic efficiency for CYP 3A5 (Table 3.1).  The catalytic efficiency of 
CYP 3A5 was found to be greater than both 2C8 and 2C19 for deltamethrin.     
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Km, Vma,x and Vmax/Km parameters for deltamethrin were similar for rat and human 
CYPs.  The large standard error assoicatated with the estimates of Km and Vmax for some 
enzymes is likely due to the inability to accurately determine Vmax because of the solubility 
limits of the pyrethroids under the experimental conditions utilized.   
Kinetic analysis of rat CYP 1A1 was not attempted due to its very low constitutive 
expression in the mammalian liver (Nebert et al., 2004).  In addition, since the induction of 
CYP1A1 is minimal in human livers (Xu et al., 2000; Silkworth et al., 2005), and 
deltamethrin is predominately metabolized by esterases in humans, CYP1A1 metabolism is 
less interesting for the purposes of this study.  Due to minimal metabolism of both 
deltamethrin and esfenvalerate by human CYP 3A4, kinetic parameters were not determined 
for this CYP.  It is, therefore, unlikely that human CYP 3A4 plays any role in the metabolism 
of these pyrethroids. 
 
Kinetic analysis of esfenvalerate metabolism by rat and human CYPs 
The kinetic parameters of esfenvalerate metabolism by rat CYPs 2C6, 2C11, and 3A2 
and human CYPs 2C8, 2C9*1, and 2C19 were examined.  Of the rat enzymes that 
metabolized esfenvalerate, CYPs 2C6 and 2C11 had the highest Km and Vmax values, and 
were similar to the values for deltamethrin (Table 3.1).  Rat CYP3A2 had lower Km and Vmax 
values then 2C6 and 2C11 (Table 3.1).  Of the human CYPs examined each had similar Vmax 
values (Table 3.1).  However, the Km for CYP2C19 was ~5-6-fold lower than the Km for 2C8 
and 2C9*1.  As with deltamethrin, Km and Vmax values were unobtainable for human CYP 
3A5 since the data displayed linear kinetics for esfenvalerate oxidation.  The catalytic 
efficiency was therefore estimated from the slope of the linear regression and, as with 
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deltamethrin, CYP 3A5 had a higher value than the other human CYPs (Table 3.1).  As 
previously noted, kinetic paramaters for human CYP 3A4 were not determined due to a lack 
of significant metabolism of esfenvalerate.   
 
Elimination of deltamethrin and esfenvalerate by pooled rat and human sera 
The ability of rat and human sera to metabolize deltamethrin and esfenvalerate was 
examined by incubating 1 µM pyrethroid in 50% rat or human sera.  In rat serum 
deltamethrin and esfenvalerate were eliminated at rates of 15.33 ± 3.24 (mean ± SD) and 
9.97 ± 2.94 pmoles/min/ml serum respectively.  Neither deltamethrin nor esfenvalerate were 
eliminated during incubation in human serum. 
 
Hydrolysis of Pyrethroids 
When the prototypical type I pyrethroid, trans-permethrin, is hydrolyzed by purified 
rat or human CEs the two products formed are 3-phenoxybenzyl alcohol (3PBAlc) and trans-
dichlorochyrsanthemic acid (Cl2CA).  Both metabolites can be analyzed by HPLC (Fig. 3.3).  
Hydrolysis of the type II pyrethroid, deltamethrin, by purified CEs liberates cis-
dibromochrysanthemic acid (Br2CA), which is a stable metabolite, and a cyanohydrin that 
spontaneously converts to 3-phenoxybenzaldehyde (3PBCHO) at pH>7 (see scheme in Fig. 
3.4).  Br2CA and 3PBCHO are also conveniently quantified by HPLC analysis (Fig. 3.3) and 
thus product formation rates can be determined.  The hydrolysis of esfenvalerate also 
liberates the same cyanohydrin that spontaneously yields 3PBCHO.  When deltamethrin is 
incubated with hepatic microsomes, 3PBCHO can undergo redox reactions to produce 
3PBAlc and 3-phenoxybenozoic acid (3PBCOOH) (Fig. 3.4), which are likely catalyzed by 
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alcohol and aldehyde dehydrogenases, respectively, present in the heterogeneous protein 
mixtures (Choi et al., 2002).    
 
Rates of deltamethrin and esfenvalerate hydrolysis: Pooled rat serum and purified rat 
serum carboxylesterase. 
 The hydrolysis of deltamethrin and esfenvalerate by pooled rat serum and a purified 
rat serum CE was examined.  The pooled rat serum sample and the purified rat serum CE 
hydrolyzed both pyrethroids, but at different rates (Fig. 3.5A and B). The specific activity of 
deltamethrin hydrolysis by the purified CE was nearly 2-fold greater than the activity for 
esfenvalerate (Fig. 3.5B).  This compares well with the greater specific activity of the pooled 
rat serum with deltamethrin than with esfenvalerate (Fig. 3.5A).  Concentration-velocity plots 
were analyzed for deltamethrin using both the pooled rat serum and the purified CE.  In the 
pooled serum sample, deltamethrin displayed linear kinetics (Fig. 3.5C).  In contrast, 
deltamethrin displayed hyperbolic kinetics with the purified CE (Fig. 3.5D).  The estimated 
kcat and Km values for the rat serum CE-catalyzed deltamethrin hydrolysis (Fig. 3.5D) were 
0.48 min-1 and 12.6 µM, respectively, and the calculated kcat/Km was 38 min-1mM-1.  
Furthermore, the hydrolysis of deltamethrin and esfenvalerate by two human esterases, BChE 
and AChE, present in human serum was also examined.  No evidence of hydrolysis was 
detected (data not shown), which is consistent with the lack of pyrethroid elimination in 
human serum (see above). 
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Quantitative Immunoblotting: hCE-1 and hCE-2 
Quantitative immunoblotting of samples of pooled human liver microsomes using 
anti hCE-1 and hCE-2 antibodies demonstrated that the average amount of hCE-1 protein 
expressed in four separate pools of human liver microsomes was 64.4 ± 16.5 µg hCE-1/mg 
microsomal protein (mean +/- SD) (Fig. 3.6).  In contrast, the level of hCE-2 protein (1.4 ± 
0.2 µg hCE-2/mg microsomal protein) in the same samples of liver microsomes was nearly 
50-fold lower than the level of hCE-1 protein (Fig. 3.6).  Thus, hCE-1 is clearly the most 
abundant CE isozyme in human liver microsomes and is found at much higher concentrations 
compared to hCE-2. 
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DISCUSSION 
 
The relative rates of oxidation and hydrolysis of the pyrethroids deltamethrin and 
esfenvalerate differ between human and rat hepatic microsomes (Godin et al., 2006). The 
current work examined the role of specific CYP isozymes responsible for deltamethrin and 
esfenvalerate metabolism in rat and human liver microsomes.  The difference between rat 
and human serum hydrolysis rates and the substrate specificities of a purified rat serum CE 
were also examined for these pyrethroids.         
 In rat liver microsomes, both deltamethrin and esfenvalerate are cleared at 
comparable rates by CYP mediated oxidation (Godin et al., 2006).  In agreement with this 
observation, the elimination of both compounds by rat CYPs 1A1, 2C6, 2C11, and 3A2  in 
the current study were similar.  CYPs 2C6, 2C11, and 3A2 are highly expressed in rat liver 
(Guengerich et al., 1982) and  likely contribute the bulk of the oxidative metabolism of 
deltamethrin and esfenvalerate in this organ.  The kinetics of deltamethrin and esfenvalerate 
metabolism by CYPs 2C6, 2C11, and 3A2 were very similar (Table 3.1).  Rat CYPs 2C6 and 
2C11 displayed higher Km and Vmax values than CYP3A2 suggesting they are responsible for 
the largest proportion of the metabolism of pyrethroids in rat liver at saturating 
concentrations.   
In contrast to rat liver microsomes, human liver microsomes primarily metabolize 
deltamethrin (hydrolysis) and esfenvalerate (oxidation) by different pathways (Godin et al., 
2006).  We have previously shown that hCE-1 is likely the principal enzyme responsible for 
human hepatic microsomal metabolism of deltamethrin (Godin et al., 2006).  In contrast, 
esfenvalerate is not hydrolyzed efficiently by hCE-1 but is primarily metabolized by 
oxidative processes in human liver microsomes (Godin et al., 2006).  Because of these 
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metabolic pathway differences, it was expected that there would be a considerable variation 
in the substrate specificity of human CYPs that are capable of metabolizing these 
pyrethroids.  This, however, was generally not the case.  Deltamethrin and esfenvalerate were 
each metabolized at comparable rates by CYPs 2C8, 2C19, and 3A5 (Fig 3.2).  An important 
exception was their metabolism by the human CYP2C9 isozymes (Fig 3.2) (Table 3.1).  
While esfenvalerate was metabolized effectively by the 2C9 isozymes, deltamethrin was not.  
Although 2C19 eliminated the greatest percentage of both deltamethrin and esfenvalerate, 
(Fig 3.2), CYP 2C9 has the highest expression in human liver (Rodrigues, 1999).  CYP2C9 is 
expressed at approximately 4-fold and 2-fold greater levels than 2C19 and 2C8 respectively 
and nearly 100 fold greater levels than 3A5 (Rodrigues, 1999).  Thus, the higher expression 
level of CYP2C9 and its ability to oxidize esfenvalerate, but not deltamethrin, may account 
for the greater rate of oxidative metabolism of esfenvalerate by human liver microsomes 
(Godin et al., 2006).   
In terms of the CYPs that metabolized the pyrethroids investigated in this study, 
individual rat and human enzymes had comparable Km and Vmax values for deltamethrin and 
esfenvalerate.  However, we had previously observed that the rates of pyrethroid oxidative 
metabolism were slower in human hepatic microsomes than in rat hepatic microsomes 
(Godin et al., 2006).  This difference is likely due to the levels of CYP expression in rat and 
human hepatic microsomes.  According to Guengerich (1982), expression of rat CYPs 2C6, 
2C11, and 3A2 ranges from 300 to >1000 pmoles P450/mg of microsomal protein.  In 
contrast, estimates of average CYP isozyme expression in human liver microsomes are much 
lower, ranging from 1-100 pmoles/mg microsomal protein (Rodrigues, 1999).  Thus, the 
abundance of CYP isozymes in rat liver compared to human liver, and not the individual 
 98 
enzyme’s activity or specificity, likely accounts for the difference in oxidation rates of 
deltamethrin and esfenvalerate that was previously observed (Godin et al., 2006). 
The current study also quantified the expression of the two major CEs in human liver 
microsomes, hCE-1 and hCE-2 (Fig. 3.6).  hCE-1 is robustly expressed in human liver, at 
>60 µg (1000 pmoles) per mg of microsomal protein.  hCE-2 is expressed at much lower 
levels, 1.4 µg (23 pmoles) per mg of microsomal protein.  If one assumes the average 
molecular weight of a CYP is 52 kDa (Lewis, 2001), then the expression of the major 
individual human CYPs in the liver ranges from approximately 0.05-5 µg (~1–100 pmoles) 
of CYP enzyme per mg microsomal protein (Rodrigues, 1999).  Thus, the expression of hCE-
1 is approximately 12–1200-fold greater than the levels of individual CYPs in human liver 
microsomes.  Therefore, the results of these studies suggest that the relative levels of 
expression of both hCE-1 and CYP2C9 are important determinants of the rate and pathway 
of metabolism of pyrethroids in human liver microsomes.     
The blood is a potential site of pyrethroid metabolism.  Rat serum possesses 
significant carboxylesterase activity that can hydrolyze pyrethroids (Anand et al., 2006; 
Crow et al., 2007), while human serum lacks carboxylesterase activity (Li et al., 2005).  
Consistent with these previous findings, deltamethrin and esfenvalerate were hydrolyzed in 
rat serum (see Fig. 3.5A). Neither pyrethroid was eliminated or hydrolyzed following 
incubation in human serum or with purified preparations of human AChE and BChE 
esterases, consistent with previous results for the pyrethroid trans-permethrin (Ross et al., 
2006).   The rate of the hydrolysis catalyzed by purified rat serum CE of deltamethrin was 2-
fold greater than the rate of esfenvalerate (Fig. 3.5B).  Similar results were observed in rat 
serum (Fig. 3.5A).  Concentration-velocity plots for deltamethrin in rat serum revealed non-
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hyperbolic kinetics (Fig. 3.5C), which is similar to the kinetic plot observed by Anand et al. 
(2005) up to 100 µM in rat serum.  However, when deltamethrin hydrolysis was studied 
using the purified rat serum CE, we found that it exhibited hyperbolic kinetics characteristic 
of a classical Michaelis-Menten enzymatic mechanism (Fig. 3.5D).  One possible explanation 
to account for the discrepancy in kinetics between whole serum and purified serum CE is that 
deltamethrin may bind non-covalently to serum albumin, thus reducing its effective 
concentration available for hydrolysis by the serum CE enzyme.  This could account for the 
much higher apparent Km for deltamethrin when investigated in whole serum. 
Hydrolase A is the most abundant rat hepatic CE (Morgan et al., 1994; Sanghani et 
al., 2002).  The kcat value obtained for deltamethrin hydrolysis by pure rat serum CE (this 
study) was ~2-fold greater than the kcat for Hydrolase A (Godin et al., 2006).     However, due 
to a slightly higher Km value for the serum CE, the calculated catalytic efficiencies (kcat/Km) 
are similar.  Therefore, the contribution of rat serum CE to deltamethrin elimination is likely 
to be important, particularly at low serum concentrations.  These results highlight a 
significant species difference between rats and humans with respect to pyrethroid metabolism 
in the blood since no hydrolysis of deltamethrin or esfenvalerate occurs in human serum.   
In vitro metabolism studies using rodent and human tissues have been used to 
estimate in vivo pharmacokinetic parameters such as half-life and clearance (Iwatsubo et al., 
1997).  In vitro metabolism pararmeters do not always directly scale to the in vivo situation 
and often a correction factor is used (Naritomi et al., 2001; Obach et al., 1997).  The species 
differences noted in this and previous work (Godin et al. 2006) indicate that the rat may not 
be a good model for understanding human metabolism of all pyrethroids.  As such, any 
correction factor used for scaling the rodent in vitro data to in vivo may not apply to scaling 
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the human data.  However, understanding these species differences  provides information on 
data gaps and uncertainties inherent in these extrapolations.   
The results obtained in this study qualitatively and quantitatively provide information 
on the relative importance of the liver and blood to the metabolic clearance of pyrethroids in 
rats and humans, which can be used to estimate metabolism parameters in a physiologically 
based pharmacokinetic model.  These results also address potential human variability in 
pyrethroid metabolism.  Identifying and quantifying the role of oxidative and hydrolytic 
enzymes in the metabolism of pyrethroids in humans can provide insight into how variability 
in the expression of these enzymes will affect exposure-dose relationships.  For example, the 
expression of both CYPs and esterases can vary greatly in human populations due to genetic 
polymorphisms, disease states, life stage, and environmental exposures (ie. induction or 
suppression of metabolizing enzymes).  If a single enzyme is primarily responsible for a 
chemical’s metabolic elimination, variability in the expression or activity of that enzyme can 
lead to altered susceptibility within a subpopulation.  Significant human variability exists in 
enzymes such as CYP 2C9 (Stubbins et al. 1996) and hCE-1 (Hosokawa et al., 1995).  
Populations with decreased 2C9 expression may have slower elimination of esfenvalerate 
and potentially greater risk associated with those exposures.  Similarly, populations with 
decreased hCE-1 activity could have significantly reduced deltamethrin clearance rates.  
 101 
REFERENCES 
 
Abernathy CO and Casida JE (1973) Pyrethroids insecticides: esterase cleavage in relation to 
selective toxicity. Science 179:1235-1236. 
 
Anand SS, Bruckner JV, Haines WT, Muralidhara S, Fisher JW and Padilla S (2006) 
Characterization of deltamethrin metabolism by rat plasma and liver microsomes. Toxicol 
Appl Pharmacol 212:156-166. 
 
Choi J, Rose RL and Hodgson E (2002) In vitro human metabolism of permethrin: the role of 
human alcohol and aldehyde dehydrogenases. Pestic Biochem Physiol 73:117-128 
 
Crow JA, Borzjani A, Potter PM, and Ross MK (2007) Hydrolysis of pyrethroids by human 
and rat tissues: examination of intestinal, liver and serum carboxylesterase. Toxicol Appl 
Pharm 221: 1-12 . 
 
Dayal M, Parmar D, Ali M, Dhawan A, Dwivedi UN and Seth PK (2001) Induction of rat 
brain cytochrome P450s (P450s) by deltamethrin: regional specificity and correlation with 
neurobehavioral toxicity. Neurotox Res 3:351-357. 
 
Elliot M (1989) The pyrethroids: early discovery, recent advances and the future. Pestic Sci  
27:337-351. 
 
Godin SJ, Scollon EJ, Hughes MF, Potter PM, DeVito MJ and Ross MK (2006) Species 
differences in the in vitro metabolism of deltamethrin and esfenvalerate: differential 
oxidative and hydrolytic metabolism by humans and rats. Drug Metab Dispos 34:1764-1771. 
 
Guengerich FP, Dannan GA, Wright ST, Martin MV and Kaminsky LS (1982) Purification 
and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, 
catalytic, and immunochemical properties and inducibility of eight isozymes isolated from 
rats treated with phenobarbital or β-napthoflavone. Biochemistry 21:6019-6030. 
 
Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y and Satoh T (1995) 
Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab 
Dispos 23:1022-1027. 
 
Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson 
CA and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in 
vitro metabolism data. Pharmacol. Ther. 73:147-171. 
 
Lewis DFV (2001) Cytochrome P450: Structure and Function. CRC Press, Boca Raton, 
USA. 
 
Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, and Lockridge O, 
(2005)  Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, 
are present in human plasma. Biochem Pharmacol 70, 1673-1684. 
 102 
 
Mirfazalian A, Kim KB, Anand SS, Kim HJ, Tornero-Velez R, Bruckner JV and Fisher JW 
(2006) Development of a physiologically based pharmacokinetic model for deltamethrin in 
the adult male Sprague-Dawley rat. Toxicol Sci 93:432-442. 
 
Morgan EW, Yan B, Greenway D, Petersen DR and Parkinson A (1994) Purification and 
characterization of two rat liver microsomal CEs (hydrolase A and B). Arch Biochem 
Biophys 315:495-512.  
 
Morton CL and Potter PM (2000) Comparison of Escherichia coli, Saccharomyces 
cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 cells for recombinant gene 
expression. Application to a rabbit liver carboxylesterase. Mol. Biotechnol. 16:193-202. 
 
Narahashi T (1985) Nerve membrane ionic channels as the primary target of pyrethroids.  
Neurotoxicology 6:3-22. 
 
Naritome Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama A (2001) 
Prediction of human hepatic clearance from in vivo animals experiments and in vitro 
metabolic studies with liver microsomes from animals and humans. DMD 29:1316-1324. 
 
Nebert DW, Dalton TP, Okey AB and Gonzalez FJ (2004) Role of aryl hydrocarbon 
receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J 
Biol Chem 279:23847-23850. 
 
Nishi K, Huang H, Kamita SG, Kim IH, Morisseau C and Hammock BD (2006) 
Characterization of pyrethroid hydrolysis by the human liver CEs hCE-1 and hCE-2. Arch. 
Biochem Biophys 445:115-123. 
 
Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ and Wastall 
P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro 
metabolism data. J. Pharmacol. Exper. Therap. 283:46-58. 
 
Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to 
bridge the gap between cDNA-expressed cytochromes P450 and native human liver 
microsomes. Biochem Pharmacol 57:465-480. 
 
Ross, M.K. and Borazjani, A. (2007) Unit 14.6: Enzymatic activity of human 
carboxylesterases. Curr. Protocol. Toxicol.  In press. 
 
Ross MK, Borazjani A, Edwards CC and Potter PM (2006) Hydrolytic metabolism of 
pyrethroids by human and other mammalian CEs.  Biochem Pharmacol 71:657-669. 
 
Sanghani SP, Davis WI, Dumaual NG, Mahrenholz A, and Bosron WF (2002)  Identification 
of microsomal rat liver CEs and their activity with retinyl palmitate. Eur J Biochem 
269:4387-4398.  
 
 103 
Silkworth JB, Koganti A, Illouz K, Possolo A, Zhao M, and Hamilton SB (2005) 
Comparison of TCDD and PCB CYP1A induction sensitivities in fresh hepatocytes from 
human donors, Sprague-Dawley rats and Rhesus monkeys and hepG2 cells. Toxicol Sci 
87:508-519. 
 
Smith TJ, Lee SH, Ingles PJ, Knipple DC and Soderlund DM (1997) The L1014F point 
mutation in the house fly Vssc1 sodium channel confers knockdown resistance to 
pyrethroids. Insect Biochem Mol Biol 27:807-12. 
 
Soderlund DM (1992) Metabolic considerations in pyrethroid design. Xenobiotica 22:1185-
1194 
 
Soderlund DM and Casida JE (1977) Effects of pyrethroid structure on rates of hydrolysis 
and oxidation by mouse liver microsomal enzymes. Pestic Biochem Physiol 7:391-401. 
 
Soderlund DM, Clark JM, Sheets LP, Mullin LS, Piccirillo VJ, Sargent D, Stevens JT, and 
Weiner ML (2002)  Mechanisms of pyrethroid neurotoxicity: implications for cumulative 
risk assessment. Toxicology 171:3-59. 
 
Stubbins MJ, Harries LW, Smith G, Tarbit MH, and Wolf CR (1996) Genetic analysis of the 
human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429-439. 
 
Xu L, Li AP, Kaminski DL, Ruh MF (2000) 2,3,7,8 Tetrachlorodibenzo-p-diozin induction 
of cytochrome P4501A in cultured rat and human hepatocytes. Chem-Biol Interact 124:173-
189. 
 
White INH, Verschoyle RD, Moradian MH, and Barnes JM (1976) The relationship between 
brain levels of cismethrin and bioresmethrin in female rats and neurotoxic effects.  Pestic 
Biochem Physiol 6:491-500. 
 104 
Footnotes 
This article has been reviewed in accordance with the policy of the National Health and 
Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, and 
approved for publication. Approval does not signify that the contents necessarily reflect the 
views and policies of the Agency, nor does mention of trade names or commercial products 
constitute endorsement or recommendation for use.  S.J.G. was supported by NHEERL-
DESE, EPA CT826513 and NIEHS Research Grant T32-ES07126. Research support to 
M.K.R and J.A.C. was provided by NIH grant P20 RR017661. 
 
Send Correspondence to: 
Michael J DeVito 
US EPA, MD B143-01 Research Triangle Park, NC, 27711 
 105 
Table 3.1. Kinetic parameters for deltamethrin and esfenvalerate metabolism by rat 
and human CYPs. 
 
 Km (µM) Vmax Vmax/Kma Vmax/Kmb 
  (pmoles/min/pmoleP450)   
Deltamethrin    
Rat CYPs     
2C6 21.6 ± 9.4 150.0 ± 36.6 6.9 3.4 ± 0.3 
2C11 31.9 ± 25.7 205.8 ± 107.6 6.5 5.2 ± 0.7 
3A2 6.4 ± 3.8 25.9 ± 5.8 4.0 2.1 ± 0.2 
     
Human CYPs    
2C8 10.2 ± 9.5 42.7 ± 16.6 4.2 1.6 ± 0.1 
2C19 9.0 ± 5.6 61.6 ± 17.7 6.8 2.2 ± 0.5 
3A5 - - - 4.8 ± 0.6 
     
Esfenvalerate    
Rat CYPs     
2C6 38.2 ± 26.2 158.2 ± 72.8 4.1 3.2 ± 0.3 
2C11 33.5 ± 21.8 219.4 ± 92.8 6.5 4.4 ± 0.4 
3A2 4.3 ± 1.8 39.5 ± 6.1 9.2 2.4 ± 0.5 
     
Human CYPs    
2C8 19.1 ± 11.6 59.2 ± 21.6 3.1 1.6 ± 0.3 
2C9*1 24.3 ± 5.6 79.8 ± 6.3 3.3 2.9 ± 0.2 
2C19 4.1 ± 2.2 64.4 ± 12.3 15.7 4.4 ± 0.6 
3A5 - - - 4.7 ± 0.7 
     
 
Kinetic assays conducted with concentrations ranging from 0.5-25 µM pyrethroid.  Data is 
the mean ± SE (N=3) 
aCalculated value using kinetic parameters obtained from non-linear regression analysis 
bCatalytic efficiency estimated from the slope of the linear regression analysis of 
concentration versus velocity plots. 
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Figure 3.1. Elimination of deltamethrin and esfenvalerate by rat CYPs. 
Elimination of 1 uM deltamethrin (black bars) or esfenvalerate (white bars) by rat CYP 
isoforms.  Assays were run with 10 pmoles P450 isozyme/ml.  Results are expressed as the 
average of the % eliminated over 10 min of duplicate samples. 
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Figure 3.2. Elimination of deltamethrin and esfenvalerate by human CYPs. 
Elimination of 1 uM deltamethrin (black bars) or esfenvalerate (white bars) by human CYP 
isoforms.  Assays were run with 10 pmoles P450 isozyme/ml.  Results are the average of the 
% eliminated over 10 min of duplicate samples. 
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Figure 3.3. Comparison of hydrolysis products of trans-permethrin and deltamethrin 
by esterases.  A, Overlay of HPLC chromatograms of hydrolysis products derived from each 
pyrethroid catalyzed by human carboxylesterase 1.  B and C, UV spectra of the hydrolysis 
products of trans-permethrin (type I pyrethroid) and deltamethrin (type II pyrethroid). 
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Figure 3.4. Hydrolytic metabolism of deltamethrin.  
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Figure 3.5. Comparison of hydrolysis rates of esfenvalerate and deltamethrin by whole 
rat serum and purified rat serum CE.   
A, Specific hydrolysis activity for each pyrethroid (50 µM) catalyzed by rat serum.   
B, Specific hydrolysis activity for each pyrethroid (50 µM) catalyzed by pure rat serum CE.  
C, Substrate concentration-velocity plot of deltamethrin hydrolysis in whole serum.   
D, Substrate concentration-velocity plot of deltamethrin hydrolysis by pure rat serum CE. 
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Figure 3.6. Quantitative immunoblotting of hCE1 protein (A) and hCE2 protein (B) in 
pooled human liver microsomes from four sources.   
Sources of pooled human liver microsomes: a, Cellz Direct; b, CDR; c, Xenotech; d, BD 
Biosciences.  Equal quantities of microsomal protein were loaded on each individual gel; 
however, 25-fold less protein was loaded on the gel in A (0.2 µg protein per lane) than in B 
(5 µg per lane).  Membranes were probed with rabbit anti-hCE1 antibody (A) or rabbit anti-
hCE2 antibody (B). 
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ABSTRACT 
 
 The pyrethroid pesticide deltamethrin is cleared nearly twice as rapidly in human 
liver microsomes compared to rat liver microsomes.  A species difference such as this could 
influence the relative toxic potency of deltamethrin in rats and humans.  A PBPK model was 
utilized to examine the impact of this species difference on exposure-dose relationships.  A 
previously-developed PBPK model for deltamethrin in the rat by Mirfazaelian et al. (2006) 
suggests that absorption is inversely dose-dependent, with little absorption of this pesticide at 
environmentally relevant exposures.  In addition, the Mirfazaelian et al. model employs a 
combination of flow- and diffusion-limited compartments and divides the blood compartment 
into plasma and red blood cells. Oral bioavailability studies were conducted to examine the 
dose-dependency in absorption of deltamethrin in the rat.  There was no significant 
difference in the fraction absorbed of oral doses of 0.3 and 3.0 mg deltamethrin/kg.  In 
contrast to the previous model, the current model described all tissue compartments with 
diffusion-limited kinetics and the blood as a single compartment.  These changes resulted in 
an improved ability of the current deltamethrin PBPK model to describe the shape of the 
deltamethrin tissue concentration-time curves for both literature data and data from the 
present oral bioavailability studies.  The description of the liver using diffusion- limited 
kinetics reduced the impact of the species difference in metabolism since diffusion is the 
rate-limiting step in the metabolic elimination of deltamethrin.  A proposed human PBPK 
model was also developed to explore differences in target tissue concentration of 
deltamethrin at the current reference dose (RfD) for human safety assessment. 
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INTRODUCTION 
 
Pyrethroids are synthetic pesticides used in the protection of a wide range of 
commercial crops, ornamentals, and trees.  They are also used in domestic insect control and 
as ectoparasiticides in both human and veterinary medicine (Roberts and Hutson 1999).  Due 
to restriction and removal of other pesticides from the market, the use of pyrethroids 
continues to increase.  Pyrethroid use has risen from 2.8% of the market share of lawn and 
garden pesticide use in 1993 to an expected 30% in 2008 (Freedonia Market Research, 2004).  
Numerous studies describe human exposure to pyrethroids (Zhang et al. 1991; Smith et al. 
2002; Heudorf and Angerer 2001; Schettgen et al. 2002).  Not only are humans exposed to 
pyrethroids, reported cases of acute pyrethroid poisoning reveal a similar set of symptoms 
(He et al. 1989) to those seen in laboratory animals, suggesting similar modes of action 
across species.  A better understanding of the human health risks associated with pyrethroid 
exposure is therefore increasingly important. 
Understanding human health risks associated with environmental contaminants such 
as the pyrethroids necessitates extrapolation from laboratory animal data.  In the absence of 
human data, physiologically based pharmacokinetic (PBPK) models can improve the 
scientific basis of extrapolating the relationships between external exposures to internal 
measures of dose between laboratory animals and humans (Andersen, 2003).  PBPK models 
allow the incorporation of species-specific physiological and biochemical data to aid species 
extrapolation of exposure dose relationships.   
Recently, species differences in the in vitro hepatic and serum metabolism of the 
pyrethroid deltamethrin were identified between rats and humans (Godin et al 2006, 2007).  
Intrinsic hepatic clearance of deltamethrin clearance is nearly twice as rapid in human 
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hepatic microsomes as compared to rat hepatic microsomes (Godin et al., 2006).  In addition, 
rat serum contains carboxylesterases which metabolize deltamethrin (Annand et al. 2006; 
Godin et al., 2007), while deltamethrin remains intact in human serum because of its lack of 
carboxylesterases (Godin et al., 2007; Crow et al. 2007).  Pharmacokinetic (PK) differences 
such as these have the potential to influence exposure-dose relationships at target tissues and 
thus alter the relative potency of a chemical between a test species and humans.  Application 
of PBPK models allow for the quantitative examination of how species differences, such as 
those for deltamethrin metabolism, affect the extrapolation of exposure-dose relationships. 
Mirfazaelian et al (2006) developed a PBPK model for deltamethrin in the adult male 
Sprague-Dawley rat, and applied a saturable efflux process in the gastrointestinal (GI) 
compartment that predicts very low absorption of deltamethrin at low, environmentally 
relevant exposures.  However, the available data in the literature does not demonstrate an 
inverse dose-dependent absorption of deltamethrin as the model indicates (see Fig 1).  Fecal 
excretion of deltamethrin is approximately 13- 37% of an administered oral dose and weakly 
linearly dose dependent (Bosch 1990; Ruzo et al., 1978).   
The Mirfazaelian et al. model describes the fat and slowly perfused tissues as 
diffusion-limited while using flow-limited descriptions for the brain, liver and richly perfused 
compartments.  Lacking in the assessment of this model is data from the liver, which may be 
important to understand whether deltamethrin displays diffusion-limited or flow-limited 
pharmacokinetics.  The liver is the primary organ for metabolic clearance of deltamethrin.  
Literature regarding liver concentration time courses for deltamethrin is limited to two IV 
studies (Gray and Rickard 1981 and 1982).  These two studies reported only total 
radioactivity in the liver.  The use of total radioactivity as the measure of tissue dose limits 
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the utility of these data for model development or evaluation because a major portion of the 
radioactivity could be deltamethrin metabolites.  The choice of describing the liver as either 
flow- or diffusion-limited has implications for the contribution of species differences in 
hepatic clearance of deltamethrin to species differences in the toxicity of deltamethrin.  In the 
flow-limited description hepatic clearance will have a larger impact on blood concentrations 
than in the diffusion-limited description.  This difference arises because in the diffusion-
limited description diffusion limitation dampens the influence of the intrinsic hepatic 
clearance rate on the blood levels of the chemical.  Given the pivotal role of the liver in the 
disposition of deltamethrin, it is important to include data for this compartment in the 
assessment of the model.  
Several of the assumptions outlined above in the Mirfazaelian et al. (2006) model 
were because of inconsistencies in the literature or from a lack of data.  Based on these 
identified uncertainties and data gaps, a series of experiments were performed in this work.  
An oral bioavailability experiment was conducted to explore possible dose-dependent 
absorption of deltamethrin.  In addition, a time-course study examining tissue disposition of 
deltamethrin after an oral dose was conducted to aid model development and assessment.  
Using these new data and the Mirfazaelian et al (2006) model as a framework, a refined 
PBPK model for deltamethrin in rats was developed.  This refined model was then used as 
the basis for the development of a human PBPK model for deltamethrin.  Predictions 
obtained with the human and rat model suggested that, for the same oral exposure, humans 
would have a marginally higher peak concentration in the target tissue, despite having the 
intrinsic ability to metabolize deltamethrin more rapidly.  
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MATERIALS AND METHODS 
 
Chemicals 
Deltamethrin (98.9% purity) ((αS)--cyano-3-phenoxybenzyl (1R, 3R)-cis-3-(2,2-
dibromovinyl)-2,2-dimethylcyclopropane carboxylate) was a gift from Bayer Crop Sciences 
(Research Triangle Park, NC, USA).  Labeled cis- and trans-permethrin (phenoxy-13C6) were 
purchased from Cambridge Isotope Laboratories (Andover, MA).  Chromasolv® acetonitrile 
and methanol for LC/MS applications were from Riedel-de Haën (Seelze, Germany).  
Solvents, including acetone, hexanes (Fisher Scientific, Pittsburgh, PA) and methanol (VWR, 
West Chester, PA), were pesticide grade.  Glycerol formal, heparin, dextrose, and saline were 
purchased from Fisher Scientific (Pittsburgh, PA).  Unless otherwise specified all chemicals 
were of the highest grade commercially available.   
 
Animals 
The USEPA National Health and Environmental Effects Research Laboratory 
Institutional Animal Care and Use Committee approved all animal procedures.  Male Long 
Evans rats (approximately 70 days old) were obtained from Charles River Laboratory 
(Raleigh, NC USA) with or without jugular vein catheters.  Animals were allowed to 
acclimate for a minimum of four days in an Association for Assessment and Accreditation of 
Laboratory Animal Care approved animal facility prior to their use.  Two animals were 
housed per plastic cage (45 cm x 24 cm x 20 cm) with heat-treated pine shavings bedding for 
disposition stuidies.  Cannulated animals for bioavailability studies were housed one animal 
to a cage.  Animals were maintained at 21 ± 2°C, 50 ± 10% humidity and a photoperiod of 
12L:12D (0600-1800 hr).  Feed (Purina Rodent Chow 5001, Barnes Supply Co., Durham, 
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NC USA) and tap water were provided ad libitum.  Animals were exposed to deltamethrin in 
either glycerol formal (iv) or corn oil (po) at 1 mg/ml dosing volume.  Doses included a 1 
mg/kg iv dose and 0.3 and 3.0 mg/kg oral doses via gavage.  Oral doses were determined 
from the work of Wolanskiy et al. (2006), which examined the dose response relationship of 
deltamethrin for decreased motor activity.  The 3.0 mg/kg dose was approximately an ED30 
for decreased motor activity and the 0.3 mg/kg dose was used to compare absorption 
differences at a lower and more environmentally relevant dose. 
 
Blood Collection 
 Cannulated rats were dosed orally via gavage or iv through the indwelling jugular 
vein catheter.  There were four animals for each dose by the oral route and four animals for 
the iv route.  Serial blood samples were taken at time points ranging from 5 min – 36 hr post-
dosing.  300 uL aliquots of blood were removed via the catheter and immediately flash 
frozen in liquid nitrogen.  Between each sampling time, catheters were rinsed with 300 uL 
saline and filled with a void volume of heparanized dextrose as a lock solution to maintain 
catheter patency.  
 
Liver, Brain, and Fat Collection 
A second group of rats were exposed via gavage with 0.3 or 3.0 mg/kg deltamethrin 
in corn oil at a volume of 1 ml/kg.  At time points ranging from 1-48 hrs, animals were 
sacrificed via CO2-induced anesthesia and blood was collected via cardiac puncture.  Brain, 
liver and fat were immediately removed, weighed, and flash frozen in liquid nitrogen.  Tissue 
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samples were stored at -80 °C until residue analysis was performed.  For each dose, there 
were 4 rats per time point. 
 
Tissue Extraction 
Brain, liver, and fat were homogenized in a Spex CertiPrep 6850 freezer/mill 
(Metuchen, NJ) to form a fine homogeneous tissue powder.  Aliquots of thawed blood (0.3 
ml) and tissue homogenate (300-500 mg) were vortex extracted with 20:80 acetone:hexane.  
25 µL of 6 µM labeled trans-permethrin (phenoxy-13C6) was added prior to extraction as a 
surrogate of recovery.  Samples were vortexed for 10 min in 16 x 100 mm culture tubes with 
5 ml solvent and centrifuged at 4000 x G for 10 min.  The organic layer was collected.  The 
process was repeated twice more with 3 ml solvent, combining organic fractions of each 
extraction.  Pyrethroid-containing organic fractions were dried under nitrogen and 
reconstituted in 1 ml hexane.  Brain samples were then loaded onto a hexane rinsed Sep-pak 
500 mg silica solid phase extraction (SPE) columns (Waters, Inc., Milford, MA).  SPE 
columns were washed with 5 ml hexane and the pyrethroids were eluted with 5 ml 94:6 
hexane:ethyl acetate.  Column eluants were dried under a stream of nitrogen, and 
reconstituted in 1 ml of 90:10 methanol:water with 25 µL of 6 µM cis-permethrin added as 
an internal standard of instrument efficiency for LC/MS analysis.  The solid phase cleanup 
was automated using a RapidTrace SPE Workstation (Hopkinton, MA).  Liver and fat 
extracts were loaded onto a silica containing analytical GPC preparatory column and run 
with a 70% ethyl acetate, 30% cyclopentane mobile phase at 5 mL/min.  A 25 mL fraction 
containing the pyrethroids was collected with a fraction collector and then dried under a 
stream of nitrogen.  Samples were reconstituted  in 3 ml hexane.  Liquid-liquid extraction 
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was conducted with equal volumes of the hexane extracts and hexane saturated acetonitrile.  
The liquid-liquid extraction was repeated 3 times and the acetonitrile fractions were 
combined, dried under a stream of nitrogen and reconstituted in 1 ml of 90:10 
methanol:water with 25 µL of 6 µM Labeled cis-permethrin (phenoxy-13C6) added as an 
internal standard of instrument efficiency for LC/MS analysis.  
 
Residue Determination 
An Agilent (Palo Alto, CA USA) 1100 series LC/MSD VL ion trap mass 
spectrometer and HP Chemstation software were used for identification and quantification of 
pyrethroid parent chemicals as previously described by Godin et al (2006) with minor 
modifications. Briefly, isocratic elution of chemicals was accomplished with an Agilent 
Zorbax Eclipse XDB – C18 column (4.6 x 100 mm, 3.5 µm pore size) and XDB C-18 guard 
column with a mobile phase of 90% methanol and 10% 5 mM ammonium formate at a flow 
rate of 0.5 ml/min.  Deltamethrin identification and quantification was accomplished by 
fragmentation of the ammonium adducted ion [M+NH4]+  (m/z 523) to produce the parent ion 
[M+H]+ (m/z 506).  Pyrethroids were quantified using at least a five-point calibration curve, 
prepared in tissue appropriate matrix, containing 13C6-cis-permethrin internal standard.  
Residue concentrations were determined by the ratio of internal standard response to the 
analyte response.  Calibration standards ranged from 1 to 500 ng/ml.  Method limits of 
deltamethrin quantification were approximately 5 ng/ml or g for blood and brain, and 10 ng/g 
for liver and fat.  Extraction integrity was ensured by adding trans-permethrin (phenoxy-13C6) 
surrogate standard to each sample prior to extraction.  Surrogate recovery values of 80-120% 
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of expected were deemed acceptable and required no correction.  Samples with surrogate 
recoveries above or below the acceptable range were reanalyzed. 
 
Bioavailability Analysis 
 Bioavailability was calculated for 0.3 mg/kg and 3.0 mg/kg po doses using equation 
(1) and a 1mg/kg iv dose.  
 
Bioavailability = (AUCpo/AUCiv)*(Doseiv/Dosepo)    (1) 
 
Where AUCpo represents the area under the curve to infinity for the blood after an oral dose 
(Dosepo) and AUCiv represents the area under the curve for the blood to infinity after an 
intravenous dose (Doseiv). 
 
PBPK Modeling  
 All PBPK modeling employed AcslXtreme software version 2.3.0.12 (The AEgis 
Technologies Group Inc., Huntsville, AL).  An initial PBPK model for deltamethrin was 
developed based on the model of Mirfazaelian et al (2006); this initial model is further 
referred to as the mixed kinetics model.  Tissue compartments included brain (target tissue), 
liver (metabolic compartment), fat, slowly perfused, and richly perfused tissues.  Tissue 
compartments were connected via a single blood compartment.  The model includes a two 
compartment GI tract for description of uptake and fecal excretion of an oral dose similar to 
that of Timchalk et al (2002).  This model varied from that of Mirfazaelian et al (2006) by 
removal of the GI Juice compartment and the rate constant for ‘stomach’ (Ks) absorption.  
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These parameters were removed as they were found by preliminary modeling to have no 
influence on model predictions of peak and time to peak blood and tissue concentrations.  
The present model describes the blood as a single compartment since there was no difference 
in deltamethrin blood and plasma concentrations (Mirfazaelian et al., 2006).  Fecal excretion 
was also modified as the saturable absorption process described by Mirfazaelian et al. (2006) 
is inconsistent with reported data on fecal excretion of deltamethrin (Fig. 1) (Bosch 1990; 
Cole et al., 1982; Crawford et al., 1981a, b; Ruzo et al., 1978) and the current bioavailability 
study (see Results below).  Fecal excretion was therefore described by a first order rate 
constant (see Modeling Equations).  The fecal excretion rate constant was therefore set so 
that excretion equaled 25% of the oral dose since this is approximately the median of the 
range of reported values in the literature (Bosch 1990; Cole et al., 1982; Crawford et al., 
1981a, b; Ruzo et al., 1978).  Figure 2 depicts the general model structure.  Fat and slowly 
perfused tissues were modeled as diffusion-limited compartments and the brain, liver, and 
richly perfused compartments were modeled as flow-limited.  This model is therefore 
referred to as the mixed kinetics model.  All chemical parameters (partition coefficients) 
were from Mirfazaelian et al (2006) with the exception of hepatic clearance, which was taken 
from Godin et al. (2006).  In order to achieve comparable simulations to Mirfazaelian et al. 
(2006), hepatic clearance required attenuation by a factor of 4 (from 5.3 – 1.325 L/hr/Kg).  
The initial mixed model, effectively equivalent to Mirfazaelian model, was unable to 
adequately simulate the data from the current study or from the iv dose study of Gray and 
Rickard 1982.  Consistent with this finding, we note that Mirfazaelian et al. 2006 were also 
unable to adequately simulate the date of Gray and Rickard 1982. 
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Diffusion-Limited Model Development and Computational Approaches 
Further model development focused on diffusion-limited descriptions in all tissue 
compartments (Fig 2 and Modeling Equations).  This model is referred to as the diffusion-
limited computational (comp) model.  As in the previous model physiological parameters 
were determined from the available literature (see Table 1).  Partition coefficients (PT) for 
each tissue compartment were calculated by the computational approach of Poulin and Theil 
(2000).  This method is based on tissue composition and describes the expected solubility of 
the chemical in each tissue compartment based on water and lipid content of different tissues.  
Description of oral absorption was based on the model of Timchalk et al (2002) with the 
exception of the rate constant for stomach absorption (Ks) which was removed.  Initial results 
and optimization of Ks resulted in values close to zero, which did not influence peak and time 
to peak blood concentrations.  Metabolism parameters for liver and blood clearance were 
based on the data of Godin et al. (2006, 2007).  Permeability area coefficients (PATC) 
(diffusion limitation) were first fit to the 3 mg/kg po data from this study via visual fitting 
and subsequently optimized with AcslXtreme OpStat parameter estimation software.   
AcslXtreme OpStat software utilizes maximum likelihood estimation to fit parameter 
values.  The likelihood function assumes that the data are statistically independent and 
normally distributed.  When the heteroscedascity parameter (γ) is set equal to 0, error is 
calculated as absolute error (normal) and when γ is equal to 2 error is calculated as relative 
error (log-normal).  Model parameters were estimated with γ equal to 2 as data error was 
proportional to concentration (constant coefficient of variation).  
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Diffusion-Limited Model Optimization 
The diffusion limited computational model severely overestimated brain tissue 
concentrations at all time points.  Because of possible bias in other partition coefficients and 
the interdependence with permeability area coefficients, both sets of parameters were 
optimized for all compartments using Acsl OpStat.  Furthermore, a diffusion-limited 
structure was maintained for all compartments. The optimized model is referred to as the 
optimized diffusion-limited model.  Parameter optimization was done in the following 
stepwise manner.  PT and PATC for richly and slowly perfused compartments were optimized 
to the 1 mg/kg iv blood concentration data in order remove oral absorption as a confounding 
factor.  Blood, liver, brain, and fat PT and PATC were then optimized to fit the blood, liver, 
brain, and fat tissue concentration data from the 3.0 mg/kg po dose.  All tissue distribution 
parameters were estimated with the fraction of the oral dose absorbed set to 25% as 
previously described.  Oral absorption parameters were then estimated to further optimize the 
fit of model predictions to the blood, liver, fat and brain data from the 3 mg/kg oral dose.  
Final parameterization resulted in approximately 27% of the oral dose excreted in the feces.  
While estimated partition and permeability coefficients for the fat accurately predicted data 
from this study final parameters required adjustment post optimization via visual fit.  This 
was due to underestimation of later time points from two literature studies (Ruzo et al. 1978; 
Mirfazaelian et al. 2006). Literature data included time points at 8, 14, and 21 days post 
exposure whereas the present study only included time points out to 48 hr.  The discrepancy 
was determined to be due to the weighting of the numerous time points in the first 48 hours 
of this study by Acsl OpStat during the error minimization routine influencing final 
parameter estimates.  This change did not influence model predictions in other tissue 
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compartments including target tissue concentrations as it did not significantly affect fat  
concentration predictions out through 48hrs (see results).  
 
Sensitivity analysis 
 Sensitivity analysis was conducted utilizing the sensitivity analysis software in 
AcslXtreme OpStat.  Analyses were conducted for the optimized diffusion-limited model 
structure.  Model parameters were increased by 0.1% to assess their impact on model 
prediction of peak blood and brain concentrations.  Sensitivity coefficients were normalized 
to both the response variable (model output value) and the parameters of interest (parameter 
being adjusted) (Evans and Anderson 2000; Mirfazaelian et al 2006). 
 
Extrapolation from rat to human PBPK model 
The optimized diffusion-limited (op) rat PBPK model was extrapolated to develop a 
human PBPK model for deltamethrin.  The model was extrapolated by the use of human 
physiological parameters for cardiac output, cardiac output to individual tissue, volume of 
individual tissues, and blood volume fractions from the literature (Table 1).  All other model 
parameters were held constant from the rat models except for metabolic parameters that were 
obtained from Godin et al. (2006; 2007). 
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RESULTS 
 
Bioavailability analysis 
 Blood concentration data after iv dosing of 1 mg/kg deltamethrin in glycerol formal 
and 0.3 and 3.0 mg/kg oral doses in corn oil were used to assess the oral  bioavailability of 
deltamethrin.  The blood concentrations vs time graphs and the AUCs for the 1 mg/kg iv 
dose and 0.3 and 3.0 mg/kg oral doses are presented in Figures 3a-c and Table 2.  The oral 
bioavailability of deltamethrin was 25% ± 5% (mean ± SD?) at the 0.3 mg/kg dose and 28% 
± 7% at the 3.0 mg/kg dose (Table 2).  Based on the dose range utilized and the tissue 
concentrations of deltamethrin observed (below Km for deltamethrin metabolism, Godin et al 
2006), hepatic clearance of deltamethrin is expected to be in the linear range.  This result 
indicates that there is no significant difference in the extent of absorption of deltamethrin at 
these two doses.  Bioavailability of deltamethrin was higher in this work as compared to 
previous reports by Kim et al (2007) and Anadon et al. (1996), which reported approximately 
15% bioavailability at oral doses of 10 and 26 mg/kg, respectively.  This difference is likely 
due to experimental conditions including dosing vehicle and volume (Crofton et al. 1995; 
Kim et al 2007).   
 
Simulation of Blood Concentrations 
 IV exposure to deltamethrin leads to its rapid distribution to all tissues.  A biphasic 
decline in deltamethrin concentrations in the blood (Fig 3a inset) was observed in the first 4 
hr after injection of a bolus dose, a result similar to the data of Gray and Rickard (1982) (Fig 
4.4).  The optimized diffusion limited model accurately predicted the shape of this blood 
concentration time course data (Fig 4.3 and Fig 4.4). 
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 Blood concentrations of deltamethrin after single 0.3 and 3.0 mg/kg oral doses were 
compared to model predictions (Figs 3b and c).  Deltamethrin is rapidly absorbed after oral 
exposure with peak blood concentrations 1-2 hr post-exposure.  Model predictions from the 
optimized diffusion limited model resulted in peak blood concentrations after 1.5 hrs.  The 
optimized diffusion-limited model accurately predicted the rapid rise in blood concentration, 
peak concentration and the rapid elimination of deltamethrin from the blood at both doses.  
These results further confirm the bioavailability results indicating that there does not appear 
to be any dose-dependent absorption of deltamethrin at the doses examined.  Metabolism of 
deltamethrin in the serum did not affect model predictions (data not shown) and only 
accounted for a fraction (less than 1%) of the metabolism of the absorbed dose in the model. 
 
Simulation of Brain Concentrations 
 Brain concentrations of deltamethrin were at or below limits of detection in the 0.3 
mg/kg exposure group at all time points examined.  Brain concentration data peaked at 3 hrs 
in animals exposed to 3 mg deltamethrin/kg.  The use of a computationally derived brain 
partition coefficient resulted in drastic over estimation of brain concentrations of 
deltamethrin by the model.  Accurate prediction of peak brain concentrations could be 
obtained by adjusting the permeability area coefficient alone however doing so could not 
describe the shape of the concentration time curve in the brain.  Lowering the brain partition 
coefficient by nearly 300-fold resulted in more accurate model predictions of the brain 
concentration-time course data (Table 1).  The optimized diffusion-limited model predicted 
peak brain concentrations at 2.6 hrs and accurately fit declining concentrations of 
deltamethrin (Fig. 5).  The delay in peak brain concentration relative to peak blood 
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concentrations is a good indication that the diffusion-limited description of the brain 
compartment is appropriate.  Initial modeling attempts with the mixed model structure of 
Mirfazaelian et al (2006) resulted in more rapid peak brain concentrations (results not 
shown). 
 
Simulation of Liver Concentrations after oral exposure 
 The concentration of deltamethrin in the liver rose rapidly after the oral dose of 3.0 
mg/kg, peaking 1-2 hrs after exposure and decreasing to undetectable levels within 8-10 hrs 
of exposure (Fig 6).  Liver concentrations were below detection limits in the 0.3 mg/kg dose 
group.  The optimized diffusion-limited model accurately predicted peak tissue 
concentrations of deltamethrin as well as the rapid decline in tissue concentrations (Fig 6).  
The liver is the main tissue for metabolic elimination of pyrethroids and rapidly metabolizes 
deltamethrin (Godin et al 2006; Mirfazaelian et al 2006).  The rapid decline of deltamethrin 
concentrations in the liver is consistent with its rapid metabolism in this tissue. 
 
Simulation of Fat Concentrations after oral exposure 
 Fat concentrations of deltamethrin were determined out to 48 hr after oral exposures 
of 0.3 and 3.0 mg/kg.  Fat concentrations of deltamethrin peaked within 8 hrs of dosing (Fig 
7).  The optimized diffusion limited model accurately predicted the concentration time curves 
at both exposures (Fig 7).  Model predictions using the computationally derived fat partition 
coefficient were similar to model predictions using the final optimized partition coefficient 
(Fig 7).  Despite a five-fold difference in the partition coefficients, the use of either value 
resulted in fits consistent with the data up to 48 hr hours post exposure.      
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Simulation of literature data 
 PBPK model prediction were compared to available literature data on deltamethrin 
tissue dosimetry obtained by Gray and Rickard (1982) (Fig 4.4, and Fig 4.8), Mirfazaelian et 
al. (2006) (Fig 4.9), and Ruzo et al. (1978) (Fig 4.10).  Gray and Rickard (1982) exposed 
animals to 1.75 mg deltamethrin/kg iv and followed blood concentrations over 4 hrs post 
dosing.  As previously described, the blood concentration data of Gray and Rickard (1982) 
displays a biphasic distribution over the first 4 hrs.  This biphasic clearance is similar to that 
seen in the current study, which is accurately described by the optimized diffusion-limited 
model (Fig 4.3 and Fig 4.4).  Gray and Rickard (1982) also reported concentrations of 
deltamethrin in three different regions of the brain with very little variability between 
regions. Fig 4.8 depicts model prediction compared to the average brain concentration of 
deltamethrin from Gray and Rickard (1982).  The optimized diffusion-limited model 
predictions compared very well with this data.  The brain data, similar to the blood data, has 
a biphasic time course which is also described well by the optimized diffusion-limited model. 
There were some inconsistencies in predictions of the optimized diffusion-limited 
model of the Mirfazaelian et al (2006) data.  Some of the inconsistencies are related to study 
design and data.  For example, the fat concentration data from both studies are similar up to 
the last time point (48 hrs) examined in the present study.  However, the Mirfazaelian et al 
data includes time points to 336 and 504 hr.  The diffusion-limited model using the 
computationally derived partition coefficient for fat overpredicts the fat concentration data of 
Mirfazaelian et al (2006) at the later time points (not shown).  Optimization towards the fat 
data from this study resulted in underprediction of the late time points.  Visual fitting of the 
fat partition coefficient and permeability area coefficient resulted in good agreement with the 
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data for the 2 and 10 mg/kg oral doses from Mirfazaelian et al. (2006) (Fig 9 B and C).  
Simulation of blood concentrations from Mirfazaelian et al (2006) with the optimized 
diffusion-limited model also resulted in good agreement with the published data (Fig 9 B and 
C).  In contrast, the optimized diffusion-limited model was unable to accurately describe the 
time course for the brain deltamethrin concentration of Mirfazaelian et al. (2006).  The brain 
concentration time course from Mirfazaelian et al (2006) has a significantly different shape 
to the tissue concentration time curves than the data from this study (Fig 5 compared to Fig 9 
B and C).  Brain concentrations remain elevated for a greater period of time in the study of 
Mirfazaelian et al. (2006). 
 Ruzo et al. (1989) reported tissue residues of deltamethrin in the fat at 8 days (192) 
hr) hours post oral dosing at three different dose levels.  The final optimized diffusion limited 
model resulted in good agreement with these data (Fig 10).  This further increases confidence 
in the visually optimized fat partition and permeability area coefficients determined with the 
data of Mirfazaelian et al. (2006). 
 
Sensitivity Analysis 
 Sensitivity analysis was conducted on the optimized diffusion-limited model 
structure.  Model parameters were increased by 0.1% to evaluate their influence on peak 
blood and brain concentrations of deltamethrin.  Figure 11 presents the normalized sensitivity 
coefficients for each parameter in the model.  The parameter that had the greatest impact on 
both blood and brain concentrations was the volume of the slowly perfused tissue 
compartment (vsc).  This is the largest compartment in the model.  The muscle accounts for 
most of its mass.  Parameters that influence the liver, liver blood flow (qlc) and the diffusion 
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limitation (palc), were also highly sensitive model parameters.  Increasing any of these 
parameters leads to increased diffusion of the chemical from blood into the liver, resulting in 
increased hepatic metabolism and decreased blood and brain concentrations of deltamethrin.  
Hepatic clearance is diffusion limited, so the metabolic clearance parameter is not itself a 
sensitive parameter. 
Absorption parameters were also relatively sensitive.  Fecal excretion (kfe), when 
increased, decreased peak blood and brain concentrations by reducing the amount of 
deltamethrin absorbed into the systemic circulation.  Conversely, increases in Ki and Ksi, 
which describe the transfer and uptake of deltamethrin through the GI compartment, resulted 
in increases in peak blood concentrations due to more rapid and greater deltamethrin 
absorption.  Partitioning (pb) and the diffusion limitation (pbrc) in the brain impact peak 
brain concentration but have no significant effect on blood concentrations.   
 
Human Modeling 
Utilizing the diffusion-limited (op) model structure, the rat model was extrapolated to 
a human model using human physiological and metabolic parameters.  The human 
physiological parameters are from Brown et al. (1995) and are presented in Table 1.  Human 
metabolic parameters for hepatic and serum clearance are from Godin et al (2006; and 2007).   
Data from controlled human exposure to deltamethrin is limited to an oral absorption 
study in three healthy volunteers conducted by Roussel-Uclaf in 1984.  Volunteers were 
given a single 3 mg oral dose of deltamethrin in a suspension of 10 mL of poly (oxyethlene 
glycol)-300 and diluted with water to a final volume of 150 mL.  This corresponds to 
approximately a 0.43 mg/kg dose of deltamethrin in these subjects, all of whom were 
  133 
approximately 70 kg.  Data was reported as total radioactivity in the blood, urine, and feces 
and does not differentiate between parent chemical and metabolites.  This makes 
comparisons with the current model difficult as it was based on actual measured deltamethrin 
concentrations.  Cumulative urinary excretion of radioactivity averaged 48 ± 3% of the oral 
dose after 96 hrs.  Cumulative fecal excretion averaged 17 ± 8%, with a range of 10-25%, of 
the administered dose after 72 hrs.  This range is within literature values for fecal excretion 
in rats (Bosch 1990; Cole et al., 1982; Crawford et al., 1981a, b; Ruzo et al., 1978).  Based 
on the limited number of subjects, the use of a large volume of an aqueous vehicle, and the 
use of total radioactivity as a measure of dose, it is difficult to compare the fecal excretion in 
the human study to those of rodent studies.  Therefore, we decided to use the rat fecal 
excretion rate in the human model 
The cumulative urinary and excretion in the human study accounts for approximately 
48% of the total radioactivity of the administered dose (Roussel-Uclaf 1984).  Based on 
literature reports, only hydrolyzed metabolites of pyrethroids are present in the urine and the 
parent chemical, with minor amounts of hydroxylated metabolites, are excreted in the feces 
(Bosch 1990; Cole et al., 1982; Crawford et al., 1981a, b; Ruzo et al., 1978).  In vitro studies 
suggest that in humans, deltamethrin is primarily metabolized by hepatic esterases to 
hydrolyzed products (Godin et al 2006). Thus, it would be expected that the radioactivity in 
the urine from the human study was primarily hydrolyzed deltamethrin metabolites.  
Therefore, the percent of the administered dose metabolized in the human PBPK model may 
be able to be used as a surrogate to compare to the human urinary excretion data.  The 
diffusion-limited (op) model, however, predicted 66% percent of an oral dose was 
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metabolized over 96 hr.  Based on these data it is unclear whether there is a correlation 
between urinary excretion of radioactivity and the total predicted metabolized dose. 
Simulation of brain tissue concentrations of a 1 mg/kg oral dose of deltamethrin (rat 
NOAEL), based on the current optimized model, revealed that the diffusion-limited model 
structure leads to brain concentrations that are 1.8-fold greater in the human model than in 
the rat model (Fig 12).  Concentrations of deltamethrin in the brain also remain elevated for a 
significantly longer time in the human than in the rat model.  These differences are the result 
of physiological differences in the brain of rats and humans, which are reflected in the model.  
Cardiac output to the brain and brain volume (% BW) in humans is five and four times 
greater, respectively, than in the rat, resulting in a greater predicted CNS exposure of 
deltamethrin in humans. 
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DISCUSSION 
An initial PBPK model for deltamethrin by Mirfazaelian et al (2006) makes several 
assumptions necessitated by either inconsistent or limited data available from the literature.  
One of the inconsistencies involves oral absorption.  Mirfazaelian et al (2006) assumed that 
oral absorption of deltamethrin was dose-dependent (inversely).  Our analysis of the 
available literature indicated that there was a potentially linear relationship (Fig 1).  In order 
to resolve ambiguities in the data, the present study examined the bioavailability of 
deltamethrin at two doses, one at the approximate ED30 (3.0 mg/kg) for motor activity 
(Wolansky et al. 2006) impairment and a second ten-fold lower (0.3 mg/kg).  Results indicate 
that there is no significant difference in the oral bioavailability of deltamethrin at the dose 
levels examined.  In addition the present model, incorporating a first order rate constant for 
hepatic clearance, was able to accurately predict blood concentrations across a range of doses 
(0.3 – 10.0 mg/kg) from these studies and literature studies (Gray and Rickard 1982; 
Mirfazaelian et al 2006; Ruzo et al 1978). These results indicate that there is no significant 
difference in the oral absorption of deltamethrin and that oral absorption of deltamethrin is 
not dose-dependent within the range of available data sets and dose range in the literature.  
Changes in oral bioavailability are most likely to be vehicle dependent (Kim et al 2007) 
Due to the lack of dose-dependent absorption of deltamethrin, we developed a 
simpler model for oral absorption than was used by Mirfazaelian et al (2006).  Our 
description of oral absorption was based on the PBPK model of Timchalk et al (2002) for 
chlorpyrifros, an organophosphate pesticide.  The oral absorption consists of a two 
compartment model (Fig 2).  Of note is the similarity in the KSI parameter, as compared to 
the model of Timchalk et al (2002), which describes the passage of the chemical from 
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compartment 1 to compartment 2 in the GI tract and was necessary to describe time to peak 
blood concentration.  This similarity may have some physiological relevance as a parameter 
describing gastric emptying and may be useful in future modeling of other pyrethroids.  
Parameter estimations were initially completed with KSI, KI and KFE parameters set and held 
constant so that fecal excretion equaled 25% of the oral dose.  Final optimization of 
absorption and excretion parameters to optimize fits in all other tissue compartments resulted 
in fecal excretion of 27% of the oral dose.  Both values are within the range of fecal 
excretion found in the literature for deltamethrin and other pyrethroids (Bosch 1990; Cole et 
al., 1982; Crawford et al., 1981a, b; Ruzo et al., 1978).  As stated previous, fecal excretion 
and therefore oral absorption is likely a vehicle dependent parameter (Kim et al 2007). 
Initial modeling of deltamethrin based on the mixed model structure does not 
accurately describe tissue time course data for deltamethrin, particularly after an iv dose (data 
not shown) The mixture model required attenuation of the hepatic clearance constant from 
Godin et al (2006) by 4-fold in order to approximate tissue concentrations but still could not 
accurately describe the shape of the tissue concentration time curves.  Because there is no 
evidence of significant protein binding of pyrethroids in hepatic microsomes (Abu-Qare and 
Abou-Donia, 2002; Hoellinger et al 1985) which could affect their free concentration in the 
liver, there does not appear to be a physiologically relevant reason to attenuate metabolism.  
Based on this result and the inability of the initial mixed kinetic model to describe the shape 
of tissue concentration time curves, the model was modified to describe all tissues as 
diffusion-limited.  Diffusion limitation in the liver reduces the rate at which a chemical enters 
and exits a tissue compartment, decreasing the amount of chemical available for metabolism.  
Comparison of liver tissue concentrations to model predictions showed the diffusion-limited 
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model accurately described the rapid decrease in liver tissue concentrations of deltamethrin 
(Fig 6).  The use of a diffusion-limited description of the liver allows for the incorporation of 
the hepatic clearance values of Godin et al (2006) without attenuation. 
The clearest evidence supporting a diffusion-limited description of deltamethrin was 
found in the ability of the model to describe the shape of the blood concentration time curves 
after iv dosing.  In this study and the study of Gray and Rickard (1982) iv administration of a 
bolus dose of deltamethrin was followed by a biphasic distribution of deltamethrin from the 
blood within a few hours of exposure (Figs 3a inset and 4).  This was accurately described by 
the diffusion limited model in contrast to the initial mixed kinetic model.  The diffusion-
limited model was also able to describe the shape of the tissue concentration time curve in 
the brain after the same 1.75 mg/kg dose (Gray and Rickard 1982) (Fig 8).  The brain, like 
the blood displayed a biphasic distribution that was accurately depicted by the diffusion-
limited model, but not by the mixed model with flow limitations.  While other model 
structures may be able to provide adequate descriptions of some deltamethrin tissue 
concentration time curves (see Mirfazaelian et al 2006), they do not appear to be able to 
accurately describe the rapid changes in tissue concentrations after an iv dose, while the 
diffusion limited model can. 
The target tissue for pyrethroid neurotoxicity is the central nervous system (Rickard 
and Brodie 1985).  Accurate prediction of brain concentrations is therefore central to the 
ability to scale rat toxicity data to humans.  The diffusion-limited model accurately predicted 
brain tissue time course data from a 3 mg/kg dose in this study and after a 1.75 mg/kg iv dose 
(Gray and Rickard 1982).  However, this model did not accurately predict the brain 
concentrations time curves from Mirfazaelian et al (2006) or Anadon et al (1996).  There is 
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inconsistency in the data for brain deltamethrin concentrations between these studies.  The 
data from Mirfazaelian et al (2006) (Fig 9) and Anandon et al (1996) indicate that 
concentrations in the brain remain elevated for extended periods.  It is difficult to assess why 
differences exist from each of these studies.  However, the work of Mirfazaelian et al (2006) 
and Anandon et al (1996) used HPLC/UV quantification.  Gray and Rickard (1982) 
conducted their study utilizing radiolabeled deltamethrin with TLC.  Our study utilized mass 
spectrometry to identify and quantify deltamethrin. Modeling indicates that our data 
correlates well with the data of Gray and Rickard (1982).   Mass spectrometry and radiolabel 
analysis are more specific identification methods than HPLC/UV and this could be a 
potential reason for differences in the results across these studies. 
Our modeling efforts utilized computational methods to estimate partition coefficients 
for the different tissues of the body.  The computationally derived parameters were very near 
optimized values in tissue compartments except for the fat and brain (Table 1).  The 
discrepancies between computational and optimized values in the brain and adipose tissue 
suggest that there are unidentified biological processes that regulate the distribution of 
deltamethrin to these tissues.  It is also possible that there are limitations to the ability of the 
computational methods to accurately predict lipid rich tissues.    In the brain this may be due 
to thermodynamic limitations of the compound crossing the blood brain barrier (BBB) or 
potential interactions with transporters at the BBB reducing the ability of deltamethrin to 
distribute into the brain.  It is difficult to determine why discrepancies between the 
computationally derived fat partition coefficient and the optimized value necessary to fit the 
available fat data exist.  The computational value appears to fit peak fat concentrations of 
deltamethrin (Fig 7) and allow accurate estimation of other tissue concentration profiles (Fig 
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3-9) because there is little discrepancy within the first 48 hours (Fig 7).  The computational 
value however predicts that the level of deltamethrin in the fat remains elevated for 
considerably longer than literature data suggests.  This could be due to minor metabolic 
processes in the fat or blood within the fat tissue, or due to non-enzymatic degradation of 
deltamethrin in the fat over the length of the study.  It is currently unknown however, why 
the fat partition coefficient had to be lowered four-fold for such a highly lipophilic chemical 
such as deltamethrin.  Modeling of another highly lipophillic compound, TCDD, also reveals 
that lower than expected partition coefficients, based on these computational methods, are 
needed to accurately model fat concentrations (Emond et al 2004).  This may be indicative of 
deficiencies in the computational methods for predicting partition coefficients in lipohillic 
tissues for highly lipophillic compounds. 
The rat model was used as the framework for developing a human deltamethrin 
PBPK model.  Comparing predictions of the rat and human diffusion limited models at the 
rat NOAEL (1mg/Kg) (USEPA, 1998) for deltamethrin indicates that humans would have 
slightly greater brain deltamethrin concentrations (Fig. 12) despite the fact that humans 
metabolize deltamethrin more rapidly.   
Model structure can have a significant impact on risk assessment of pyrethroids.  A 
diffusion-limited model such as the one presented here minimizes the effect of the species 
difference in metabolism of deltamethrin (Godin et al 2006).  In a diffusion-limited 
description of the liver, the rate limiting step in the clearance of deltamethrin is not the 
clearance rate but rather the rate of diffusion of compound from blood into tissue.  Diffusion-
limited kinetics would also have the effect of reducing the impact of inter-individual 
differences in the capacity for metabolism of deltamethrin in the human population.  One of 
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the limitations of applying this model for risk assessments would be the description of the 
distribution of deltamethrin to the brain.  Further research in this area is needed to better 
identify mechanisms for the lower than expected brain concentrations in rats.  Understanding 
this process would enhance our confidence that the model predictions of target tissue 
concentrations are more accurate.    
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Table 4.1. PBPK Model parameters 
Values in parentheses are computationally derived partition coefficients and corresponding 
permeability area coefficients.  1-Brown et al., 1997; 2- Mirfazaelian et al.,  2006; 3-Godin et 
al., 2006; 4-Godin et al., 2007. a - set to Liver. b - set to muscle from Brown et al., 1997. c - 
estimated by AcslXtreme OpStat parameter estimation software.  
Parameter Description 
Rat 
 Model 
Proposed 
Human 
Model 
Body Weight (BW) 0.4 70 
Cardiac Output (QCC) (L/hr/Kg^.75) 14.11 14.11 
Cardiac Output to Liver (QLC) (% QCC) 0.1831 0.2141 
Cardiac Output to Fat (QFC) (% QCC) 0.071 0.0521 
Cardiac Output to Brain (QBrC) (% QCC) 0.021 0.1141 
Cardiac Output to Slowly Perfused Tissues (QSC) (% QCC) 0.2361 0.2821 
Cardiac Output to Richly Perfused Tissues (QRC) (% QCC) QRC = 1-QLC-QFC-QBrC-QSC 
Blood Volume (VBlC) (%BW) 0.071 0.071 
Liver Tissue Volume (VLC) (%BW) 0.031 0.031 
Fat Tissue Volume  (VFC) (%BW) 0.071 0.221 
Brain Tissue Volume  (VBrC) (%BW) 0.0051 0.021 
Slowly Perfused Tissue Volume  (VSC) (%BW) 0.781 0.621 
Richly Perfused Tissue Volume  (VRC) (%BW) VRC=1-VBlC-VLC-VFC-VBrC- VSC 
Blood Volume Fraction in Liver (%VLC) 0.211 0.211 
Blood Volume Fraction in Fat  (%VFC) 0.0252 0.0252 
Blood Volume Fraction in Brain (%VBrC) 0.031 0.031 
Blood Volume Fraction in Slowly Perfused Tissues (%VSC)  0.04a 0.04a 
Blood Volume Fractoin in Richly Perfused Tissues  (%VRC) 0.21b 0.21b 
Liver Partition Coeffcient (PL) (9)  19c 19 
Fat Partition Coeffcient (PF) (412)  752 75 
Brain Partition Coeffcient (PBr) (30)  0.14c 0.14 
Slowly Perfused Tissue Partition Coeffcient (PS) (7)  5.64c 5.64 
Richly Perfused Tissue Partition Coeffcient (PR) (12)  8.10c 8.10 
Liver Permeability Area Coefficient (PALC) (0.28) 0.288c 0.288 
Fat Permeability Area Coefficient  (PAFC) (0.02) 0.025c 0.025 
Brain Permeability Area Coefficient (PABrC) (0.1) 0.002c 0.002 
Slowly Perfused Tissue Permeability Area Coefficient 
(PASC) (0.045) 0.043c 0.043 
Richly Perfused Tissue Permeability Area Coeffcient 
(PARC) (0.14) 0.093c 0.093 
Stomach-Intestine Transfer Rate Constant (KSI) (hr-1) 0.42c 0.42 
Intestinal Uptake Rate Constant (KI) (hr-1) 1.51c 1.48 
Fecal Excretion Rate Constant (KFE) (hr-1) 0.59c 0.6 
Hepatic Clearance Rate Constant (KCL) (L/hr/Kg BW) 5.33 9.73 
Plasma Clerance Rate Constant (KBlC) (L/hr//mL serum) 0.00124 04 
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Table 4.2. Deltamethrin Oral Bioavailability 
 
 1mg/kg iv 0.3 mg/kg po 3.0 mg/kg po 
Average AUC0-∞ 2.22 0.167 1.86 
STD 0.63 0.034 0.46 
F%  25 ± 5 28 ± 7 
 
Oral Bioavailability of Deltamethrin after oral doses of 0.3 and 3.0 mg/kg in corn oil.   
N=4, mean ± SD
  147 
 
0 2 4 6 8 10
0
10
20
30
40
50
Administered Dose
%
 
 
Fe
ca
lly
 
Ex
cr
et
ed
 
Figure 4.1.  Fecal excretion of deltamethrin (literature values).  Individual data points 
from ● - Bosch 1990 and▼ - Ruzo et al., 1978.
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Figure 4.2. Basic PBPK Model Structure Representation
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Figure 4.3.  Model 
predictions of deltamethrin 
blood concentrations after iv 
and oral dosing.  
 
 
A. Blood concentrations 
after an iv dose. Inset = 1-4 
hours.  Individual data points 
(▲, 1 mg/kg) (N=4). Dashed 
line represents predictions of 
the optimized diffusion-
limited model.  
 
 
 
 
 
 
B. Blood Concentratoins 
after a 0.3 mg/kg po dose 
individual data points(▲, 0.3 
mg/kg) (N=4). Dashed line 
represents predictions of the 
optimized diffusion-limited 
model. 
 
 
 
 
 
 
 
 
 
C. Blood Concentratoins 
after a 3.0 mg/kg po dose 
 compared to individual data 
points( ●, 3.0 mg/kg) (N=4). 
Dashed line represents 
predictions of the optimized 
diffusion-limited model. 
A 
B 
C 
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Figure 4.4. Model predictions of deltamethrin in blood after a 1.75 mg/kg iv dose 
(▲,data of Gray and Rickard 1982). Dashed line represents predictions of the optimized 
diffusion-limited model compared to data points.
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Figure 4.5. Model predictions compared to brain concentration of deltamethrin after 
oral dosing. Dashed line represents predictions of the optimized diffusion-limited model 
compared to data points (▲, 3mg/kg) (N=4). 
  152 
0 4 8 12 16 20 24
0.001
0.01
0.1
1 Model Prediction
po 3mg/Kg
Time (hr)
De
lta
m
e
th
rin
 
(ug
/g
)
 
 
Figure 4.6. Model prediction compared to liver tissue concentration of deltamethrin 
after oral dosing.  Dashed line represents predictions of the optimized diffusion-limited 
model compared to individual data points (▲, 3 mg/kg) (N=4). 
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Figure 4.7. Model simulation of deltamethrin fat concentrations after oral dosing 
Dashed line represents predictions of the optimized diffusion-limited model compared to 
individual data points (A-▲, 0.3 mg/kg and B-●, 3.0 mg/kg) (N=4).  Solid line represents 
prediction of the diffusion limited model with a computationally derived partition coefficient 
for the fat compartment. 
A 
B 
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Figure 4.8. Model predictions of averaged brain concentrations of deltamethrin from 
the cerebrum, cerebellum and spinal cord after a 1.75 mg/kg iv dose (▲, data from 
Gray and Rickard 1982).  Error bars equal standard deviation between average 
concentrations in each brain region. Dashed line represents predictions of the optimized 
diffusion-limited model. 
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Figure 4.9. Model predictions of the deltamethrin tissue time course data of 
Mirfazaelian et al (2006) (▲). A) 1 mg/kg iv.  B) 2 mg/kg po.  C) 10 mg/kg po.  Dashed 
line represents predictions of the optimized diffusion- limited model. 
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Figure 4.10. Model predictions vs fat concentration of deltamethrin from Ruzo et al. 
(1978). Lines represent predictions of the optimized diffusion limited model. ▼, 0.64 mg/kg 
oral dose; ●, 0.90 mg/kg oral dose; ■, 1.60 mg/kg oral dose. 
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Figure 4.11. Sensitivity analysis of the optimized diffusion-limited model for peak arterial and brain 
concentrations of deltamethrin.  See Table 1 for parameter descriptions. 
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Figure 4.12. Model predictions of brain concentrations of deltamethrin from optimized 
diffusion limited rat model and proposed human model after a 1 mg/kg oral dose. 
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Modeling Equations 
 
 
Oral Absorption and Fecal Excretion 
Rate of mass input from intestines (mg/hr)  
 KI*AI 
 AI = mass in intestines (mg) 
Rate of fecal excretion (mg/hr)  
 KFE*AI 
 
iv Infusion 
Rate of iv infusion (mg/hr) 
RIC = ivDOSE*BW/TINF 
ivDOSE = Mass dosed (mg/Kg) 
TINF = Time of infusion (hr-1) 
 
Blood Compartment 
 
Rate of change in blood (mg/hr) 
QL*CVL + QBr*CVBr + QF*CVF + QS*CVS + QR*CVR - QC*CA - RMBL + iv  
Concentration in blood (mg/L) 
CA = ABL/VBL 
Rate of clearance from blood (mg/hr) 
RMBL = (Kbl*CA) 
Serum esterase clearance rate constant (L/hr) 
Kbl = KblC*(VBL/2)  
iv = Riv*Ivr 
Ivr = iv dosing timing switch 
 
Flow-Limited Compartments 
  
 Rate of blood:tissue exchange (mg/hr) 
 QT*(CA-CVT) 
 Concentration in venous blood leaving tissue (mg/L)   
     CVT = CT/PT 
 Concentration in tissue 
      CT   = AT/VT  
 
Diffusion-limited tissues 
  
 Rate of change is extracellular tissue blood (mg/hr) 
QT*(CA-CVT) + PAT*(CIT/PT-CVT) 
 Concentration in venous blood leaving tissue 
 CVT  = AET/(VT*BVT) (mg/L) 
 Rate of blood:tissue exchange (mg/hr) 
 PAT*(CVT-CIT/PT)    
 Concentration in intracellular tissue (mg/L) 
 CIT  = AIT/(VT*(1-BVT)) 
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Liver Compartment 
Rate of Change in Liver blood 
QL*(CA-CVL) + PAL*(CIL/PL-CVL) + RAO    
Rate of blood:liver exchange (mg/hr) 
PAL*(CVL-CIL/PL)- RAM        
Scaled intrinsic hepatic clearance 
Clint    = KCL*BW 
Rate of metabolism in diffusion-limited liver 
RAM = CLint*CIL
  
CHAPTER V 
 
GENERAL DISCUSSION
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Pyrethroid pesticides are currently undergoing evaluation for a potential cumulative 
risk assessment by the EPA Office of Pesticide Programs under the auspices of the Food 
Quality Protection Act of 1996.  Risk assessment of environmental toxicants is a process that 
consists of numerous uncertainties.  Typically, there is a lack of human data available for 
environmental contaminants; the case of the pyrethroids is no exception.  This necessitates 
extrapolation of data from non-human species to humans.  The extrapolation of toxicological 
data from laboratory animals to humans often simply relies on default safety assumptions in 
the absences of appropriate data.  This dissertation has focused on developing appropriate 
data sets and models to address uncertainties in the description of pyrethroid 
pharmacokinetics. 
SUMMARY OF RESEARCH RESULTS 
The working hypothesis for this dissertation was that hepatic clearance of pyrethroids 
drives blood and brain concentrations of the pyrethroids influencing pyrethroid potency. 
 
Metabolism of Deltamethrin and Esfenvalerate 
The metabolic detoxification of pyrethroids has long been understood to take place 
through two general pathways, esterase-mediated hydrolysis and cytochrome P450 oxidation 
in the liver of laboratory animals (Abernathy and Casida 1973; Casida et al., 1975; Soderlund 
and Casida 1977).  Identification of common metabolites between rats and humans (Cole et 
al. 1982; Heudorf and Angerer 2001) indicates that there are common pathways of 
metabolism for pyrethroids between species.  However, till now there has been no data 
comparing the pathways and relative rates of metabolism of individual pyrethroids in 
laboratory species and humans. 
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Preliminary work for this dissertation revealed that hepatic metabolism of 
deltamethrin and esfenvalerate by rat and human microsomes differed in rate and/or pathway.  
Utilizing a parent depletion approach, deltamethrin and esfenvalerate were both metabolized 
by NADPH dependent oxidative metabolism in rat liver microsomes (RLM) at similar rates.  
Only minor amounts of NADPH independent hydrolysis of deltamethrin and esfenvalerate 
occurred in RLM (Table 2.2 and Figure 2.2).  In contrast, in human liver microsomes (HLM) 
deltamethrin and esfenvalerate were metabolized primarily via different pathways.  
Esfenvalerate was metabolized via NADPH dependent oxidation in HLM, as in RLM; 
however, the rate of metabolic clearance was nearly three fold slower than in RLM (Table 
2.1).  Unexpectedly, deltamethrin was metabolized by NADPH independent hydrolysis in 
HLM nearly twice as rapidly as it is in RLM (Fig 2.3).   
Deltamethrin is a cis-isomer pyrethroid.  Cis-isomer pyrethroids are metabolized in 
rats and mice primarily by oxidative mechanisms (Shono et al. 1979; Soderlund and Casida 
1977).    Cis-isomer pyrethroids are hydrolyzed significantly slower by purified rat, mouse, 
and rabbit carboxylesterases compared to trans-isomer pyrethroids (Ross et al. 2006; Stok et 
al. 2004).  In contrast, human carboxylesterase – 1 (hCE-1) rapidly metabolized deltamethrin 
(Table 2.3).  The rate of deltamethrin hydrolysis by a rat carboxylesterase is similar to cis-
permethrin and esfenvalerate while in humans its hydrolysis is similar to the trans-isomer 
pyrethroids trans-permethrin and bioresmethrin by hCE-1 (Figure 2.5). 
The species difference in hydrolysis of deltamethrin as compared to esfenvalerate is 
in part the result of increased metabolism of deltamethrin by hCE-1 as compared to 
esfenvalerate (Fig 2.3).  In addition comparison of hydrolysis of deltamethrin by hCE-1 and 
rat hydrolase A indicates that the human esterase has greater capacity to metabolize 
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deltamethrin (Table 2.4 and Fig 2.4).  The differences in oxidative metabolism of 
esfenvalerate and deltamethrin between rats and humans however, appear to be simply due to 
differential expression of P450s, in rat and human liver microsomes, which metabolize the 
pyrethroids.  Table 3.1 and Figures 3.1 and 3.2 shows that both deltamethrin and 
esfenvalerate are metabolized with similar Km values and at similar rates by both rat and 
human P450s.  The exception is that of human CYP2C9 which efficiently metabolizes 
esfenvalerate, but not deltamethrin.  This likely explains the greater oxidative metabolism of 
esfenvalerate in human liver microsomes compared to deltamethrin.  CYP2C9 is one of the 
most highly expressed CYPs in the human liver.  Estimates of average individual CYP 
isozyme expression in human liver microsomes range from 1-100 pmoles P450/mg 
microsomal protein (Rodrigues, 1999).  CYPs 3A4 and 2C9 are the most abundant of the 
human hepatic P450s expressed near 100 pmoles/mg microsomal protein (Rodrigues, 1999).  
The expression of pyrethroid metabolizing P450s in hepatic microsomes of rats however 
reveals that the expression of rat pyrethroid metabolizing P450s (CYPs 2C6, 2C11, and 3A2) 
ranges from 300 to >1000 pmoles P450/mg of microsomal protein (Guengerich 1982).  This 
likely explains the differences in oxidative clearance of these pyrethroids between rats and 
humans.  In addition comparison of the expression of hCE-1 to human P450s reveals that the 
expression of hCE-1 is approximately 12–1200-fold greater than the levels of individual 
CYPs in human liver microsomes (Godin et al 2007), describing why deltamethrin is so 
rapidly metabolized in HLM. 
Extrahepatic metabolism of pyrethroids occurs in the blood, brain, lung and intestines 
of rats (Anand et al. 2006, Godin et al. 2007; Crow et al. 2007; Bruckner et al. 2007).  
Metabolism in the brain and lungs has been found to be minimal, requiring large quantities of 
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subcellular tissue in order to detect metabolism (Bruckner et al. 2007).  Metabolism in these 
tissues would likely have no influence on local tissue concentrations and would have no 
impact on systemic clearance of the pyrethroids.  Intestinal metabolism of the pyrethroids in 
rats appears to be chemical specific and dependent on the expression of intestinal esterases.  
Trans-permethrin is metabolized in rat intestinal microsomes however, no intestinal 
metabolism of deltamethrin occurred (Crow et al. 2007).  This corresponds with the greater 
activity of rat esterases with trans-permethrin compared to deltamethrin (Godin et al. 2006; 
Ross et al. 2006).  Based on similarities in deltamethrin and esfenvalerate hydrolysis by rat 
esterases this also indicates that esfenvalerate metabolism is unlikely in the intestines of rats 
as well (Godin et al. 2006; Ross et al. 2006).  Human intestinal metabolism of pyrethroids is 
unlikely to influence disposition either.  The major esterase in the human intestines is hCE-2 
(Imai et al. 2005) which does not efficiently metabolize deltamethrin or esfenvalerate (Table 
2.3) and corresponds to the lack of deltamethrin metabolism in human intestinal microsomes 
(Crow et al. 2007). 
The blood of rats contains carboxylesterase that are capable of metabolizing 
pyrethroids (McCraken et al. 1993; Anand et al 2006).  Deltamethrin is metabolized by rat 
serum and a purified rat serum carboxylesterase (Fig 3.5).  The purified rat serum 
carboxylesterase metabolized deltamethrin with similar efficiency to the rat hepatic 
carboxylesterase, rat hydrolase A (Godin et al. 2006 and 2007).  Hepatic concentrations of 
carboxylesterases are expected to be greater than serum carboxylesterase.  Thus, serum 
metabolism was thought to be unlikely to influence systemic clearance.  In contrast to rats, 
human serum does not contain carboxylesterases (Li et al. 2005) and does not metabolize 
deltamethrin (Godin et al. 2007). 
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 The current findings regarding the metabolism of deltamethrin reveal that the vast 
majority of metabolism of deltamethrin is occurring in the liver of rats and humans.  There 
are species difference in the pathways and rates of hepatic clearance in the liver of rats and 
humans that may influence systemic concentrations of deltamethrin.  This could influence 
peak brain concentrations and therefore the relative potency of deltamethrin between rats and 
humans.  Experimentally determined hepatic clearance rates were utilized in developing 
PBPK models in rats and humans to examine the impact of the species difference on 
exposure-dose relationships. 
 
PBPK Modeling of Deltamethrin 
 To explore the impact of the species differences in the hepatic metabolism of 
deltamethrin on exposure-dose relationships, PBPK models were developed in the rat and 
extrapolated to humans.  These models utilized species-specific physiological and metabolic 
parameters.  To examine uncertainties in model structure, including absorption and model 
structure, oral bioavailability and time course studies were conducted. 
 A published PBPK model of deltamethrin utilized both flow- and diffusion-limited 
kinetics to describe the distribution of deltamethrin (Mirfazaelian et al. 2007).  Initial 
modeling efforts utilized the model structure of Mirfazaelian et al. (2007), however, this 
model was unable to accurately describe the tissue concentration time course of deltamethrin 
from published data of Gray and Rickard (1982) (data not shown) or the data generated in 
chapter IV (Fig 4.3 - 4.10).  A new model structure was therefore developed in which 
deltamethrin tissue kinetics were described by diffusion limitations in all tissue 
compartments.  The model consists of tissue compartments for the brain (target tissue), liver 
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(metabolism), and fat, richly perfused and slowly perfused tissues (distribution).  A single 
blood compartment connected each tissue compartment.  These were the tissue compartments 
from the initial hypothesis driven model described in the general introduction. 
Computationally derived tissue:blood partition coefficients were utilized to 
parameterize the model.  Doing so allowed a hypothesis driven examination of deltamethrin 
tissue distribution based on expected tissue solubility.  With the exception of the brain and 
the fat, the use of the computationally derived partition coefficients adequately described the 
distribution of deltamethrin.  Computational determination of partition coefficients resulted 
in drastic overestimation of brain concentration.  The brain partition coefficient had to be 
reduced by nearly 300-fold to accurately describe the data from the current study presented in 
chapter IV and that of Gray and Rickard (1982).  This suggests that the BBB is having a 
significant influence on the distribution of deltamethrin into the brain.  This may be due to 
simple diffusional limitations of the BBB or the interaction of deltamethrin with transporters 
on the endothelial lining of the BBB. 
It is difficult to determine why discrepancies between the computationally derived fat 
partition coefficient and the optimized value necessary to fit the available fat data exist.  The 
computational value appears to fit peak fat concentrations of deltamethrin out through 48 hrs 
(Fig 4.7) and allows accurate estimation of other tissue concentration profiles (Fig 4.3 - 4.9) 
because this occurs within the first 48hrs after exposure.  The computational value, however, 
predicts that the level of deltamethrin in the fat remains elevated for considerably longer than 
literature data suggests.  This may be due to minor amounts of metabolism in the fat, or 
possibly over the extended fat time course in the studies of Mirfazaelian et al (2006) and 
Ruzo et al. (1978) non-enzymatic degradation of deltamethrin occurs in the fat.  Stability of 
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the pyrethroids in fat at physiological temperatures over the course of days or weeks is 
unknown.  It is possible that the computational predictions are correct and elimination from 
the fat is occurring by a yet to be described processes.  Further data sets on the stability of 
deltamethrin in the fat may result in a better understanding of this discrepancy between the 
computational and optimized fat partition coefficients.  
 The diffusion-limited model was able to more accurately describe the tissue 
distribution of deltamethrin for data sets from the current work, the work of Gray and 
Rickard (1982), Ruzo et al. (1978) and the work of Mirfazalein et al. (2007) (Fig 4.3 – 4.10) 
as compared to the published model structure of Mirfazalein et al. (2007).  The modeling of 
deltamethrin by diffusion-limited kinetics appears to minimize the impact that the rate of 
hepatic clearance, and species differences in the metabolism of deltamethrin, have on peak 
brain concentration.  This infers that our initial hypothesis was incorrect and that hepatic 
clearance does not significantly influence brain concentrations.  These results imply that 
diffusion of deltamethrin into the liver and brain influence blood concentrations and 
ultimately influences the potency of individual pyrethroids.  
SIGNIFICANCE OF RESEARCH RESULTS 
Implications for Species Extrapolation 
The results presented in Chapters II and III regarding the metabolism of deltamethrin 
and esfenvalerate are the first published reports comparing the metabolism of pyrethroids in 
laboratory animals and humans.  These results identified species differences in the 
metabolism of pyrethroids that were previously unknown.  These studies are also the first 
published studies to identify the major individual enzymes that are responsible for the 
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metabolism of pyrethroids.  The result of which was identification of determinants of the 
major pathway a pyrethroid is likely to be metabolize by in rats and humans.   
Clearance rates from the metabolism studies were utilized to develop PBPK models 
of exposure to deltamethrin.  This allowed an extrapolation of the impact that the rate of 
hepatic clearance of deltamethrin has on exposure-dose relationships and relative potencies 
between rats and humans.  The description of a PBPK models’ kinetic structure can have a 
significant impact on predictions of exposure-dose relationships for pyrethroids.  The 
previous model structure of Mirfazalien et al (2006) utilized a flow-limited description of the 
liver and brain compartments.  The result of which is that the rate of hepatic clearance would 
have a significant impact on peak tissue concentrations in the blood and brain (see sensitivity 
analysis in Mirfazalein et al. 2006).  The model presented in Chapter IV finds that a 
diffusion-limited description of these tissues may be more appropriate.  This would have the 
effect of minimizing the impact of the species difference in the hepatic clearance of 
deltamethrin.  In the diffusion-limited model, the rate of deltamethrin metabolism is limited 
by the diffusion into the liver.   
Until now, it had been thought that the rate of hepatic clearance of pyrethroids 
significantly influenced the potency of individual pyrethroids, especially between cis- and 
trans-isomers of some pyrethroids.  It was unclear how this related to individual chemicals.  
The diffusion-limited descriptions of the liver and the brain for deltamethrin in chapter IV 
result in the permeability of the pyrethroid into these tissues having a greater impact on peak 
brain concentrations than the rate of hepatic clearance (see sensitivity analysis Fig 4.11).  
This does not eliminate the pharmacokinetic influence on pyrethroid potency it simply alters 
how we might think of what impacts it.  Due to the diffusion-limited description of tissue 
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compartments and the lipohilicity of deltamethrin, changes in metabolism, decreases for 
example, are going to result in greater distribution of deltamethrin.  Based on the size and 
partition coefficients’ of tissue compartments the majority of deltamethrin that is not 
metabolized will distribute to the fat and slowly perfused tissues resulting in comparatively 
small increases in brain concentrations (due to BBB influences on brain penetration).  
The no observable adverse effect level (NOAEL) for deltamethrin is 1mg/kg after 
oral exposure in the rat (Crofton et al. 1995).  This has been extrapolated by the EPA to a 
human reference dose (RfD) of 0.01mg/Kg/day by dividing by a 100-fold uncertainty factor 
(Federal Register 2004).  That uncertainty factor can be broken into factors of 10 for species 
extrapolation and inter-individual variability.  Based on a human model extrapolated from 
the rat PBPK model developed here, and a comparison of a 1mg/Kg oral dose, humans would 
be slightly more sensitive to deltamethrin exposure based on target tissue (brain) 
concentrations (Fig 4.12).  Peak brain concentration is 1.8-fold higher in the human model 
than in the rat model and remains elevated for a longer period.  This is likely due in large part 
to physiological differences between the brain of rats and humans.  The human brain has 
significantly greater blood flow and volume compared to the rat (Table 4.1).  These 
physiological differences may make humans more sensitive to neurotoxicants in general due 
to increased exposure to the brain.  Thus even though humans metabolize deltamethrin more 
rapidly they appear as though they are more sensitive based on this analysis.  In addition, 
modeling of deltamethrin with diffusion-limited kinetics reduces the impact that genetic 
polymorphisms or mutations, which can influence the activity of metabolizing enzymes, will 
have on pyrethroid potency.  It would also be less likely that metabolic interactions during 
exposure to mixtures of pyrethroids would influence systemic clearance. 
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Modeling deltamethrin with diffusion-limited kinetics is a more health 
conservative/protective approach compared to utilizing flow-limited kinetics in which the 
more rapid rate of intrinsic hepatic clearance in humans for deltamethrin would have a more 
significant impact on brain concentrations.  The 10-fold uncertainty factor for species 
extrapolation can also be further broken down. Renwick (1993) and the world health 
organization (WHO 1994) suggest a pharmacokinetic component of 4.0 and a 
pharmacodynamic component of 2.5.  The EPA utilizes a factor of 3 for pharmacokinetics 
(Barnes and Dourson 1988).  Based on the current analysis, humans would be nearly two fold 
more sensitive to a rat NOAEL dose of 1mg/kg (Chapter IV) on a brain concentration basis.  
This is in good agreement with a suggested three or four-fold uncertainty factor for 
pharmacokinetic differences between species.  
FUTURE STUDIES 
  To best aid the risk assessment process for the pyrethroids, future studies should 
focus on modeling of other pyrethroids and developing a better understanding of 
determinants of brain distribution profiles for pyrethroids. 
 Development of PBPK models for other pyrethroids will help to validate the 
diffusion-limited structure of the deltamethrin PBPK model presented in this dissertation.  
Further modeling may also help to validate the use of computationally derived partition 
coefficients, which appear to have worked well in the current model with the exception of the 
brain.  Discrepancy in computational and optimized partitioning into fat is also an area of 
continued uncertainty; however, the computational value only required a 4-fold reduction to 
fit the available data.  This was also only required to model the later fat time points out to 
500 hrs and did not influence the description of other tissue concentrations in the important 
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first 24 hrs after exposure.  Discrepancy between the computational and optimized values 
could be due to a small amount of metabolism in the fat or potentially due to non-enzymatic 
degradation of deltamethrin in the fat over time.  These are factors that could be examined in 
an in vitro setting and results could be applied to the model to increase confidence in the 
description of the fat compartment. 
The brain, in which the partition coefficient had to be reduced nearly 300 fold to 
describe tissue concentrations, is of much more interest from a risk assessment standpoint 
because it is the target tissue for the neurotoxicity of pyrethroids.  The drastic difference in 
brain partitioning of deltamethrin could be the result simply of the blood brain barrier 
reducing exposure to the brain through inhibition of diffusion.  The basic cell membrane 
structure is the same in all tissues of the body and simple diffusion through the membrane 
should be similar in all tissues.  Partitioning of a chemical is then determined by the affinity 
or solubility of the chemical in the composition of individual tissues.  However, the capillary 
membrane of the blood brain barrier contains tighter junctions than those of other tissues.  
This acts to reduce the extravascular exposure of the brain to xenobiotics in the blood.  
Another possibility is that deltamethrin distribution into the brain is regulated by some yet to 
be described process.   
 In recent years, the influence of transporters on the distribution of xenobiotics into the 
brain has come into focus.  Could export transporters be the reason for the lower than 
expected levels of deltamethrin in the brain?  Could there be a correlation between the rate of 
transport and the rate of metabolism?  Would this explain why it has been thought that the 
rate of metabolism correlated with potency?  Would a structure activity relationship in 
transport be similar to those of metabolism for the pyrethroids?  Gray et al. (1980) and Gray 
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and Rickard (1981) observed differences in brain distribution of cismethrin and deltamethrin 
compared to their distribution in other tissues.  In those studies, based on equitoxic doses of 
deltamethrin and cismethrin, tissue concentration ratios were proportional to the dose ratios 
between chemicals in all tissues except in brain.  This indicates that differences in 
metabolism are not affecting distribution into the brain.  An unidentified factor however does 
appear to be influencing distribution into the brain.  Does the difference in the tissue 
distribution ratios in the brain equate to differences in transport or simple differences in the 
thermodynamic properties of each chemical structure resulting in different diffusional 
characteristics.  Deltamethrin is a larger more polar molecule compared to cismethrin.  This 
does not however appear to affect their diffusion into other tissues of the body however as 
stated the BBB is different from capillary membranes in other tissues.  So could transport 
explain these differences? 
 There is some circumstantial evidence to suggest that the pyrethroids may interact 
with the multidrug resistance protein, P-glycoprotein (P-gp).  Lemaire et al. (2004) studied 
induction of P450s via activation of the human pregnane X receptor (PXR) by a number of 
pesticides including pyrethroids.  They found that pyrethroids are capable of activating PXR.  
PXR is also involved in the regulation of P-gp (Geick et al 2001).  P-gp is not only found in 
mammals but also insects and recently it has been found that some pesticide (including 
pyrethroid) resistant insect strains have significantly increased P-gp activity compared to 
non-resistant strains (Srinvas et al. 2005).  Does this indicate that P-gp may have a significant 
role in the potency of pyrethroids in both insects and mammals?  In another study however 
Bain and LeBlanc (1996) studied the interaction of a number of different pesticides with P-
gp.  Included in their studies were three pyrethroids. Their findings indicated that there was 
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very little interaction of the pyrethroids studied (esfenvalerate, fluvalinate and permethrin) 
with P-gp. 
Another implication of P-gp transport of pyrethroids would be on absorption after an 
oral dose.  P-gp is located not only in the brain endothelium of the BBB, but is also located in 
the liver and intestinal tract (Mei et al. 2004).  Does P-gp play a role in the fecal excretion of 
the pyrethroids?  The apparent lack of dose dependent absorption of deltamethrin in the 
bioavailability study in chapter IV and literature reports do not appear to suggest that 
intestinal transport is occurring.  
These questions regarding pyrethroid transport if examined could aid the 
understanding of pyrethroid potency and aid extrapolation of exposure-dose-response 
relationships in risk assessment.  If transporters are interacting with deltamethrin this could 
be utilized in the PBPK model to better explain distribution into the brain.  If transporters are 
not involved in pyrethroid transport it likely indicates that pyrethroid absorption is mediated 
by solubility and vehicle dynamics while brain concentrations are largely dependent on the 
ability of each pyrethroid to cross the BBB.  Other studies in our laboratory (unpublished) 
indicate that there are significant differences in brain permeability between pyrethroids that 
are not indicative of metabolic differences.  In vitro examination of BBB permeability of 
pyrethroids would likely be highly useful in understanding the distribution of pyrethroids into 
the brain.   
CONTRIBUTION TO THE FIELD OF PYRETHROID PHARMACOKINETICS 
In summary, this dissertation has yielded a further understanding of the metabolism 
of pyrethroids in rats and humans.  We have identified the enzymes that are responsible for 
the metabolism of pyrethroids in both rats and humans and pointed to likely determinants of 
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the pathway that will metabolize a pyrethroid in each species.  We have also developed a 
refined PBPK model for deltamethrin, which will enable development and comparison to 
models for other pyrethroids.  This will allow a determination of whether a common model 
structure can be applied to all pyrethroids.  We have pointed out that the distribution of 
deltamethrin into the brain does not appear to be mediated solely by its concentration in the 
blood and that uncertainties remain regarding its distribution into and out of the brain.  If 
correct this PBPK model structure also indicates that the rate of hepatic metabolism of the 
pyrethroids does not have as significant an effect on pyrethroid potency as has been thought.  
In addition, these results if validated may lead to the development of future pyrethroids 
designed to limit their brain distribution minimizing their mammalian toxicity while 
maintaining their insecticidal activity. 
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